Combinations of mRNAs encoding immunomodulatory polypeptides and uses thereof

MRNA therapeutics using immunomodulatory polypeptides delivered via LNPs address the limitations of current cancer treatments by minimizing immune activation and optimizing protein expression, effectively reducing tumor size and inhibiting growth.

JP7586883B2Active Publication Date: 2024-11-19MODERNATX INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2022197763
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-04-01
Filing Date
2022-12-12
Publication Date
2024-11-19
Estimated Expiration
2037-05-18

AI Technical Summary

Technical Problem

Current cancer treatments such as chemotherapy and radiotherapy have undesirable consequences, and genetic therapies face challenges like immune responses and safety concerns due to random genome integration, necessitating a more targeted and efficient therapeutic approach.

Method used

Development of mRNA therapeutics using immunomodulatory polypeptides delivered via lipid nanoparticles (LNPs) to minimize immune activation and optimize protein expression, incorporating nucleotide modifications and sequence optimizations to enhance efficacy.

Benefits of technology

The mRNA therapeutics effectively reduce tumor size and inhibit growth by stimulating immune responses and optimizing protein translation, providing a targeted and safer treatment for cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007586883000161
    Figure 0007586883000161
  • Figure 0007586883000162
    Figure 0007586883000162
  • Figure 0007586883000163
    Figure 0007586883000163
Patent Text Reader

Abstract

Providing mRNA therapeutics for the treatment of cancer; The present disclosure relates to compositions and methods for the preparation, manufacturing, and therapeutic use of combinations of immune modulatory polynucleotides (e.g., mRNA) encoding immune response primer polypeptides (e.g., interleukin-23 (IL-23) polypeptides or interleukin-36 gamma (IL-36 gamma) polypeptides) and immune response costimulatory signal polypeptides (e.g., OX40L polypeptides). The mRNA therapeutics of the present disclosure are particularly well suited for the treatment of cancer, as this technology results in the de novo synthesis of functional proteins in target cells, e.g., in tumors, following intracellular delivery of mRNA encoding the immune modulatory polypeptides.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application is a continuation of U.S. Provisional Patent Application No. 62 / 338,496, filed May 18, 2016, U.S. Provisional Patent Application No. 62 / 338,506, filed May 18, 2016, U.S. Provisional Patent Application No. 62 / 338,467, filed May 18, 2016, U.S. Provisional Patent Application No. 62 / 338,483, filed May 18, 2016, U.S. Provisional Patent Application No. 62 / 404,173, filed October 4, 2016, U.S. Provisional Patent Application No. 62 / 404,175, filed October 4, 2016, and U.S. Provisional Patent Application No. 62 / 404,176, filed October 4, 2016. This application claims the benefit of U.S. Provisional Patent Application No. 62 / 415,424, filed October 31, 2016, U.S. Provisional Patent Application No. 62 / 438,945, filed December 23, 2016, U.S. Provisional Patent Application No. 62 / 438,942, filed December 23, 2016, U.S. Provisional Patent Application No. 62 / 443,693, filed January 7, 2017, U.S. Provisional Patent Application No. 62 / 472,513, filed March 16, 2017, and U.S. Provisional Patent Application No. 62 / 480,400, filed April 1, 2017. The entire contents of the above-referenced patent applications are incorporated herein by this reference. [Background technology]

[0002] Cancer is a disease characterized by uncontrolled cell division and proliferation in the body. In the United States, approximately one-third of all women and half of all men will experience cancer in their lifetime. Currently used standard treatments, such as chemotherapy and radiation therapy, have many undesirable outcomes, and genetic therapies to manipulate disease-associated peptides and the function of these peptides offer a more targeted approach to the diagnosis, treatment, and management of disease. However, gene therapy also has several challenges, including undesirable immune responses and safety concerns due to gene integration at random locations within the genome. Therefore, improved therapeutic approaches for treating tumors are needed. Summary of the Invention [Problem to be solved by the invention]

[0003] An object of the present invention is to provide mRNA therapeutic agents for the treatment of cancer. [Means for solving the problem]

[0004] The present disclosure provides mRNA therapeutics for the treatment of cancer. The mRNA therapeutics of the present disclosure are particularly well suited for cancer treatment because this technology results in de novo synthesis of functional proteins within target cells, e.g., tumors, following intracellular delivery of mRNA encoding immune-modulating polypeptides (e.g., oncology-related polypeptides useful in immuno-oncology (“IO”) methods, including immune response stimulators, costimulators, checkpoint inhibitors, etc.). The present disclosure features therapeutic mRNAs with nucleotide modifications that (1) minimize unwanted immune activation (e.g., innate immune responses associated with the in vivo introduction of foreign nucleic acids) and (2) optimize mRNA-to-protein translation efficiency. Exemplary embodiments of the present disclosure feature therapeutic mRNAs with a combination of nucleotide modifications that reduce the innate immune response and sequence optimization within the open reading frame (ORF) of the therapeutic mRNA encoding the immune-modulating polypeptide to enhance protein expression, among other things.

[0005] In another aspect, the disclosed mRNA therapy technology features delivery of mRNA(s) encoding immunomodulatory (e.g., oncology-related) polypeptides via a lipid nanoparticle (LNP) delivery system. In an exemplary embodiment, the disclosed mRNA therapy technology features delivery of mRNA(s) encoding immunomodulatory polypeptides to tumors via a lipid nanoparticle (LNP) delivery system. The disclosure also features novel ionic lipid-based LNPs with improved properties, e.g., cellular uptake, intracellular trafficking, and / or endosomal release or endosomal escape, when administered in vivo in combination with mRNA(s) encoding immunomodulatory (e.g., oncology-related) polypeptides. The disclosed LNP formulations also demonstrate reduced immunogenicity associated with in vivo administration of LNPs.

[0006] Accordingly, the present disclosure features methods and compositions for treating cancer, particularly immunotherapy methods and compositions. In some embodiments, the present disclosure features methods and compositions for treating cancer using combination therapy featuring two or more immune-modulating (e.g., oncology-related) polynucleotides (e.g., mRNAs) encoding a first immune response primer polypeptide and a second, different immune response primer polypeptide, and optionally a polynucleotide encoding an immune response costimulatory signal polypeptide, and optionally a polynucleotide encoding a checkpoint inhibitor polypeptide or a polypeptide comprising a checkpoint inhibitor polypeptide. In some embodiments, the present disclosure provides an immune-modulating composition comprising a polynucleotide encoding an interleukin-23 (IL-23) polypeptide, a polynucleotide encoding an interleukin-36 gamma (IL-36 gamma) polypeptide, and optionally a polynucleotide encoding an OX40L polypeptide. In other embodiments, the present disclosure provides an immune-modulating composition comprising a polynucleotide encoding an IL-23 polypeptide, a polynucleotide encoding an interleukin-18 (IL-18) polypeptide, and optionally a polynucleotide encoding an OX40L polypeptide.

[0007] Other aspects of the present disclosure feature treatments using polynucleotide mRNA encoding an IL-23 polypeptide in combination with mRNA encoding an IL-36 polypeptide. Other aspects of the present disclosure feature treatments using mRNA encoding an IL-23 polypeptide in combination with mRNA encoding an IL-18 polypeptide. Still other aspects of the present disclosure feature treatments using mRNA encoding an immune response primer polypeptide in combination with an additional therapeutic agent, such as a checkpoint inhibitor polypeptide (e.g., an anti-PD-1 antibody, an anti-PDL-1 antibody, an anti-CTLA4 antibody, or a combination thereof). An exemplary embodiment features treatments using mRNA encapsulated in lipid nanoparticles (LNPs). An exemplary embodiment features intratumoral administration of mRNA in ionic amino lipid-based LNPs.

[0008] In some embodiments, the present disclosure provides a method of reducing or decreasing tumor size or inhibiting tumor growth in a subject in need thereof, wherein the at least two polynucleotides are selected from a first polynucleotide encoding a first immune response primer polypeptide (e.g., an IL-23 polypeptide) and a second polynucleotide encoding a second immune response primer polypeptide (different from the first), e.g., an IL-36 gamma polypeptide or an IL-18 polypeptide, and optionally a third polynucleotide encoding an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

[0009] In one embodiment, the first polynucleotide comprises an mRNA encoding a first polypeptide, the second polynucleotide comprises an mRNA encoding a second polypeptide, and / or the third polynucleotide comprises an mRNA encoding a third polypeptide. In one embodiment, the first polynucleotide, the second polynucleotide, and / or the third polynucleotide comprises at least one chemically modified nucleoside. In some embodiments, the at least one chemically modified nucleoside is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and combinations thereof.

[0010] In one embodiment, the disclosure provides a composition, e.g., an immunomodulatory composition, comprising at least two polynucleotides (e.g., at least two mRNAs), wherein the at least two polynucleotides are: (i) at least one polynucleotide encoding a first immune response primer polypeptide and at least one polynucleotide encoding a second immune response primer polypeptide (different from the first immune response primer polypeptide) ("two agents"); (ii) at least one polynucleotide encoding a first immune response primer polypeptide, at least one polynucleotide encoding a second immune response primer polypeptide (different from the first), and at least one polynucleotide encoding an immune response costimulatory signal polypeptide (the "triple agent"); The present invention provides a composition selected from the group consisting of:

[0011] In some embodiments, the composition further comprises at least one polynucleotide encoding a checkpoint inhibitor polypeptide. In some embodiments, the composition is administered to a subject in need thereof in combination with another cancer therapy, such as a polypeptide comprising a checkpoint inhibitor polypeptide (e.g., an anti-PD-L1 antibody, an anti-PDL-1 antibody, an anti-CTLA4 antibody, or a combination thereof).

[0012] In one embodiment, the composition comprises at least one polynucleotide (e.g., mRNA) encoding a first immune response primer polypeptide and at least one polynucleotide (e.g., mRNA) encoding a second immune response primer polypeptide (different from the first immune response primer polypeptide), wherein the first and second immune response primer polypeptides are (a) stimulating dendritic cells; (b) promoting the maturation of dendritic cells; (c) promoting antigen-presenting cell cytokine and / or chemokine production; (d) expanding or maintaining Th17 cells; (e) enhancing Th1 and / or Th9 differentiation; and (f) Any combination of (a) to (f) The compound has one or more activities selected from the group consisting of:

[0013] In one aspect, the immune response primer polypeptide is a member of the IL-12 family. In one embodiment, the member of the IL-12 family is a polypeptide selected from the group consisting of IL-12, IL-23, IL-12p40 subunit, IL-23p19 subunit, IL-27, IL-35, and combinations thereof. In one embodiment, the immune response primer polypeptide is IL-23. In one embodiment, the IL-23 polypeptide comprises the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, or SEQ ID NO: 140. In one embodiment, the IL-23 polypeptide is encoded by a nucleotide sequence comprising the nucleotide sequence set forth in SEQ ID NO: 141 or 142.

[0014] In another aspect, the immune response primer polypeptide is a member of the IL-1 family. In one embodiment, the IL-1 family member is a polypeptide selected from the group consisting of IL-1α, IL-1β, IL-1Ra, IL-18, IL-33, IL-36Ra, IL-36α, IL-36β, IL-36γ, IL-37, IL-38, and combinations thereof. In one embodiment, the immune response primer polypeptide is an IL-36 gamma polypeptide or an IL-18 polypeptide. In one embodiment, the IL-36 gamma polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 16. In one embodiment, the IL-36 gamma polypeptide is encoded by a nucleotide sequence comprising the nucleotide sequence set forth in SEQ ID NO: 143 or 144. In one embodiment, the immune response primer polypeptide is IL-18. In one embodiment, the IL-18 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 147, 149, 151, or 153. In one embodiment, the IL-18 polypeptide is encoded by a nucleotide sequence selected from SEQ ID NOs: 148 and 155-162.

[0015] In one aspect, the disclosure provides a composition (e.g., an immunomodulatory composition) comprising at least two polynucleotides (e.g., two mRNAs) encoding a first immune response primer polypeptide and a second immune response primer polypeptide, wherein the first immune response primer polypeptide is a member of the IL-12 family and the second immune response primer polypeptide is a member of the IL-1 family. In one embodiment, the first immune response primer polypeptide is an IL-23 polypeptide and the second immune response primer polypeptide is an IL-36-gamma polypeptide. In one embodiment, the first immune response primer polypeptide is an IL-23 polypeptide and the second immune response primer polypeptide is an IL-18 polypeptide.

[0016] In another aspect, the disclosure provides a composition (e.g., an immunomodulatory composition) comprising at least three polynucleotides (e.g., three mRNAs) encoding at least one polynucleotide encoding a first immune response primer polypeptide, at least one polynucleotide encoding a second immune response primer polypeptide (different from the first), and at least one polynucleotide encoding an immune response costimulatory signal polypeptide. In some embodiments, the immune response costimulatory signal polypeptide is (a) activating, stimulating, promoting, or enhancing T cell proliferation, T cell survival, T cell recruitment, or a combination thereof; and / or (b) activating, stimulating, promoting or enhancing NK cell proliferation, NK cell survival, NK cell recruitment, or a combination thereof; and has at least one activity selected from the group consisting of:

[0017] In some embodiments, the immune response co-stimulatory signal polypeptide is (c) promoting or enhancing T cell proliferation and / or function; (d) promoting or enhancing Th1, Th2 and / or Th9 cell development; (e) inhibiting or inhibiting the development and / or activity of Tregs; (f) promoting or enhancing the development and / or activity of memory cells; and (g) Any combination of (c) to (f) and has at least one activity selected from the group consisting of:

[0018] In one embodiment, the immune response costimulatory signal polypeptide is selected from the group consisting of OX40L, CD80, IL-15, and combinations thereof. In one embodiment, the immune response costimulatory signal polypeptide is selected from the group consisting of OX40L, CD80, IL-15, and combinations thereof. In one embodiment, the immune response costimulatory signal polypeptide is OX40L. In one embodiment, the OX40L polypeptide comprises the amino acid sequence set forth in SEQ ID NO:21. In one embodiment, the OX40L polypeptide is encoded by a nucleotide sequence comprising the nucleotide sequence set forth in SEQ ID NO:145 or 146.

[0019] In one aspect, the disclosure provides a composition (e.g., an immunomodulatory composition) comprising at least three polynucleotides (e.g., three mRNAs) encoding a first immune response primer polypeptide, a second immune response primer polypeptide, and an immune response costimulatory signal polypeptide, wherein the first immune response primer polypeptide is an IL-23 polypeptide, the second immune response primer polypeptide is an IL-18 polypeptide, and the immune response costimulatory signal polypeptide is OX-40L. In another aspect, the disclosure provides a composition (e.g., an immunomodulatory composition) comprising at least three polynucleotides (e.g., three mRNAs) encoding a first immune response primer polypeptide, a second immune response primer polypeptide, and an immune response costimulatory signal polypeptide, wherein the first immune response primer polypeptide is an IL-23 polypeptide, the second immune response primer polypeptide is an IL-36-gamma polypeptide, and the immune response costimulatory signal polypeptide is OX-40L. In other embodiments, the composition further comprises a polynucleotide (e.g., mRNA) encoding a checkpoint inhibitor polypeptide.

[0020] In other embodiments, the present disclosure provides a composition for reducing tumor size or inhibiting tumor growth, comprising at least two polynucleotides (e.g., two mRNAs) encoding at least a first and a second polypeptide, wherein the at least two polynucleotides are: (i) a polynucleotide encoding an IL-23 polypeptide; (ii) a polynucleotide encoding an IL-36 gamma polypeptide; (iii) a polynucleotide encoding an IL-18 polypeptide; (iv) a polynucleotide encoding an OX40L polypeptide; (v) a polynucleotide encoding a CD80 polypeptide; (vi) a polynucleotide encoding an anti-CTLA4 antibody, and (vii) any combination thereof The present invention provides a composition selected from the group consisting of:

[0021] In one embodiment, the at least two polynucleotides are (i) a polynucleotide encoding an IL-23 polypeptide; (ii) a polynucleotide encoding an IL-36 gamma polypeptide; (iii) a polynucleotide encoding an IL-18 polypeptide; (iv) a polynucleotide encoding an OX40L polypeptide, and (v) any combination of these is selected from the group consisting of:

[0022] In yet another embodiment, the at least two polynucleotides are (i) a polynucleotide encoding an IL-23 polypeptide; (ii) a polynucleotide encoding an IL-36 gamma polypeptide; (iii) a polynucleotide encoding an OX40L polypeptide, and (iv) any combination of these is selected from the group consisting of:

[0023] In another embodiment, the at least two polynucleotides are (i) a polynucleotide encoding an IL23 polypeptide and a polynucleotide encoding an IL36 gamma polypeptide; (ii) a polynucleotide encoding an IL23 polypeptide and a polynucleotide encoding an OX40L polypeptide; (iii) a polynucleotide encoding an IL36 gamma polypeptide, and a polynucleotide encoding an OX40L polypeptide; (iv) a polynucleotide encoding an IL23 polypeptide and a polynucleotide encoding an IL18 polypeptide; (v) a polynucleotide encoding an IL36 gamma polypeptide and a polynucleotide encoding an IL18 polypeptide; and (vi) a polynucleotide encoding an IL18 polypeptide and a polynucleotide comprising an OX40L polypeptide is selected from the group consisting of:

[0024] In another embodiment, the present disclosure provides a composition for reducing gastric tumor size or inhibiting tumor growth, comprising at least three polynucleotides (e.g., three mRNAs) encoding at least a first, second, and third polypeptide, wherein the at least three polynucleotides are: (i) a polynucleotide encoding an IL23 polypeptide, a polynucleotide encoding an IL36 gamma polypeptide, and a polynucleotide encoding an OX40L polypeptide; and (ii) a polynucleotide encoding an IL23 polypeptide, a polynucleotide encoding an IL18 polypeptide, and a polynucleotide encoding an OX40L polypeptide The present invention provides a composition selected from the group consisting of:

[0025] In some embodiments, the polynucleotide encoding an IL-23 polypeptide comprises (i) an IL-12p40 polypeptide, (ii) an IL-23p19 polypeptide, or (iii) both an IL-12p40 polypeptide and an IL-23p19 polypeptide. In one embodiment, the polynucleotide encoding an IL-23 polypeptide comprises an IL-12p40 polypeptide, an IL-23p19 polypeptide, and a linker operably positioned between the IL-12p40 polypeptide and the IL-23p19 polypeptide. In one embodiment, the linker is a Gly / Ser linker (e.g., G4S) having an amino acid sequence set forth in any of SEQ ID NOs: 136-139. In one embodiment, the polynucleotide encoding an IL-23 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 140. In another embodiment, the polynucleotide encoding an IL-23 polypeptide comprises the nucleotide sequence set forth in SEQ ID NO: 141.

[0026] In some embodiments, the polynucleotide encoding the IL-18 polypeptide comprises a heterologous signal sequence. In one embodiment, the polynucleotide encoding the IL-18 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 147, 149, 151, or 153. In one embodiment, the polynucleotide encoding the IL-18 polypeptide comprises a nucleotide sequence selected from SEQ ID NOs: 148 and 155-162.

[0027] In some embodiments, the polynucleotide encoding the IL-36 gamma polypeptide comprises a heterologous signal sequence. In one embodiment, the polynucleotide encoding the IL36-gamma polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 16. In one embodiment, the polynucleotide encoding the IL-36 gamma polypeptide comprises the nucleotide sequence set forth in SEQ ID NO: 143.

[0028] In one aspect, the polynucleotide encoding the OX40L polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 21. In one embodiment, the polynucleotide encoding the OX40L polypeptide comprises the nucleotide sequence set forth in SEQ ID NO: 145.

[0029] In one aspect, the present disclosure provides a composition for, e.g., reducing tumor size or inhibiting tumor growth, comprising at least three polynucleotides (e.g., three mRNAs) encoding at least a first, second, and third polypeptide, wherein the at least three polynucleotides comprise a first polynucleotide encoding OX40L, a second polynucleotide encoding an IL-23 polypeptide, and a third polynucleotide encoding IL-36 gamma, and wherein the first, second, and third polynucleotides are present in the composition in a mass ratio of approximately 1:1:2, respectively. In one embodiment, the first and second polynucleotides encoding OX40L and IL-23, respectively, are present in the composition in approximately equal masses, and the third polynucleotide encoding IL-36 gamma is present in the composition in a mass greater amount than the first and third polynucleotides. Additional mass ratios for compositions are disclosed herein.

[0030] Other aspects of the present disclosure relate to lipid nanoparticles comprising any of the above-mentioned or related compositions.In some embodiments, the lipid nanoparticles are formulated with pharmaceutically acceptable carriers or excipients.In some embodiments, the lipid nanoparticles are formulated for intratumoral administration (iTu).

[0031] In one embodiment, the present disclosure provides a lipid nanoparticle comprising: A polynucleotide encoding a human OX40L polypeptide, the polynucleotide comprising an ORF encoding the human OX40L polypeptide; a polynucleotide encoding a human IL23 polypeptide, the polynucleotide comprising an ORF encoding a human IL-12p40 polypeptide operably linked to a human IL-23p19 polypeptide; and a polynucleotide encoding a human IL-36 gamma polypeptide, the polynucleotide comprising an ORF encoding the human IL-36 gamma polypeptide.

[0032] In some embodiments, the human IL-12p40 polypeptide is operably linked to the human IL-23p19 polypeptide via a peptide linker. In some embodiments, the IL-12p40 polypeptide is positioned at the 5' end of the IL-23p19 polypeptide or linker (e.g., a peptide linker). In other embodiments, the IL-12p40 polypeptide is positioned at the 5' end of the IL-23p19 polypeptide or linker (e.g., a peptide linker). In some embodiments, the linker is a peptide linker, e.g., a Gly / Ser linker (e.g., G6S). In some embodiments, the Gly / Ser linker comprises (GnS)m, where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20, and m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20. In some embodiments, the Gly / Ser linker comprises (GnS)m, where n is 6 and m is 1 (ie, G6S).

[0033] In related embodiments, the polynucleotide comprising an ORF encoding a human IL23 polypeptide or the polynucleotide comprising an ORF encoding a human IL-36 gamma polypeptide further comprises a signal peptide. In some embodiments, the signal peptide is a heterologous signal peptide, for example, a signal peptide derived from the human immunoglobulin kappa light chain variable region (hIGVK4).

[0034] In some embodiments, the human OX40L polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 21. In some embodiments, the human IL-12p40 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 1. In some embodiments, the human IL-23p19 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the human IL-36 gamma polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 16.

[0035] In some embodiments, the present disclosure provides any of the above-mentioned or related polynucleotides, further comprising one or more microRNA (miRNA) binding sites. In some embodiments, the miRNA binding site is a miR-122 binding site (e.g., a miR-122-3p binding site, a miR-122-5p binding site, or both). In some embodiments, the miR binding site is at least one miR-122-5p binding site. In some embodiments, the polynucleotide comprises a 3'UTR comprising at least one miR-122-5p binding site. In some embodiments, the miR-122-5p binding site comprises the nucleotide sequence set forth in SEQ ID NO: 126. In some embodiments, the polynucleotide comprises a 3'UTR comprising the nucleotide sequence set forth in SEQ ID NO: 120. In one embodiment, the polynucleotide comprises a 5'UTR comprising the nucleotide sequence set forth in SEQ ID NO: 27.

[0036] In another aspect, the disclosure provides use of any of the compositions described above or below or lipid nanoparticles described herein in the manufacture of a medicament for treating or delaying the progression of cancer in an individual, wherein the medicament comprises the composition or lipid nanoparticle and an optional pharmaceutically acceptable carrier, and the treatment comprises administering the medicament in combination with a composition comprising a checkpoint inhibitor polypeptide (e.g., an anti-PD-1 antibody, an anti-PDL-1 antibody, an anti-CTLA4 antibody, or a combination thereof) and an optional pharmaceutically acceptable carrier.

[0037] In some embodiments, the present disclosure provides a kit comprising a container containing a polynucleotide (e.g., mRNA) composition disclosed herein or lipid nanoparticles comprising a polynucleotide (e.g., mRNA) and an optional pharmaceutically acceptable carrier, and a package insert comprising instructions for administering the lipid nanoparticles or pharmaceutical composition to treat or delay the progression of cancer in an individual. In some embodiments, the package insert further comprises instructions for administering the pharmaceutical composition in combination with a composition comprising a checkpoint inhibitor polypeptide and an optional pharmaceutically acceptable carrier to treat or delay the progression of cancer in an individual.

[0038] In still other aspects, the present disclosure provides kits comprising a pharmaceutical agent comprising any of the compositions or lipid nanoparticles described herein above or below and an optional pharmaceutically acceptable carrier, and a package insert containing instructions for administering the pharmaceutical agent alone or in combination with a composition comprising a checkpoint inhibitor polypeptide (e.g., an anti-PD-1 antibody, an anti-PDL-1 antibody, an anti-CTLA4 antibody, or a combination thereof) and an optional pharmaceutically acceptable carrier to treat or delay the progression of cancer in an individual. In some embodiments, the kit further comprises a package insert containing instructions for administering the first pharmaceutical agent and the second pharmaceutical agent to treat or delay the progression of cancer in an individual.

[0039] Another aspect of the present disclosure relates to a composition comprising any of the lipid nanoparticles described herein above or below and an optional pharmaceutically acceptable carrier, for use in treating or delaying the progression of cancer in an individual, wherein the treatment comprises administering the lipid nanoparticles in combination with a second composition, the second composition comprising a checkpoint inhibitor polypeptide (e.g., an anti-PD-1 antibody, an anti-PDL-1 antibody, an anti-CTLA4 antibody, or a combination thereof) and an optional pharmaceutically acceptable carrier.

[0040] In some embodiments, the checkpoint inhibitor polypeptide inhibits PD1, PD-L1, CTLA4, or a combination thereof. In one embodiment, the checkpoint inhibitor polypeptide is an antibody or a polynucleotide encoding an antibody. In one embodiment, the antibody is an anti-CTLA4 antibody or antigen-binding fragment thereof that specifically binds CTLA4, an anti-PD1 antibody or antigen-binding fragment thereof that specifically binds PD1, an anti-PD-L1 antibody or antigen-binding fragment thereof that specifically binds PD-L1, or a combination thereof. In one embodiment, the anti-PD-L1 antibody is atezolizumab, avelumab, or durvalumab. In one embodiment, the anti-CTLA4 antibody is tremelimumab or ipilimumab. In one embodiment, the anti-PD1 antibody is nivolumab or pembrolizumab.

[0041] In various embodiments of the composition, the polynucleotides in the composition are mRNAs each comprising at least one chemical modification. In one embodiment, the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methyluridine, 5-methoxyuridine, and 2'-O-methyluridine. In some embodiments, the mRNA comprises at least one chemically modified nucleoside selected from the group consisting of pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and combinations thereof. In some embodiments, the at least one chemically modified nucleoside is N1-methylpseudouridine. In some embodiments, the polynucleotide is a fully modified N1-methylpseudouridine mRNA. Additional chemical modifications are disclosed herein.

[0042] In various embodiments of the composition, the composition is formulated in a lipid nanoparticle carrier. For example, as described herein, a composition comprising a first and second polynucleotide, and optionally a third polynucleotide, is formulated so that all of the polynucleotides in the composition are carried by the same lipid nanoparticle carrier. In one embodiment, the lipid nanoparticle carrier comprises a molar ratio of approximately 20-60% ionizable amino lipid, 5-25% phospholipid, 25-55% sterol, and 0.5-15% PEG-modified lipid. In one embodiment, the ionizable amino lipid is selected from the group consisting of, for example, 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319). In one embodiment, the ionic amino lipid is compound 18.

[0043] In another embodiment, the lipid nanoparticles comprise a molar ratio of about 20-60% ionic amino lipid, 5-25% phospholipid, 25-55% sterol, and 0.5-15% PEG-modified lipid. In another embodiment, the lipid nanoparticle carrier comprises a molar ratio of about 20-60% Compound 18, 5-25% phospholipid, 25-55% cholesterol, and 0.5-15% PEG-modified lipid. In another embodiment, the lipid nanoparticle carrier comprises a molar ratio of about 50% ionic amino lipid, about 10% phospholipid, about 38.5% cholesterol, and about 1.5% PEG-modified lipid. In another embodiment, the lipid nanoparticle carrier comprises a molar ratio of about 50% Compound 18, about 10% phospholipid, about 38.5% cholesterol, and about 1.5% PEG-modified lipid. In another embodiment, the lipid nanoparticle carrier comprises a molar ratio of about 49.83% ionic amino lipid, about 9.83% phospholipid, about 30.33% cholesterol, and about 2.0% PEG-modified lipid. In another embodiment, the lipid nanoparticle carrier comprises a molar ratio of about 49.83% Compound 18, about 9.83% phospholipid, about 30.33% cholesterol, and about 2.0% PEG-modified lipid.

[0044] In another aspect, the present invention relates to a method for reducing or decreasing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering any of the compositions described herein to the subject. In one embodiment, the composition is administered intratumorally. In another embodiment, the composition is administered regionally (i.e., to the area where the tumor is growing), for example, the composition can be administered intraperitoneally to a tumor in the peritoneal cavity. In one embodiment, the tumor is hepatocellular carcinoma. In another embodiment, the tumor is an ovarian tumor, a colon tumor, or a disseminated gastric tumor. Other tumors and cancers suitable for treatment are described herein.

[0045] In some embodiments, the IL-23 polypeptide comprises an IL-12p40 subunit comprising an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to a sequence listed in Table 1, which amino acid sequence is capable of binding to an IL-23p19 subunit to form IL-23 having IL-23 activity. In other embodiments, the IL-23 polypeptide comprises an IL-23p19 subunit comprising an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to a sequence listed in Table 1, which amino acid sequence is capable of binding to an IL-12p40 subunit to form IL-23 having IL-23 activity. In some embodiments, the IL-12p40 subunit and the IL-23P19 subunit are on a single polypeptide chain or on two different chains.

[0046] In some embodiments, the IL-36-gamma polypeptide comprises an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to a sequence listed in Table 1, and that has IL-36-gamma activity.

[0047] In some embodiments, the methods of the present disclosure further include administering a third protein or a third polynucleotide encoding the third protein. In one embodiment, the third protein comprises an OX40L polypeptide. In another embodiment, the OX40L polypeptide comprises an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to a sequence listed in Table 1A, and having OX40L activity.

[0048] In certain embodiments, the first polynucleotide (e.g., mRNA), the second polynucleotide (e.g., mRNA), and / or the third polynucleotide (e.g., mRNA) further comprises a nucleic acid sequence comprising an miRNA binding site, e.g., miR-122, e.g., aacgccauua ucacacuaaa ua (SEQ ID NO: 23) or uggaguguga caaugguguu ug (SEQ ID NO: 25).

[0049] The first polynucleotide and / or the second polynucleotide and / or the third polynucleotide can further comprise a 5' UTR, a 3' UTR, a 5' cap, and / or a 3' poly-A tail. In other embodiments, the first polynucleotide (e.g., mRNA), the second polynucleotide (e.g., mRNA), and / or the third polynucleotide (e.g., mRNA) are codon-optimized, in vitro transcribed, chimeric, or circular.

[0050] In some embodiments, the first polynucleotide (e.g., mRNA), the second polynucleotide (e.g., mRNA), and / or the third polynucleotide (e.g., mRNA) are formulated with a delivery agent, e.g., lipid nanoparticles. In other embodiments, the delivery agent is a polypeptide represented by Formula (I):

[0051] [ka]

[0052] or a salt or stereoisomer thereof, wherein R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR" or R2 and R3 taken together with the atoms to which they are attached form a heterocyclic or carbocyclic ring; R4 is C 3~6 Carbocyclic ring, -(CH2) n Q, (CH2) n CHQR, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, wherein Q is a carbocycle, a heterocycle, -OR, -O(CH) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -N(R)2, -C(O)N(R)2, -N( R)C(O)R, -N(R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -N(R)R8, -O(CH2) n -OR, -N(R)C(=NR9)N(R), -N(R)C(=CHR9)N(R), -OC(O)N(R), -N(R)C(O)OR, -N(OR)C(O)R, -N(OR)S(O)R, -N(OR)C(O)OR, -N(OR)C(O)N(R), -N(OR)C(S)N(R), -N(OR)C(=NR9)N(R), -N(OR)C(=CHR9)N(R), -C(=NR9)N(R), -C(=NR9)R, -C(O)N(R)OR, and -C(R)N(R)C(O)OR; each n is independently selected from 1, 2, 3, 4, and 5; Each R5 is independently 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)2-, -SS-, an aryl group, and a heteroaryl group; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8 is C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; Each R is independently 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * selected from the group consisting of Y-R″, -Y-R″, and H; Each R" is independently 3~14 Alkyl and C 3~14 alkenyl, Each R * independently, C 1~12 Alkyl and C 2~12 alkenyl, Each Y is independently 3~6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; However, R4 is -(CH2) n Q, -(CH2) nWhen CHQR, -CHQR, or -CQ(R), (i) when n is 1, 2, 3, 4, or 5, Q is not -N(R), or (ii) when n is 1 or 2, Q is not a 5-, 6-, or 7-membered heterocycloalkyl.

[0053] In other embodiments, the delivery agent has formula (I):

[0054] [ka]

[0055] or a salt or stereoisomer thereof, wherein R1 is C 5~20 Alkyl, C 5~20 Alkenyl, -R * -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR" or R2 and R3 taken together with the atoms to which they are attached form a heterocyclic or carbocyclic ring; R4 is C 3~6 Carbocyclic ring, -(CH2) n Q, (CH2) n CHQR, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, wherein Q is a carbocycle, a heterocycle, -OR, -O(CH) n selected from the group consisting of N(R), -C(O)OR, -OC(O)R, -CX, -CXH, -CXH, -CN, -N(R), -C(O)N(R), -N(R)C(O)R, -N(R)S(O)R, -N(R)C(O)N(R), -N(R)C(S)N(R), and -C(R)N(R)C(O)OR, wherein each n is independently selected from 1, 2, 3, 4, and 5; Each R5 is independently 1~3 Alkyl, C 2~3selected from the group consisting of alkenyl, and H; Each R6 is independently 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)-, an aryl group, and a heteroaryl group; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R is independently 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * selected from the group consisting of Y-R″, -Y-R″, and H; Each R" is independently 3~14 Alkyl and C 3~14 alkenyl, Each R * independently, C 1~12 Alkyl and C 2~12 alkenyl, Each Y is independently 3~6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; However, R4 is -(CH2) n Q, -(CH2) n When CHQR, -CHQR, or -CQ(R), (i) when n is 1, 2, 3, 4, or 5, Q is not -N(R), or (ii) when n is 1 or 2, Q is not a 5-, 6-, or 7-membered heterocycloalkyl.

[0056] In some embodiments, the compound has the formula (IA):

[0057] [ka]

[0058] or a salt or stereoisomer thereof, wherein: l is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M1 is a bond or M'; R4 is an unsubstituted C 1~3 Alkyl, or -(CH2) n Q, wherein n is 1, 2, 3, 4, or 5, and Q is OH, —NHC(S)N(R), or —NHC(O)N(R), —NHC(O)N(R), —N(R)C(O)R, —N(R)S(O)R, —N(R)R, —NHC(═NR)N(R), —NHC(═CHR)N(R), —OC(O)N(R), —N(R)C(O)OR, heteroaryl, or heterocycloalkyl; M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -P(O)(OR')O-, -SS-, an aryl group, and a heteroaryl group; R2 and R3 are independently H, C 1~14 Alkyl, and C 2~14 alkenyl.

[0059] In some embodiments, m is 5, 7, or 9. In some embodiments, the compound is of formula (IA) or a salt or stereoisomer thereof, wherein: l is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M1 is a bond or M'; R4 is an unsubstituted C 1~3 Alkyl, or -(CH2) nQ, where n is 1, 2, 3, 4, or 5, and Q is OH, —NHC(S)N(R), or —NHC(O)N(R); M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -P(O)(OR')O-, an aryl group, and a heteroaryl group; and R2 and R3 are independently H, C 1~14 Alkyl, and C 2~14 alkenyl.

[0060] In some embodiments, m is 5, 7, or 9. In some embodiments, the compound has the formula (II):

[0061] [ka]

[0062] or a salt or stereoisomer thereof, wherein: l is selected from 1, 2, 3, 4, and 5; M1 is a bond or M'; R4 is an unsubstituted C 1~3 Alkyl, or -(CH2) n Q, where n is 2, 3, or 4, and Q is OH, —NHC(S)N(R), or —NHC(O)N(R), —N(R)C(O)R, —N(R)S(O)R, —N(R)R, —NHC(═NR)N(R), —NHC(═CHR)N(R), —OC(O)N(R), —N(R)C(O)OR, heteroaryl, or heterocycloalkyl; M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -P(O)(OR')O-, -SS-, an aryl group, and a heteroaryl group; and R2 and R3 are independently H, C 1~14 Alkyl, and C 2~14 alkenyl.

[0063] In some embodiments, the compound is of Formula (II), or a salt or stereoisomer thereof, wherein: l is selected from 1, 2, 3, 4, and 5; M1 is a bond or M'; R4 is an unsubstituted C 1~3 Alkyl, or -(CH2) n Q, where n is 2, 3, or 4, and Q is OH, —NHC(S)N(R)2, or —NHC(O)N(R)2; M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -P(O)(OR')O-, an aryl group, and a heteroaryl group; and R2 and R3 are independently H, C 1~14 Alkyl, and C 2~14 alkenyl.

[0064] In some embodiments, M1 is M'. In some embodiments, M and M' are independently -C(O)O- or -OC(O)-.

[0065] In some embodiments, 1 is 1, 3, or 5. In some embodiments, the compound is selected from the group consisting of Compounds 1 through 232, their salts and stereoisomers, and any combination thereof. In some embodiments, the compound is selected from the group consisting of Compounds 1 through 147, their salts and stereoisomers, and any combination thereof.

[0066] In certain embodiments, the delivery agent has formula (IIa):

[0067] [ka]

[0068] or a salt or stereoisomer thereof. In certain embodiments, the delivery agent has formula (IIb):

[0069] [ka]

[0070] or a salt or stereoisomer thereof. In certain embodiments, the delivery agent has formula (IIc) or (IIe)

[0071] [ka]

[0072] or a salt or stereoisomer thereof. In some embodiments, R4 is as described herein. In some embodiments, R4 is -(CH2) n Q and -(CH2) n Selected from CHQR.

[0073] In certain embodiments, the delivery agent has formula (IId):

[0074] [ka]

[0075] or a salt or stereoisomer thereof, wherein n is selected from 2, 3, and 4, and m, R′, R″, and R2 through R6 are as described herein. For example, each of R2 and R3 can independently be C 5~14 Alkyl and C 5~14 alkenyl.

[0076] In some embodiments, the compound has Formula (IId), or a salt or stereoisomer thereof, wherein R and R are independently C 5~14 Alkyl and C 5~14alkenyl, n is selected from 2, 3, and 4, and R', R", R, R, and m are as described herein.

[0077] In some embodiments, R2 is C8 alkyl. In some embodiments, R3 is a C5 alkyl, a C6 alkyl, a C7 alkyl, a C8 alkyl, or a C9 alkyl.

[0078] In some embodiments, m is 5, 7, or 9. In some embodiments, each R5 is H. In some embodiments, each R6 is H.

[0079] In other embodiments, the delivery agent further comprises a phospholipid, a structured lipid, a PEG lipid, an ionic lipid, and / or a quaternary amine compound. The present disclosure further includes compositions comprising a first polynucleotide (e.g., mRNA) disclosed herein, a second polynucleotide (e.g., mRNA) disclosed herein, a third polynucleotide (e.g., mRNA) comprised herein, or combinations thereof, wherein the first polynucleotide, second polynucleotide, and / or third polynucleotide is formulated in a delivery agent disclosed herein.

[0080] The present disclosure further includes a composition comprising a first polynucleotide (e.g., mRNA) disclosed herein, a second polynucleotide (e.g., mRNA) disclosed herein, and a third polynucleotide (e.g., mRNA) disclosed herein, wherein the first polynucleotide, the second polynucleotide, and the third polynucleotide are formulated in a delivery agent disclosed herein.

[0081] The present disclosure also discloses kits that include the compositions disclosed herein and instructions for use in accordance with the methods disclosed herein. In some embodiments of the methods of the disclosure, administration of a composition of the disclosure, or a kit of the disclosure, a polynucleotide to a subject in need thereof results in (i) an increase in the level of granulocytes in one or more samples obtained from the subject after administration of the two or three agents relative to a threshold level or relative to the level after administration of a single polynucleotide encoding an IL-23, IL-36-gamma, or OX40L polypeptide; (ii) an increase in the level of cross-presenting dendritic cells in one or more samples obtained from the subject after administration of the two or three agents relative to a threshold level or relative to the level after administration of a single polynucleotide encoding an IL-23, IL-36-gamma, or OX40L polypeptide; (iii) an increase in the level of dendritic cells in one or more samples obtained from the subject after administration of the two or three agents relative to a threshold level or relative to the level after administration of a single polynucleotide encoding an IL-23, IL-36-gamma, or OX40L polypeptide; (iv) an increase in the effector:suppressor T cell ratio in one or more samples obtained from the subject after administration of the two or three drugs relative to the ratio after administration of a single polynucleotide encoding an OX40L polypeptide; (v) an increase in the level of effector memory T cells in one or more samples obtained from the subject after administration of the two or three drugs relative to a threshold level or relative to the level after administration of a single polynucleotide encoding an OX40L polypeptide; (v) an increase in the level of PDL1 expression in one or more samples obtained from the subject after administration of the two or three drugs relative to a threshold level or relative to the level after administration of a single polynucleotide encoding an IL-23, IL-36-gamma, or OX40L polypeptide; or (vi) a combination thereof.

[0082] The present disclosure provides a method of decreasing or reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to a subject in need thereof a composition comprising: (a) two polynucleotides in combination (two-agent), wherein a first polynucleotide encodes a first protein comprising an interleukin-23 polypeptide (IL-23) and a second polynucleotide encodes a second protein comprising an interleukin-36-gamma polypeptide (IL-36-gamma), or (b) three polynucleotides in combination (three-agent), wherein a first polynucleotide encodes a first protein comprising an IL-23 polypeptide, a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide, and a third polynucleotide encodes a third protein (OX40L) comprising an OX40L polypeptide, wherein administration of the two-agent or triple-agent to a subject results in: (i) a decrease in tumor size or tumor growth relative to a threshold level or a decrease in tumor size ... (ii) an increase in the level of cross-presenting dendritic cells in one or more samples obtained from the subject after administration of the two or three drugs relative to a threshold level or to a level after administration of a single polynucleotide encoding an IL-23, IL-36-gamma, or OX40L polypeptide; (iii) an increase in the effector:suppressor T cell ratio in one or more samples obtained from the subject after administration of the two or three drugs relative to a threshold level or to a ratio after administration of a single polynucleotide encoding an OX40L polypeptide; (iv) an increase in the level of effector memory T cells in one or more samples obtained from the subject after administration of the two or three drugs relative to a threshold level or to a level after administration of a single polynucleotide encoding an OX40L polypeptide; (v) an increase in PDL1 expression level in one or more samples obtained from the subject after administration of the two or three drugs relative to a threshold level or to a level after administration of a single polynucleotide encoding an IL-23, IL-36-gamma, or OX40L polypeptide.or (vi) a combination thereof. In some embodiments, the elevated granulocyte level is quantified as (i) granulocytes as a percentage of CD45+ cells, or (ii) granulocytes per mg of tumor. In some embodiments, the cross-presenting dendritic cells are CD103+ cells. In some embodiments, the elevated cross-presenting dendritic cell level is quantified as (i) cross-presenting dendritic cells per mg of tumor, (ii) cross-presenting CD103+ dendritic cells in tumor-draining lymph nodes (TdLNs), or (iii) cross-presenting CD103+ dendritic cells as a percentage of CD45+ cells. In some embodiments, the effector:suppressor T cell ratio is quantified as a CD8:Treg ratio. In some embodiments, the effector memory T cells are CD4+ and / or CD8+ cells. In some embodiments, the PDL1 expression level is quantified as (i) the number of positive CD11b+ cells, or (ii) PDL1 expression in CD11b+ cells. ,

[0083] The present disclosure also provides a method of increasing granulocyte levels in a subject in need thereof, comprising administering to the subject a composition comprising: (a) two polynucleotides in combination (a dual-agent), wherein a first polynucleotide encodes a first protein comprising an IL-23 polypeptide, and a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide, or (b) three polynucleotides in combination (a triple-agent), wherein a first polynucleotide encodes a first protein comprising an IL-23 polypeptide, a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide, and a third polynucleotide encodes a third protein comprising an OX40L polypeptide, wherein the granulocyte levels are measured in one or more samples obtained from the subject. In some embodiments, the increase in granulocyte levels is measured as (i) granulocytes as a percentage of CD45+ cells and / or (ii) granulocytes per mg of tumor relative to a threshold level or relative to the level after administration of a single polynucleotide encoding IL-23 or a single polynucleotide encoding IL-36-gamma.

[0084] The present disclosure also provides a method of increasing cross-presenting dendritic cell levels in a subject in need thereof, comprising administering to the subject a composition comprising: (a) two polynucleotides in combination (two-drug), wherein a first polynucleotide encodes a first protein comprising an IL-23 polypeptide, and a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide, or (b) three polynucleotides in combination (three-drug), wherein a first polynucleotide encodes a first protein comprising an IL-23 polypeptide, a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide, and a third polynucleotide encodes a third protein comprising an OX40L polypeptide, wherein the cross-presenting dendritic cell levels are measured in one or more samples obtained from the subject. In some embodiments, the cross-presenting dendritic cells are CD103+ cells. In some embodiments, the increase in the level of cross-presenting CD103+ dendritic cells is measured relative to a threshold level or relative to levels following administration of a single polynucleotide encoding IL-23, a single polynucleotide encoding IL-36-gamma, or a single polynucleotide encoding OX40L as (i) cross-presenting CD103+ dendritic cells per mg of tumor, (ii) cross-presenting CD103+ dendritic cells in TdLNs, (iii) cross-presenting CD103+ dendritic cells as a percentage of CD45+ cells, or (iv) a combination thereof.

[0085] The present disclosure also provides methods of increasing the effector:suppressor T cell ratio in a subject in need thereof, comprising administering to the subject a composition comprising: (a) two polynucleotides in combination (two-drug), wherein a first polynucleotide encodes a first protein comprising an IL-23 polypeptide, and a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide, or (b) three polynucleotides in combination (three-drug), wherein a first polynucleotide encodes a first protein comprising an IL-23 polypeptide, a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide, and a third polynucleotide encodes a third protein comprising an OX40L polypeptide, wherein the effector:suppressor T cell ratio is measured in one or more samples obtained from the subject. In some embodiments, the effector:suppressor T cell ratio is measured as a CD8:Treg ratio.

[0086] The present disclosure also provides methods of increasing effector memory T cell levels in a subject in need thereof, comprising administering to the subject a composition comprising: (a) two polynucleotides in combination (a two-drug), wherein a first polynucleotide encodes a first protein comprising an IL-23 polypeptide, and a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide, or (b) three polynucleotides in combination (a three-drug), wherein a first polynucleotide encodes a first protein comprising an IL-23 polypeptide, a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide, and a third polynucleotide encodes a third protein comprising an OX40L polypeptide, wherein the effector memory T cell levels are measured in one or more samples obtained from the subject. In some embodiments, the effector memory T cells are CD4+ and / or CD8+ cells. In some embodiments, an increase in effector memory T cell levels is measured as effector memory T cells within the tumor relative to a threshold level or relative to the level following administration of a single polynucleotide encoding OX40L.

[0087] The present disclosure also provides a method for increasing PDL1-positive cell levels in a subject in need thereof, comprising administering to the subject a composition comprising: (a) two polynucleotides in combination (two-drug), wherein a first polynucleotide encodes a first protein comprising an IL-23 polypeptide, and a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide; or (b) three polynucleotides in combination (three-drug), wherein a first polynucleotide encodes a first protein comprising an IL-23 polypeptide, a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide, and a third polynucleotide encodes a third protein comprising an OX40L polypeptide; wherein the PDL1-positive cell levels are measured in one or more samples obtained from the subject. In some embodiments, the PDL1-positive cells are CD11b+ cells.

[0088] In some embodiments of the methods disclosed herein, the sample obtained from the subject is selected from, for example, tumor tissue, tumor infiltrate, blood, plasma, or a combination thereof.Those skilled in the art will understand that any of the cells (e.g., granulocytes, cross-presenting dendritic cells, effector T cells, suppressor T cells, PDL1-positive cells, etc.) measured in the methods disclosed herein and the parameters corresponding to these measurements (e.g., absolute or relative levels of cells, ratios to other cells, levels of specific subtypes, activation levels, presence / absence of markers, etc.) can be measured in any tissue sample in which these cells exist using methods known in the art without undue experimentation.

[0089] In some embodiments of the methods disclosed herein, the one or more control samples are one or more samples obtained from healthy subjects or tumor-bearing subjects. In some embodiments, the threshold level is a predetermined value or a value obtained from one or more samples.

[0090] The present disclosure provides a method for treating a subject suffering from a neoplastic disease, comprising: (1) administering to the recipient an initial dose of two or three agents; and (2) treating the subject if, after administration of the initial dose of two or three agents, the subject is determined to have an elevation, relative to a threshold, in (a) the level of granulocytes, (b) the level of cross-presenting dendritic cells, (c) the effector:suppressor T cell ratio, (d) the level of effector memory T cells, (e) the level of PDL1 positive cells, (f) expression of PDL1, or (g) a combination thereof. The present disclosure provides a method for treating a subject suffering from a neoplastic disease, comprising: (a) administering to the recipient an initial dose of two or three agents; and (b) administering to the recipient an initial dose of two or three agents; and a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide (a dual-drug); or (b) three polynucleotides in combination (a triple-drug), wherein a first polynucleotide encodes a first protein comprising an IL-23 polypeptide, a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide, and a third polynucleotide encodes a third protein comprising an OX40L polypeptide.

[0091] The disclosure provides a method for treating a subject with a medicament for the treatment of a tumor, the method comprising: (1) administering to the subject an initial dose of two or three agents; and (2) selecting the subject for treatment if, after administration of the initial dose of two or three agents, the subject is determined to have an elevation in, with respect to a threshold level, (a) the level of granulocytes, (b) the level of cross-presenting dendritic cells, (c) the effector:suppressor T cell ratio, (d) the level of effector memory T cells, (e) the level of PDL1 positive cells, (f) PDL1 expression, or (g) a combination thereof, wherein (a) a first polynucleotide encodes a first protein comprising an IL-23 polypeptide and a second polynucleotide encodes a second protein comprising an IL-23 polypeptide, the method comprising: (1) administering to the subject an initial dose of two or three agents; and (2) selecting the subject for treatment if, after administration of the initial dose of two or three agents, the subject is determined to have an elevation in, with respect to a threshold level, (a) the level of granulocytes, (b) the level of cross-presenting dendritic cells, (c) the effector:suppressor T cell ratio, (d) the level of effector memory T cells, (e) the level of PDL1 positive cells, (f) PDL1 expression, or (g) a combination thereof. Also provided are methods for selecting a subject diagnosed with a tumor as a candidate for treatment with a composition comprising (a) two polynucleotides in combination (a dual-agent), wherein the nucleotides encode a second protein comprising an IL-36-gamma polypeptide, or (b) three polynucleotides in combination (a triple-agent), wherein a first polynucleotide encodes a first protein comprising an IL-23 polypeptide, a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide, and a third polynucleotide encodes a third protein comprising an OX40L polypeptide.

[0092] The present disclosure provides a method for measuring the efficacy of a composition for treating a tumor in a subject in need thereof, wherein the composition comprises: (a) two polynucleotides in combination (two agents), wherein a first polynucleotide encodes a first protein comprising an IL-23 polypeptide and a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide; or (b) a first polynucleotide encodes a first protein comprising an IL-23 polypeptide, a second polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide, and a third polynucleotide encodes a second protein comprising an IL-36-gamma polypeptide. and a third protein comprising an OX40L polypeptide, the third polynucleotide encoding the third protein comprising the OX40L polypeptide. The method also provides a method for treating a subject comprising measuring, in at least one sample taken from the subject, (a) levels of granulocytes, (b) levels of cross-presenting dendritic cells, (c) effector:suppressor T cell ratio, (d) levels of effector memory T cells, (e) levels of PDL1-positive cells, (f) expression of PDL1, or (g) a combination thereof, wherein an increase in at least one of the measurements relative to a threshold level indicates that the subject is responding to treatment with the two- or three-drug regimen. [Effects of the Invention]

[0093] As described above, the present invention provides an mRNA therapeutic agent for treating cancer. [Brief explanation of the drawings]

[0094] [Figure 1] A and B show the efficacy of IL-23 mRNA monotherapy in an A20 lymphoma animal model. A shows treatment with NST-FIX control (2.5 μg mRNA). A complete response was observed in 1 of 12 subjects (8.3%). B shows treatment with mIL-23 miRless (2.5 μg mRNA). A complete response was observed in 5 of 12 subjects (41.6%). Dosing conditions: 2.5 μg mRNA, intratumoral (iTu) administration, compound 18-based lipid nanoparticles (SM68 LNP). NST-FIX is a negative control mRNA. [Figure 2] A and B show the efficacy of IL-23 mRNA monotherapy in the MC38-C colon cancer animal model. A shows treatment with NST-OX40L (2.5 μg mRNA). B shows treatment with mIL-23 mRNA (2.5 μg mRNA) lacking the miR binding site in the 3'UTR, i.e., "miRless." Complete responses were observed in 4 of 10 subjects (40%). Partial responses were observed in 2 of 10 subjects (20%). Dosing conditions: 2.5 μg mRNA, iTu, Compound 18-based LNP. NST-OX40L is a negative control mRNA. [Figure 3-1] Figures A-F show that the addition of mRNA encoding either IL-36-gamma or IL-18 to IL-23 mRNA therapy enhances efficacy in the MC38-C colon cancer model. Figure A shows treatment with mRNA encoding IL-23 and NST-FIX (2.5 μg each). A complete response was observed in 3 of 10 subjects (30%). A partial response was observed in 6 of 10 subjects (60%). Figure B shows treatment with mRNA encoding IL-23 (2.5 μg each) in combination with mRNA encoding IL-36-gamma. A complete response was observed in 9 of 10 subjects (90%). A partial response was observed in 1 of 10 subjects (10%). Figure C shows treatment with mRNA encoding IL-23 (2.5 μg each) in combination with mRNA encoding IL-18. Complete responses were observed in 6 of 10 subjects (60%). Partial responses were observed in 3 of 10 subjects (30%). D shows treatment with NST-FIX control (5 μg mRNA). Dosing conditions: 2.5 μg mRNA for each mRNA (5 μg for control), iTu, Compound 18-based LNP. NST-FIX is a negative control mRNA. E, F, and G show data corresponding to the same experiments presented in A, B, and D, respectively, but extending the experimental time frame to 90 days. [Figure 3-2] Same as above. [Figure 3-3] Same as above. [Figure 4-1] Figures A-C show the efficacy of mRNA therapy combining IL-23 with IL-36-gamma or IL-18 in the A20 lymphoma model. Figure A shows treatment with mRNA encoding IL-23miRless and NST-FIX (2.5 μg of mRNA each). A complete response was observed in 8 of 12 subjects (66.6%). A partial response was observed in 1 of 12 subjects (8.3%). Figure B shows treatment with mRNA encoding IL-23miRless in combination with mRNA encoding IL-36-miR-122 (2.5 μg of mRNA each). A complete response was observed in 10 of 12 subjects (83.3%). Figure C shows treatment with "miRless" mRNA encoding IL-23 and "miRless" mRNA encoding IL-18 (2.5 μg of mRNA each). A complete response was observed in 6 of 12 subjects (50%). D shows treatment with NST-FIX control (5 μg mRNA). Dosing conditions: 2.5 μg mRNA for each RNA (5 μg for control), iTu, Compound 18-based LNP. NST-FIX is a negative control mRNA. [Figure 4-2] Same as above. [Figure 5-1]Figures A-C show early indications of superior efficacy of mRNA encoding IL-36-gamma plus mRNA encoding IL-23 over mRNA encoding IL-23 alone using a fixed dose of 5 μg of mRNA in the A20 lymphoma model. A shows treatment with mRNA encoding IL-23 (5 μg of mRNA). A complete response was observed in 1 of 10 subjects (10%). A partial response was observed in 4 of 10 subjects (40%). B shows treatment with mRNA encoding IL-36-gamma (5 μg of mRNA). A complete response was observed in 2 of 10 subjects (20%). A partial response was observed in 1 of 10 subjects (10%). C shows treatment with mRNA encoding IL-23 and mRNA encoding IL-36-gamma (2.5 μg of mRNA each). D shows treatment with NST-FIX mRNA control (5 μg of mRNA). Dosing conditions: 2.5 μg of mRNA for each mRNA (5 μg for control), iTu, Compound 18-based LNP. NST-FIX is the negative control mRNA. The IL-23 / IL-36 gamma combination is superior to the single components at a fixed dose of 5 μg of mRNA. [Figure 5-2] Same as above. [Figure 6] Figures A-C show a comparison of immune infiltrates in the MC38 colon cancer model. Figure A shows quantification of CD4+, CD8+, and CD11b+ cell infiltrates in the MC38 model system in terms of cells per milligram of tissue. Results are shown for MC38-M (negligible immunogenicity) and MC38-C (strongly immunogenic). Figure B shows a histomicrograph of the MC38-M sample, which is hardly immunogenic, and Figure C shows a comparison of immune infiltrates in the MC38 colon cancer model. Figure C shows a histomicrograph of the MC38-C sample, which is highly immunogenic. [Figure 7-1]Figures A–D show the efficacy of IL-23 mRNA monotherapy and combined IL-23 / IL-36-gamma or IL-23 / IL-18 mRNA therapy in the MC38-M colon cancer model. Figure A shows treatment with NST-OX40L (2.5 μg mRNA) in compound 18-based LNPs. No response was observed. Figure B shows treatment with IL-23 mRNA "miRless" (2.5 μg mRNA) in compound 18-based LNPs. Only one partial response was observed (1 of 10, 10%). MC38-M is a relatively insensitive model in which monotherapy with OX40L, anti-PD-1 antibodies, and IL-23 is ineffective. Figure C shows treatment with mRNA encoding IL-23 and IL-36-gamma (2.5 μg mRNA each). Complete responses were observed in 2 of 10 subjects (20%). Partial responses were observed in 5 of 10 subjects (50%). Therefore, IL-23 / IL-36-gamma mRNA combination therapy is effective in the minimally immunogenic MC38-M colon cancer. D: Treatment with NST-FIX control (5 μg of mRNA). E: Treatment with mRNA encoding IL-23 and IL-18 (2.5 μg of mRNA each). Only one partial response was observed (1 of 10, 10%). [Figure 7-2] Same as above. [Figure 7-3] Same as above. [Figure 8] To analyze the efficacy of OX40L mRNA monotherapy in the A20 tumor model, mRNA encoding OX40L (2.5 μg of mRNA) was formulated in compound 18-based LNPs. Two complete responses were observed. [Figure 9] Figures A-C show the efficacy of OX40L mRNA "miRless" or anti-PD-1 monotherapy in the MC38-M (lowly immunogenic) colon cancer model. Figure A shows treatment with OX40L mRNA "miRless" in compound 18-based LNP (2.5 μg of mRNA). Figure B shows treatment with anti-PD-1 antibody (5 mg / kg intraperitoneally twice weekly). Figure C shows a photomicrograph of MC38-M colon cancer model tissue. [Figure 10-1]Figures A–H show the effects of monotherapy, dual therapy, and triple therapy (including single-dose and multiple-dose administration at various dose levels) using mRNAs encoding IL-23, IL-36-gamma, and OX40L, each of which contains a miR122 binding site. A shows monotherapy treatment with IL-23_miR-122. No complete responses were observed, but there were eight escapes. B shows combination treatment with IL-23_miR-122 and IL-36-gamma_miR-122. Three complete responses (25%) were observed, and six escapes were observed. C shows triple therapy with IL-23_miR-122, IL-36-gamma_miR-122, and OX40L_miR-122. Three complete responses (25%) were observed, and four escapes were observed. For each sample, 5 μg of total mRNA per dose was administered intratumorally (iTu). When nontranslated control mRNA and IL-36 gamma miR-122 alone were administered, all mice progressed by 26 days (data not shown). D, E, and F show data corresponding to the same experiments as presented in A, B, and C, respectively, but extending the experimental time frame to 70 days. G shows treatment with a single dose (8 μg) of IL-23 and IL-36 gamma miR-122 dual therapy and single or multiple doses (12 μg) of IL-23, IL-36 gamma miR-122, and OX40L miR-122 triple therapy in MC38 luciferase cells versus sham controls. H shows survival up to 47 days after treatment with a single 8 μg dose of IL-23_miR-122 and IL-36-gamma_miR-122 dual therapy, a single 12 μg dose of IL-23_miR-122, IL-36-gamma_miR-122, and OX40L_miR-122 triple therapy, or multiple 12 μg doses of IL-23_miR-122, IL-36-gamma_miR-122, and OX40L_miR-122 triple therapy. Treatment-related mortality was observed with multiple 12 μg doses of IL-23_miR-122, IL-36-gamma_miR-122, and OX40L_miR-122 triple therapy. [Figure 10-2] Same as above. [Figure 10-3]Same as above. [Figure 10-4] Same as above. [Figure 10-5] Same as above. [Figure 11] The figure shows the biological activity of IL-23 protein produced from mRNA compared to recombinant IL-23 protein (e.g., induction of mouse interleukin-17 (mIL-17) expression from primary mouse splenocytes). The solid upper line shows mIL-17 (pg / ml) secreted from primary mouse splenocytes after addition of mouse IL-23 (mIL-23) obtained from HeLa cells transfected with mRNA encoding mIL-23. The solid lower line shows mIL-17 (pg / ml) expression after addition of human IL-23 (hIL-23) obtained from HeLa cells transfected with mRNA encoding hIL-23. The dotted black line shows mIL-17 secreted from primary mouse splenocytes after addition of recombinant hIL-23. The dotted gray line shows mIL-17 expression from splenocytes after addition of recombinant mIL-23. The IL-23 protein levels used in this experiment were 0.1 ng / ml, 1 ng / ml, 3.3 ng / ml, 10 ng / ml and 100 ng / ml. [Figure 12A] A shows murine interleukin 6 (mIL6) (ng / ml) in bone marrow-derived dendritic cells as induced by murine IL-36 gamma (mIL-36γ) protein. The first panel (NT) is a negative control. The second panel shows mIL6 expression after addition of recombinant mIL-36γ. The third panel shows mIL6 expression after addition of mIL-36γ obtained from HeLa cells transfected with mRNA encoding mIL-36γ. The fourth panel (sham) shows a sham control. B shows interleukin 8 (IL8) expression (OD450) in A431 cells with supernatant from B16F10 cells transfected with recombinant human IL-36-gamma and three mRNAs encoding hIL-36-gamma. [Figure 12B] Same as above. [Figure 13-1]Figures A–E show the costimulatory bioactivity of OX40L expressed on the surface of cells treated with OX40L mRNA. Figure A shows a schematic diagram of a T cell activation assay. B16F10 or HeLa cells expressing OX40L were cocultured with CD4+ T cells and anti-mouse CD3 antibody (B16F10 cells) or Dynabeads human T activating factor (HeLa cells). IL-2 production was measured using ELISA as a correlate of T cell activation. Figure B shows the results of a T cell activation assay as measured by mouse IL-2. Figure C shows the results of a T cell activation assay as measured by human IL-2. The y-axis indicates mIL-2 expression in ng / ml. Figure D shows the data from Figure 13C along with a schematic diagram illustrating the addition of OX40L-expressing cells to a naive T cell activation assay. Figure E shows a T cell activation assay using pre-stimulated T cells cultured in the presence or absence of OX40L-expressing HeLa cells and in the presence or absence of anti-human CD3 antibody. [Figure 13-2] Same as above. [Figure 13-3] Same as above. [Figure 14-1] Figures A-D show different types of immune cells infiltrating the tumor microenvironment in A20 tumors after administration of a polynucleotide containing mRNA encoding an OX40L polypeptide. Figure A shows the percentage of NK cells in the tumor infiltrate 24 hours after treatment, as detected by the DX5 marker. Figure B shows the percentage of CD4+ T cells in the tumor infiltrate 14 days after treatment, as detected by the CD4 marker. Figure C shows the percentage of CD8+ T cells in the tumor infiltrate 14 days after treatment, as detected by the CD8 marker. Figure D shows the percentage of CD8+ T cells in the tumor infiltrate of MC38 tumors 24 and 72 hours after the first and second administrations of a polynucleotide containing mRNA encoding an OX40L polypeptide. [Figure 14-2] Same as above. [Figure 15A]A and B show the in vivo antitumor efficacy of intratumorally delivered mOX40L_miR-122. A shows tumor growth in animals treated intratumorally with control mRNA ("NST-OX40L") (arrows indicate days of injection). B shows tumor growth in animals treated intratumorally with mOX40L_miR-122 mRNA ("OX40L-miR-122") (arrows indicate days of injection). [Figure 15B] Same as above. [Figure 16-1] Figures A-F show the in vivo antitumor efficacy of a combination therapy comprising a polynucleotide containing mRNA encoding an OX40L polypeptide, a miR-122 binding site, and an anti-PD-1 antibody. Figure A shows tumor growth in an animal treated with intratumoral injections of control mRNA ("NST_mOX40L_122") and a control antibody ("rat IgG2a"). Figure B shows tumor growth in an animal treated with intratumoral injections of mOX40L_miR-122 ("mOX40L_122") and a control antibody ("rat IgG2a"). Figure C shows tumor growth in an animal treated with intratumoral injections of control mRNA ("NST_mOX40L_122") and an anti-PD-1 antibody ("anti-PD-1"). Figure D shows tumor growth in an animal treated with intratumoral injections of mOX40L_miR-122 ("mOX40L_122") and an anti-PD-1 antibody ("anti-PD-1"). E shows tumor growth in animals treated with anti-PD-1 antibody and intratumoral injection of PBS. F shows tumor growth in animals treated with PBS and control antibody ("rat IgG2a"). CR = complete response. [Figure 16-2] Same as above. [Figure 16-3] Same as above. [Figure 17]Survival curves are shown for animals treated intratumorally with combination therapy including control mRNA and control antibody ("NST_mOX40L_122 + rat IgG2a"), mOX40L_miR-122 and control antibody ("mOX40L_122 + rat IgG2a"), control mRNA and anti-PD-1 antibody ("NST_mOX40L_122 + anti-PD-1"), mOX40L_miR-122 and anti-PD-1 antibody ("mOX40L_122 + anti-PD-1"), anti-PD-1 antibody and PBS ("PBS + anti-PD-1"), and PBS and control antibody ("PBS + rat IgG2a"). [Figure 18] Figures 16A and 16B show memory immune responses in animals treated with a combination therapy comprising a polynucleotide containing mRNA encoding an OX40L polypeptide, a miR-122 binding site, and an anti-PD-1 antibody. Animals were initially treated with intratumoral injections of mOX40L_miR-122 and an anti-PD-1 antibody, as shown in Figure 16D. Four animals identified as complete responders (CR) were re-challenged with MC38 tumor cells. Figure 16A shows tumor growth in naive animals challenged with MC38 tumor cells. Figure 16B shows tumor growth in four CR animals challenged with MC38 tumor cells. [Figure 19-1]Figures A-G show in vivo tumor efficacy in both primary-treated and untreated distant tumors using dual mRNA therapy (combination of mRNAs encoding IL-23 and IL-36) and triple mRNA therapy (combination of mRNAs encoding IL-23, IL-36, and OX40L). Figure A shows a schematic diagram of the MC38-S double flank model used in this experiment. Tumors implanted in one flank are treated, and the effect is measured in both the primary-treated tumor and the untreated tumor in the other flank. Figure B shows the effect of negative control mRNA (non-translating mRNA encoding OX40L) on primary-treated tumors. Figure C shows the effect of negative control mRNA on untreated tumors. Figure D shows the effect of dual mRNA therapy (mRNA encoding IL-23 and mRNA encoding IL-36-gamma) on primary-treated tumors. Figure E shows the effect of dual mRNA therapy (mRNA encoding IL-23 and mRNA encoding IL-36-gamma) on untreated distant tumors. F shows the effect of triple mRNA therapy (mRNA encoding IL-23, mRNA encoding IL-36-gamma, and mRNA encoding OX40L) on a primary treated tumor. G shows the effect of triple mRNA therapy (mRNA encoding IL-23, mRNA encoding IL-36-gamma, and mRNA encoding OX40L) on an untreated distant tumor. In each case, the total dose of mRNA (control, dual-drug, or triple-drug) injected into the tumor was 5 micrograms. The mRNA was administered intratumorally in a single dose. [Figure 19-2] Same as above. [Figure 20-1]Figures A-D show that triple mRNA therapy in combination with an anti-PD-L1 antibody has improved efficacy in the difficult-to-treat B16F10-AP3 tumor model. Figure A shows tumor growth in animals treated with a negative control. Figure B shows tumor growth in animals treated with an anti-PD-L1 antibody. Figure C shows tumor growth in animals treated with triple mRNA therapy (mRNA encoding IL-23, mRNA encoding IL-36-gamma, and mRNA encoding OX40L). Figure D shows tumor growth in animals treated with triple mRNA therapy (mRNA encoding IL-23, mRNA encoding IL-36-gamma, and mRNA encoding OX40L) plus an anti-PD-1 antibody. [Figure 20-2] Same as above. [Figure 21] A and B show memory immune responses in animals treated with dual mRNA therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma). Animals were initially treated with 5 μg of total mRNA (2.5 μg of mRNA encoding IL-23 and 2.5 μg of mRNA encoding IL-36-gamma) administered intratumorally daily for 7 days. Ten animals identified as complete responders (CR) were re-challenged with MC38-S tumor cells. A shows tumor growth in naive animals challenged with MC38-S tumor cells. B shows tumor growth in ten CR animals challenged with MC38-S tumor cells. [Figure 22A]A and B show the increase in Ly6G+ granulocytes in response to treatment of MC38 tumors with two-drug mRNA therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma). A shows the level of granulocytes as a percentage of CD45+ cells 24 hours, 72 hours, 7 days, and 14 days after treatment. B shows the level of granulocytes as granulocytes per mg of tumor 24 hours, 72 hours, 7 days, and 14 days after treatment. The results shown correspond to treatment with control ("NoRx" and "NST"), IL-23 and IL-36-gamma monotherapy ("IL23" and "IL36"), and two-drug mRNA combination therapy ("Combo," corresponding to mice receiving a single dose of combination therapy, and "Combo 2 Dose," corresponding to mice receiving two doses of combination therapy). Vertical bars represent the mean and standard deviation. Horizontal bars above the data indicate statistical significance. [Figure 22B] Same as above. [Figure 23] Figure 1 shows the increase in Ly6G+ granulocytes as a percentage of CD45+ cells 24 hours, 72 hours, and 7 days after treatment of MC38 tumors with triple mRNA combination therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma + mRNA encoding OX40L). Vertical bars represent the mean and standard deviation. Horizontal bars above the data indicate statistical significance. [Figure 24] A and B show the increase in CD103+ dendritic cells (DCs) in response to treatment of MC38 tumors with a dual mRNA therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma). A shows the level of CD103+ dendritic cells as a percentage of CD45+ cells after 7 days of treatment. B shows the level of CD103+ dendritic cells as CD103+ dendritic cells per mg of tumor after 7 days of treatment. Results shown correspond to treatment with control ("NoRx" and "NST"), IL-23 and IL-36-gamma monotherapy ("IL23" and "IL36"), and dual mRNA combination therapy ("Combo"). Vertical bars represent the mean and standard deviation. Horizontal bars above the data indicate statistical significance. [Figure 25] A and B show the increase in CD103+ dendritic cells (DCs) in response to treatment of MC38 tumors with either a two-drug mRNA therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma) or a triple-drug mRNA therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma + mRNA encoding OX40L). A shows the level of CD103+ dendritic cells as CD8+ cells per mg of tumor after 7 days of treatment. B shows the level of CD8+ dendritic cells in tumor-draining lymph nodes (TdLNs) after 7 days of treatment. The results shown correspond to treatment with control ("Naive" and "NST"), OX40L monotherapy ("OX40L"), and two- and three-drug mRNA combination therapy ("Two-Drug" and "Triple-Drug," respectively). Vertical bars represent the mean and standard deviation. Horizontal bars above the data indicate statistical significance. [Figure 26-1] Figures A-D show the increase in CD11b+ dendritic cells in MC38 tumors and draining lymph nodes in response to treatment with triple-drug mRNA therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma + mRNA encoding OX40L). Figure A shows the level of CD11+ cDC2 cells as cells per milligram of tumor after 7 days of treatment. Figure B shows the level of CD11+ cDC2 dendritic cells in tumor-draining lymph nodes (TdLN) after 7 days of treatment. Figure C shows the activation of CD86 on CD11b+ cDC2 in draining lymph nodes 24 and 72 hours after intratumoral administration of triple-drug mRNA therapy, measured as the percentage of CD24+ cDC2 cells. Figure D shows the activation of CD86 on CD11b+ cDC2 in draining lymph nodes 24 and 72 hours after intratumoral administration of triple-drug mRNA therapy, measured as the mean fluorescence intensity (MFI). Vertical bars represent the mean and standard deviation. Horizontal bars above the data indicate statistical significance. [Figure 26-2] Same as above. [Figure 27]A and B show the activation of CD86 on CD8 cDC1 in the draining lymph nodes 24 and 72 hours after intratumoral administration of triple-drug mRNA therapy to MC38 tumors, measured as the percentage of CD8 cDC1 cells (A), or the activation of CD86 on CD8 cDC1 in the draining lymph nodes 24 and 72 hours after intratumoral administration of triple-drug mRNA therapy to MC38 tumors, measured as the mean fluorescence intensity (MFI) (B). Vertical bars represent the mean and standard deviation. Horizontal bars above the data indicate statistical significance. [Figure 28-1] Figures A-D show the increase in inflammatory dendritic cells (iDCs) in MC38 tumors and draining lymph nodes in response to treatment with triple-drug mRNA therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma + mRNA encoding OX40L). Figure A shows the level of iDCs in tumors as cells per milligram of tumor after 7 days of treatment. Figure B shows the level of iDCs in tumor-draining lymph nodes (TdLNs) after 7 days of treatment. Figure C shows the activation of CD86 on iDCs in draining lymph nodes 24 and 72 hours after intratumoral administration of triple-drug mRNA therapy, measured as a percentage of iDCs. Figure D shows the activation of CD86 on iDCs in draining lymph nodes 24 and 72 hours after intratumoral administration of triple-drug mRNA therapy, measured as mean fluorescence intensity (MFI). Vertical bars represent the mean and standard deviation. Horizontal bars above the data indicate statistical significance. [Figure 28-2] Same as above. [Figure 29]Figure 1 shows the increase in the ratio of effector CD8 (killer) T cells to regulatory T cells (Tregs) in response to treatment of MC38 tumors with two-drug mRNA therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma) and three-drug mRNA therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma + mRNA encoding OX40L). Results were obtained 72 hours and 7 days after treatment. Results correspond to treatment with control ("NST"), OX40L monotherapy ("OX40L"), and two- and three-drug mRNA combination therapy ("two-drug" and "triple-drug," respectively). Vertical bars represent the mean and standard deviation. Horizontal bars above the data indicate statistical significance. [Figure 30] A and B show the increase in central and effector CD4 and CD8 cells in response to treatment of MC38 tumors with two-drug mRNA therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma) or three-drug mRNA therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma + mRNA encoding OX40L). A shows the CD4 cell levels as CD4 cells per mg of tumor after 7 and 10 days of treatment. B shows the CD8 cell levels as CD8 cells per mg of tumor after 7 and 10 days of treatment. Results correspond to treatment with control ("NST"), OX40L monotherapy ("OX40L"), and two- and three-drug mRNA combination therapy ("two-drug" and "triple-drug," respectively). Bars indicate naive, central memory, and effector memory CD4 and CD8 cell levels. [Figure 31] Figure 1 shows survival curves demonstrating the effect of CD4 cell depletion on the efficacy of triple-drug mRNA therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma + mRNA encoding OX40L) treatment of MC38 tumors. CD4 and CD8 cell levels were depleted by administering anti-CD4 and anti-CD8 antibodies to MC38 tumor-bearing mice. Arrows indicate administration of triple-drug therapy. CD4 cell-depleting doses of antibodies (indicated by circles) were administered before and after triple-drug therapy administration. [Figure 32](A) and (B) show PD-L1 expression in cancer cells from mice bearing MC38 tumors in response to triple-drug mRNA therapy. (A) shows the percentage of cancer cells (CD45-, FSchi, MHCII-) positive for PD-L1 after 7 days of treatment with triple-drug mRNA therapy. (B) shows the level of PD-L1 expression in cancer cells (CD45-, FSchi, MHCII-), measured as MFI (mean fluorescence intensity). Vertical bars represent the mean and standard deviation. Horizontal bars above the data indicate statistical significance. [Figure 33] A and B show PD-L1 expression in MC38 tumor-bearing mice in response to administration of IL-23 or IL-36-gamma monotherapy or dual mRNA therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma). A shows the percentage of CD11b+ cells positive for PD-L1. B shows the intensity of PD-L1 expression in CD11b+ cells, measured as MFI (mean fluorescence intensity). Measurements correspond to treatment with control ("NoRx" and "NST"), IL-23 and IL-36-gamma monotherapy ("IL23" and "IL36"), and dual mRNA combination therapy ("Combo"). Vertical bars represent the mean and standard deviation. Horizontal bars above the data indicate statistical significance. All measurements were performed 7 days after tumor cell implantation. [Figure 34](A) and (B) show PD-L1 expression in MC38 tumor-bearing mice in response to administration of OX40L monotherapy or two-drug (mRNA encoding IL-23 + mRNA encoding IL-36-gamma) or three-drug (mRNA encoding IL-23 + mRNA encoding IL-36-gamma + mRNA encoding OX40L) mRNA therapy. (A) shows the percentage of CD11b+ cells positive for PD-L1. (B) shows the intensity of PD-L1 expression in CD11b+ cells, measured as MFI (mean fluorescence intensity). The results shown correspond to treatment with control ("NoRx"), OX40L monotherapy ("OX40L"), and two- and three-drug mRNA combination therapy ("Two-Drug" and "Triple-Drug," respectively). Vertical bars represent the mean and standard deviation. Horizontal bars above the data indicate statistical significance. All measurements were performed 7 days after tumor cell implantation. [Figure 35-1] Figures A-D show the in vivo anti-tumor efficacy of triple mRNA therapy in combination with an anti-PD-L1 antibody (10F.9G2) in immunosuppressive MC38 tumors. Figure A shows tumor growth in animals treated with intratumoral injections of a control antibody. Figure B shows tumor growth in animals treated with intratumoral injections of an anti-PD-L1 antibody (10F.9G2). Figure C shows tumor growth in animals treated with intratumoral injections of triple mRNA therapy. Figure D shows tumor growth in animals treated with intratumoral injections of triple mRNA therapy plus anti-PD-L1 antibody (10F.9G2). Vertical dashed lines indicate the days of administration of the control antibody, anti-PD-L1 antibody, triple mRNA therapy, or triple mRNA therapy plus anti-PD-L1 antibody. [Figure 35-2] Same as above. [Figure 36] A and B show the in vivo antitumor efficacy of triple mRNA combination therapy (mRNA encoding IL-23 + mRNA encoding IL-36-gamma + mRNA encoding OX40L) in a syngeneic H22 (hepatocellular carcinoma (HCC)) model. A shows tumor growth in animals treated with intratumoral injection of control mRNA ("NST-FIX"). B shows tumor growth in animals treated with intratumoral injection of triple mRNA combination therapy. [Figure 37] The mean tumor volume (mm) for each group of mice treated according to the design outlined in Table 11 is shown. The dashed lines indicate the lack of efficacy of OX40L administered in Group 8 and the synergistic effect of the combination of OX40L and IL-23 in Group 5. [Figure 38A] Average tumor volumes (mm3) for groups of mice treated with a triple-drug combination containing murine OX40L, murine IL-23, and murine IL-36-gamma are shown. Different amounts of mRNA encoding murine IL-36-gamma were used in each triple-drug combination. The total amount of mRNA in each triple-drug dose was kept constant by adding an appropriate amount of NST control mRNA. [Figure 38B] Average tumor volumes (mm3) for groups of mice treated with a triple-drug combination containing mouse OX40L, mouse IL-23, and human IL-36-gamma are shown. Different amounts of mRNA encoding human IL-36-gamma were used in each triple-drug combination. The total amount of mRNA in each triple-drug dose was kept constant by adding an appropriate amount of NST control mRNA. [Figure 39-1] Figures A-O show the mean tumor volume (mm) for each group of mice treated according to the study design outlined in Table 11. The days on which mRNA was administered are indicated by vertical dashed lines. Each figure shows the number of animals (n) per group, the number of complete responses (CR), and the number of animals with tumors less than 100 mm in volume at the end of the study. Each figure also shows the composition administered to each animal and the ratio between each mRNA in the composition. [Figure 39-2] Same as above. [Figure 39-3] Same as above. [Figure 39-4] Same as above. [Figure 39-5] Same as above. [Figure 40] The percent change in body weight is shown for each group of mice treated according to the study design outlined in Table 11. The figure shows the mean body weight values ​​for each group. [Figure 41-1]A-O show the percent change in body weight for each group of mice treated according to the study design outlined in Table 11. The figures show the individual change in body weight values ​​for each animal in each group. [Figure 41-2] Same as above. [Figure 41-3] Same as above. [Figure 41-4] Same as above. [Figure 41-5] Same as above. [Figure 42] Figure 1 depicts survival curves showing the efficacy of treatment of MC38 tumors according to the design outlined in Table 11. Dashed arrows indicate (i) no efficacy of OX40L administered in Group 8, (ii) moderate efficacy of IL-23 in Group 9, (iii) synergistic effect of the combination of OX40L and IL-23 in Group 5, and (iv) the highest efficacy observed, corresponding to Group 1 (mOX40L / mIL-23 / mIL-36-gamma 1:1:1). [Figure 43A] The mean tumor volume (mm3) for mice bearing MC38-S tumors and treated with a triple combination containing IL-23, IL-36-gamma and OX40L is shown. [Figure 43B] The mean tumor volume (mm) for mice bearing MC38-S tumors and treated with a dual combination containing IL-23 and OX40L is shown. The total amount of mRNA in the dose was kept constant by adding an appropriate amount of NST control mRNA compared to mice treated as in Figure 43A. [Figure 44] This is a diagram showing the long-range effect of cancer treatment. DETAILED DESCRIPTION OF THE INVENTION

[0095] A particularly interesting approach to treating cancer involves preventing or treating the disease with substances that stimulate the immune response, known as immunotherapy. Immunotherapy, also referred to in the art as immuno-oncology, has begun to revolutionize cancer treatment by introducing therapies that target the host immune system rather than the tumor. These therapies have unique pharmacological response profiles and therefore represent potentially curative therapies for many different types of cancer. Cancers of the lung, kidney, bladder, and skin, among others, have reaped substantial benefits from treatment with immuno-oncology in terms of survival or tumor response, with melanoma potentially showing the greatest benefit. Immunotherapy is often characterized by checkpoint inhibitor treatment using an exciting new class of biologics known as checkpoint inhibitor antibodies.

[0096] The present disclosure features methods and compositions, particularly immunotherapeutic methods and compositions, for treating cancer. In some embodiments, the disclosure features methods and compositions for treating cancer using combination therapy featuring two or more polynucleotides (e.g., mRNAs) encoding a first immune response primer polypeptide and a second, different immune response primer polypeptide, and optionally a polynucleotide encoding an immune response costimulatory signal polypeptide, and optionally a polynucleotide encoding a checkpoint inhibitor polypeptide or a polypeptide comprising a checkpoint inhibitor polypeptide. In some embodiments, the disclosure provides immunomodulatory compositions comprising a polynucleotide encoding an interleukin-23 (IL-23) polypeptide, a polynucleotide encoding an interleukin-36 gamma (IL-36 gamma) polypeptide, and optionally a polynucleotide encoding an OX40L polypeptide. In other embodiments, the disclosure provides immunomodulatory compositions comprising a polynucleotide encoding an IL-23 polypeptide, a polynucleotide encoding an interleukin-18 (IL-18) polypeptide, and optionally a polynucleotide encoding an OX40L polypeptide.

[0097] In some embodiments, the present disclosure relates to methods of treating cancer using a combination approach featuring mRNA encoding IL-23, IL-36, or IL-18 and / or OX40L. Without being bound by theory, stimulation of an anti-cancer immune response is possible by, for example, intratumor administration of mRNA encoding an IL-12 family member (e.g., IL-23) and / or an IL-1 family member (e.g., IL-36 or IL-18). IL-23 is important, for example, in stimulating T cells, natural killer cells, macrophages, and / or dendritic cells. IL-36 is important, for example, in stimulating T cells, natural killer cells, granulocytes, and / or dendritic cells. IL-18, together with IL-12, induces cell-mediated immunity and is important, for example, in stimulating T cells, natural killer cells, and / or macrophages. mRNA encoding IL-36 or mRNA encoding IL-18, in combination with mRNA encoding IL-23, is believed to provide a first stimulatory signal to the immune system within the tumor environment, for example, via intratumoral injection of these mRNAs. Administration of an immune response costimulatory signal polypeptide, e.g., mRNA encoding OX40L, is believed to provide a second stimulatory signal, due at least in part to the ability of OX40L to stimulate T cells when provided in combination with mRNA encoding IL-23 and IL-36.

[0098] In some embodiments, the immunotherapeutic approaches disclosed herein can (1) alter the tumor microenvironment (TME) to optimize immunogenicity, and / or (2) enhance T cell responses to elicit long-range control and anti-cancer memory. The long-range effect, i.e., treating the tumor locally yet acting globally, is shown in Figure 44.

[0099] Some embodiments of the present disclosure feature treatment with mRNA encoding IL-23 in combination with mRNA encoding IL-36. Other embodiments of the present disclosure feature treatment with mRNA encoding IL-23 in combination with mRNA encoding IL-18. Exemplary embodiments feature treatment with mRNA encapsulated in lipid nanoparticles (LNPs). Exemplary embodiments feature intratumoral administration of mRNA in ionic amino lipid-based LNPs.

[0100] Other aspects of the disclosure feature compositions and methods for reducing or decreasing tumor size or inhibiting tumor growth in a subject by administering to a subject in need thereof an effective amount of a composition comprising mRNA encoding IL-23, IL-36-gamma, or IL-18, and OX40L. In some embodiments, the mRNA combination comprises a first polynucleotide encoding an IL-23 polypeptide, a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide, and a third polynucleotide encoding a third protein comprising an OX40L polypeptide. One aspect of the disclosure relates to a pharmaceutical composition comprising two or more polynucleotides (e.g., mRNA) encoding an IL-23 polypeptide, a polynucleotide (e.g., mRNA) encoding an IL-36-gamma polypeptide or an IL-18 polypeptide, and a polynucleotide (e.g., mRNA) encoding an OX40L polypeptide.

[0101] In another embodiment, the composition is a lipid composition comprising an ionic amino lipid, such as the compound of formula (I) disclosed below, for example, compound 18, 25, 26 or 48. In some embodiments of the present disclosure, the lipid composition of the pharmaceutical composition comprises additional lipids / components. For example, the lipid composition can comprise one or more phospholipids, for example, MSPC or DSPC. The lipid composition can also comprise a quaternary amine compound, such as DOTAP.

[0102] In another aspect, the present application provides a lipid composition (e.g., a lipid nanoparticle (LNP)) comprising: (1) a compound having formula (I); (2) optionally a helper lipid (e.g., a phospholipid); (3) optionally a structural lipid (e.g., a sterol); (4) optionally a lipid conjugate (e.g., a PEG-lipid); and (5) optionally a quaternary amine compound.

[0103] The headings provided herein are not limitations on the various aspects or embodiments of the present disclosure, but can be defined by reference to the specification as a whole. Accordingly, the immediately following defined terms are more fully defined by reference to the specification in its entirety. Before describing the present disclosure in detail, it is understood that this disclosure is not limited to specific compositions or process steps, as these may vary.

[0104] I. Definition In order that this disclosure may be more readily understood, certain terms are first defined. As used in this application, unless expressly provided otherwise herein, each of the following terms has the meaning set forth below. Additional definitions are set forth throughout this application.

[0105] The present disclosure includes embodiments in which exactly one member of the group is present in, employed in, or otherwise associated with a given product or process. The present disclosure includes embodiments in which more than one, or all, of the group members are present in, employed in, or otherwise associated with a given product or process.

[0106] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. The term "a" (or "an") can be used interchangeably herein, as can the terms "one or more," and "at least one." In certain embodiments, the term "a" or "an" means "single." In other embodiments, the term "a" or "an" includes "two or more" or "plural."

[0107] Furthermore, as used herein, "and / or" shall mean a specific disclosure of each of the two specified features or components, including or excluding the other. Thus, the term "and / or" as used herein in phrases such as "A and / or B" is intended to include "A and B," "A or B," "A alone," and "B alone." Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A alone; B alone; and C alone.

[0108] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. For example, Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and Oxford Dictionary of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press, along with a general dictionary of many of the terms used in this disclosure, provide those skilled in the art.

[0109] Whenever an embodiment is described herein using the language "comprising," other similar embodiments are also provided that are described in terms of "consisting of" and / or "consisting essentially of."

[0110] Units, prefixes, and symbols are shown in the recognized form of the International System of Units (SI). Numerical ranges are inclusive of the numbers defining the range. When a range of values ​​is recited, it is to be understood that each intervening integer and fractional value between the recited upper and lower limits of that range is also specifically disclosed, along with each subrange between such values. The upper and lower limits of any range can independently be included in or excluded from the range, and each range including, excluding, or including any limit is also encompassed within the disclosure. When values ​​are expressly recited, it is to be understood that quantities or amounts approximately the same as the recited values ​​are also within the scope of the disclosure. When a combination is disclosed, each subcombination of the elements of that combination is also specifically disclosed and is within the scope of the disclosure. Conversely, when different elements or groups of elements are individually disclosed, the combination is also disclosed. Where any element of the disclosure is disclosed as having multiple alternatives, instances of that disclosure in which each alternative is excluded singly or in any combination with other alternatives are also hereby disclosed, and more than one element of the disclosure may have such an exclusion, and all combinations of elements with such an exclusion are disclosed by reference.

[0111] Nucleotides are referred to by their commonly accepted single-letter codons. Unless otherwise specified, nucleic acids are written left to right in a 5' to 3' orientation. Nucleotides are referred to herein by their commonly known single-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Thus, A represents adenine, C represents cytosine, G represents guanine, T represents thymine, and U represents uracil.

[0112] Amino acids are referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Unless otherwise noted, amino acid sequences are written left to right in amino to carboxy orientation.

[0113] About: The term "about" used in connection with numerical values ​​throughout the specification and claims indicates an interval of accuracy familiar and acceptable to those skilled in the art. Generally, such an interval of accuracy is ±10%.

[0114] Where ranges are given, the endpoints are included. Additionally, unless otherwise stated or apparent from the context and the understanding of one of ordinary skill in the art, values ​​expressed as ranges can guarantee any particular value or subrange within the range set forth in different embodiments of this disclosure to one-tenth of the unit of the lower limit of that range, unless the context clearly dictates otherwise.

[0115] Administered in Combination: As used herein, the terms "administered in combination," "administration in combination," or "combined therapy" mean that two or more agents are administered to a subject simultaneously or within an interval such that there may be an overlap in the effects of each agent on the patient. In some embodiments, the two or more agents are administered within about 60, 30, 15, 10, 5, or 1 minute of each other. In some embodiments, the administration of the agents is sufficiently close to each other that a combined (e.g., synergistic) effect is achieved.

[0116] Amino acid substitution: The term "amino acid substitution" refers to the replacement of an amino acid residue present in a patient or reference sequence (e.g., a wild-type sequence) with another amino acid residue. An amino acid can be substituted in a patient or reference sequence (e.g., a wild-type polypeptide sequence) via chemical peptide synthesis or through recombinant methods known in the art. Thus, a reference to a "substitution at position X" refers to the replacement of the amino acid residue present at position X with an alternative amino acid residue. In some embodiments, the substitution pattern can be described by the scheme AnY, where A is the single-letter code corresponding to the naturally or originally occurring amino acid at position n, and Y is the substituting amino acid residue. In other embodiments, the substitution pattern can be described by the formula An(YZ), where A is the single-letter code corresponding to the amino acid residue substituting the naturally or originally occurring amino acid at position X, and Y and Z are alternative replacement amino acid residues.

[0117] In the context of the present disclosure, substitutions (particularly when referring to amino acid substitutions) are performed at the nucleic acid level, i.e., the substitution of an amino acid residue with an alternative amino acid residue is performed by substituting a codon encoding a first amino acid with a codon encoding a second amino acid.

[0118] Animal: As used herein, the term "animal" refers to any member of the animal kingdom. In some embodiments, "animal" refers to a human at any stage of development. In some embodiments, "animal" refers to a non-human animal at any stage of development. In certain embodiments, the non-human animal is a mammal (e.g., a rodent, mouse, rat, rabbit, monkey, dog, cat, sheep, cow, primate, or pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, and insects. In some embodiments, the animal is a transgenic animal, a genetically engineered animal, or a clone.

[0119] Approximately: As used herein, the term "approximately" when applied to one or more values ​​of interest refers to a value similar to a stated reference value. In certain embodiments, unless otherwise stated or clear from the context, the term "approximately" refers to a range of values ​​that falls within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less in either direction (up or down) of the stated reference value (the exception being when such a number would exceed 100% of the possible values).

[0120] Associated with: As used herein with respect to a disease, the term "associated with" means that the symptom, measurement, characteristic, or condition in question is associated with the diagnosis, onset, presence, or progression of the disease. The association may, but need not, be causally associated with the disease.

[0121] The terms "associated with," "conjugated," "linked," "attached," and "linked," when used in reference to two or more moieties, mean that the moieties are physically associated or connected to one another, either directly or through one or more additional moieties that function as linking agents, to form a structure that is sufficiently stable so that the moieties remain physically associated under the conditions in which the structure is used, e.g., physiological conditions. The "association" need not be strictly through a direct chemical covalent bond. The term can also suggest connectivity based on ionic or hydrogen bonding or hybridization that is sufficiently stable so that the "associated" entities remain physically associated.

[0122] Biocompatible: As used herein, the term "biocompatible" means compatibility with living cells, tissues, organs, or systems with little or no risk of damage, toxicity, or rejection by the immune system.

[0123] Biodegradable: As used herein, the term "biodegradable" means capable of being broken down into harmless products by the action of living organisms. Sequence optimization: The term "sequence optimization" refers to a process or set of processes in which nucleobases in a reference nucleic acid sequence are replaced with alternative nucleobases, resulting in a nucleic acid sequence with improved properties, e.g., improved protein expression or reduced immunogenicity.

[0124] Generally, the goal of sequence optimization is to produce a more synonymous nucleotide sequence than would encode the same polypeptide sequence encoded by the reference nucleotide sequence, and thus there will be no amino acid substitutions (as a result of the codon optimization) in the polypeptide encoded by the codon-optimized nucleotide sequence relative to the polypeptide encoded by the reference nucleotide sequence.

[0125] Codon substitution: The term "codon substitution" or "codon replacement" in the context of sequence optimization refers to replacing a codon present in a reference nucleic acid sequence with another codon. A codon can be replaced in a reference nucleic acid sequence, for example, through chemical peptide synthesis or recombinant methods known in the art. Thus, reference to a "substitution" or "replacement" at a particular position in a nucleic acid sequence (e.g., mRNA) or within a particular region or subsequence of a nucleic acid sequence (e.g., mRNA) refers to the replacement of the codon at such position or region with an alternative codon.

[0126] As used herein, the terms "codon region" and "coding region" and grammatical variations thereof refer to an open reading frame (ORF) in a polynucleotide that, upon expression, gives rise to a polypeptide or protein.

[0127] Compound: As used herein, the term "compound" is meant to include all stereoisomers and isotopes of the depicted structure. As used herein, the term "stereoisomer" refers to any geometric isomer (e.g., cis and trans isomers), enantiomer, or diastereomer of a compound. The present disclosure encompasses any and all stereoisomers of the compounds described herein, including stereomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric and stereoisomeric mixtures, e.g., racemates. Enantiomeric and stereoisomeric mixtures of compounds and means for resolving them into their constituent enantiomers or stereoisomers are well known. "Isotope" refers to atoms having the same atomic number but different mass numbers resulting from different numbers of neutrons in the nucleus. For example, isotopes of hydrogen include tritium and deuterium. Additionally, the compounds, salts, or complexes of the present disclosure can be prepared in combination with solvents or water molecules to form solvates and hydrates by conventional methods.

[0128] Conservative amino acid substitution: A "conservative amino acid substitution" refers to the replacement of an amino acid residue with an amino acid residue having a similar side chain. Families of amino acid residues with similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, or histidine), acidic side chains (e.g., aspartic acid or glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, or cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, or tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, or histidine). Thus, when an amino acid in a polypeptide is replaced with another amino acid from the same side chain family, the amino acid substitution is considered conservative. In another embodiment, amino acid chains can be conservatively replaced with structurally similar chains that differ in the order and / or composition of the members of the side chain family.

[0129] Non-conservative amino acid substitutions include (i) substitutions of a residue having a positively charged side chain (e.g., Arg, His, or Lys) with or by a negatively charged residue (e.g., Glu or Asp); (ii) substitutions of a hydrophilic residue (e.g., Ser or Thr) with or by a hydrophobic residue (e.g., Ala, Leu, Ile, Phe, or Val); (iii) substitutions of cysteine ​​or proline with or by any other residue; or (iv) substitutions of a bulky hydrophobic or aromatic side chain (e.g., Val, His, Ile, or Trp) with or by a smaller side chain (e.g., Ala or Ser) or no side chain (e.g., Gly).

[0130] Other amino acid substitutions can be easily identified by those skilled in the art.For example, for the amino acid alanine, substitution can be any one of D-alanine, glycine, beta-alanine, L-cysteine ​​and D-cysteine.For lysine, substitution can be any one of D-lysine, arginine, D-arginine, homoarginine, methionine, D-methionine, ornithine or D-ornithine. In general, substitutions in functionally important regions that can be expected to induce changes in the properties of an isolated polypeptide include (i) polar residues, such as serine or threonine, substituted with (or by) hydrophobic residues, such as leucine, isoleucine, phenylalanine, or alanine; (ii) cysteine ​​residues substituted with (or by) any other residue; (iii) residues with positively charged side chains, such as lysine, arginine, or histidine, substituted with (or by) negatively charged side chains, such as glutamic acid or aspartic acid; or (iv) residues with bulky side chains, such as phenylalanine, substituted with (or by) those that do not have such side chains, such as glycine. The likelihood that one of the above non-conservative substitutions will alter the functional properties of a protein correlates with the location of the substitution relative to the functionally important regions of the protein; thus, some non-conservative substitutions may have little or no effect on biological properties.

[0131] Conserved: As used herein, the term "conserved" refers to nucleotides or amino acid residues of a polynucleotide or polypeptide sequence, respectively, that remain unchanged in the same position in two or more sequences being compared. A relatively conserved nucleotide or amino acid residue is one that is more conserved in the related sequence than a nucleotide or amino acid that appears elsewhere in the sequence.

[0132] In some embodiments, two or more sequences are said to be "fully conserved" if they are 100% identical to each other. In some embodiments, two or more sequences are said to be "highly conserved" if they are at least 70% identical, at least 80% identical, at least 90% identical, or at least 95% identical to each other. In some embodiments, two or more sequences are said to be "highly conserved" if they are about 70% identical, about 80% identical, about 90% identical, about 95%, about 98%, or about 99% identical to each other. In some embodiments, two or more sequences are said to be "conserved" if they are at least 30% identical, at least 40% identical, at least 50% identical, at least 60% identical, at least 70% identical, at least 80% identical, at least 90% identical, or at least 95% identical to each other. In some embodiments, two or more sequences are said to be "conserved" if they are about 30% identical, about 40% identical, about 50% identical, about 60% identical, about 70% identical, about 80% identical, about 90% identical, about 95% identical, about 98% identical, or about 99% identical to one another. Sequence conservation can apply to the full length of a polynucleotide or polypeptide, or to portions, regions, or features thereof.

[0133] Contacting: As used herein, the term "contacting" means establishing a physical connection between two or more entities. For example, contacting a mammalian cell with a nanoparticle composition means causing the mammalian cell and the nanoparticle to share a physical connection. Methods for contacting cells with external entities both in vivo and ex vivo are well known in the biological arts. For example, contacting a nanoparticle composition and a mammalian cell placed within a mammal can be performed by various administration routes (e.g., intravenous, intramuscular, intradermal, and subcutaneous) and can involve various amounts of the nanoparticle composition. Moreover, two or more mammalian cells can be contacted by the nanoparticle composition.

[0134] Sustained release: As used herein, the term "sustained release" refers to the release characteristics of a pharmaceutical composition or compound that follows a specific release pattern to produce a therapeutic result. Covalent Derivatives: The term "covalent derivatives," when referring to polypeptides, includes modifications of the native or starting protein by organic proteinaceous or non-proteinaceous derivatizing agents and / or post-translational modifications. Covalent modifications are traditionally introduced by reacting targeted amino acid residues of the protein with organic derivatizing agents capable of reacting with selected side chains or terminal residues, or by post-translational modification tethering mechanisms that are functional in selected recombinant host cells. The resulting covalent derivatives are useful in programs directed at identifying residues important for biological activity, for immunoassays, or for the preparation of anti-protein antibodies, or for immunoaffinity purification of recombinant glycoproteins. Such modifications are within the ordinary skill in the art and are performed without undue experimentation.

[0135] Circular or cyclized: As used herein, the term "circular" refers to the presence of a continuous loop. A circular molecule need not be circular, merely joined to form an unbroken chain of subunits. Circular molecules, such as engineered RNAs or mRNAs of the present disclosure, can be single units or multimers, or can contain one or more components of a complex or higher order structure.

[0136] Cytotoxic: As used herein, "cytotoxic" refers to a killing or damaging, toxic, or lethal effect on a cell (e.g., a mammalian cell (e.g., a human cell)), bacterium, virus, fungus, protozoan, parasite, prion, or combination thereof.

[0137] Delivering: As used herein, the term "delivering" means providing an entity to a destination. For example, delivering a polynucleotide to a subject can include administering a nanoparticle composition comprising the polynucleotide to the subject (e.g., by intravenous, intramuscular, intradermal, or subcutaneous routes). Administering a nanoparticle composition to a mammal or mammalian cells can include contacting one or more cells with the nanoparticle composition.

[0138] Delivery Agent: As used herein, "delivery agent" refers to any substance that at least partially facilitates the delivery of a polynucleotide to a targeted cell in vivo, in vitro, or ex vivo.

[0139] Destabilized: As used herein, "destabilized," "destabilize," or "destabilizing region" refers to a region or molecule that is less stable than the starting, wild-type, or native form of the same region or molecule.

[0140] Detectable Label: As used herein, "detectable label" refers to one or more markers, signals, or moieties attached to, incorporated into, or associated with another entity that is readily detected by methods known in the art, including x-ray imaging, fluorescence, chemiluminescence, enzymatic activity, absorbance, and the like. Detectable labels include radioisotopes, fluorophores, chromophores, enzymes, dyes, metal ions, ligands such as biotin, avidin, streptavidin, and haptens, quantum dots, and the like. Detectable labels can be located at any position in the peptides or proteins disclosed herein. Detectable labels can be internal to an amino acid, peptide, or protein, or can be located at the N-terminus or C-terminus.

[0141] Diastereomers: As used herein, the term "diastereomers" means stereoisomers that are not mirror images of each other and are not superimposable with respect to one another. Digest: As used herein, the term "digest" means to break down into smaller pieces or components. When referring to polypeptides or proteins, digestion results in the production of peptides.

[0142] Distal: As used herein, the term "distal" means located away from the center or point or area of ​​interest. Domain: As used herein, when referring to a polypeptide, the term "domain" refers to a motif in a polypeptide having one or more identifiable structural or functional features or characteristics (e.g., binding ability, serving as a site for protein-protein interaction).

[0143] Dosage regimen: As used herein, a "dosage regimen" or "dosing regimen" is a schedule of administration or a physician-determined regimen for treatment, prevention, or palliative care.

[0144] Effective amount: As used herein, the term "effective amount" of an agent is an amount sufficient to bring about a beneficial or desired result, e.g., a clinical result; as such, the "effective amount" depends on the context in which it is applied. For example, in the context of administering an agent to treat a tumor, an effective amount of the agent is an amount sufficient to reduce or decrease tumor size or inhibit tumor growth, for example, compared to the response obtained without administration of the agent. The term "effective amount" can be used interchangeably with "effective dose," "therapeutically effective amount," or "therapeutically effective dose."

[0145] Enantiomer: As used herein, the term "enantiomer" means each individual optically active form of a compound of the present disclosure having an optical purity or enantiomeric excess (as measured by standard methods in the art) of at least 80% (i.e., at least 90% of one enantiomer and at most 10% of the other enantiomer), at least 90%, or at least 98%.

[0146] Encapsulate: As used herein, the term "encapsulate" means to surround, enclose, or enclose. Encapsulation efficiency: As used herein, "encapsulation efficiency" refers to the amount of polynucleotide that becomes part of a nanoparticle composition relative to the initial total amount of polynucleotide used in preparing the nanoparticle composition. For example, if 97 mg of polynucleotide is encapsulated in a nanoparticle composition from a total of 100 mg of polynucleotide initially provided to the composition, the encapsulation efficiency can be given as 97%. As used herein, "encapsulation" can refer to complete, substantial, or partial confinement, enclosure, surrounding, or wrapping.

[0147] Encoded protein cleavage signal: As used herein, "encoded protein cleavage signal" refers to a nucleotide sequence that encodes a protein cleavage signal. Engineered: As used herein, an embodiment of the present disclosure is "engineered" when it is designed to have characteristics or properties, whether structural or chemical, that vary from the starting, wild-type or naturally occurring molecule.

[0148] Enhanced delivery: As used herein, the term "enhanced delivery" refers to greater (e.g., at least 1.5-fold greater, at least 2-fold greater, at least 3-fold greater, at least 4-fold greater, at least 5-fold greater, at least 6-fold greater, at least 7-fold greater, at least 8-fold greater, at least 9-fold greater, at least 10-fold greater) delivery of polynucleotides by nanoparticles to a target tissue of interest (e.g., mammalian liver) compared to the level of polynucleotide delivery by control nanoparticles to the target tissue of interest (e.g., MC3, KC2, or DLinDMA). The level of nanoparticle delivery to a particular tissue can be measured by comparing the amount of protein produced in the tissue to the weight of the tissue, the amount of polynucleotides in the tissue to the weight of the tissue, the amount of protein produced in the tissue to the total amount of protein in the tissue, or the amount of polynucleotides in the tissue to the total amount of polynucleotides in the tissue. It is understood that enhanced delivery of nanoparticles to a target tissue need not be measured in a subject undergoing treatment; enhanced delivery can be measured in a surrogate, such as an animal model (e.g., a rat model).

[0149] Exosome: As used herein, "exosome" is a vesicle secreted by mammalian cells or a complex involved in RNA degradation. Expression: As used herein, "expression" of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription), (2) processing of the RNA transcript (e.g., splicing, editing, 5' capping, and / or 3' end processing), (3) translation of the RNA into a polypeptide or protein, and (4) post-translational modification of the polypeptide or protein.

[0150] Ex vivo: As used herein, the term "ex vivo" refers to an event that occurs outside of a living organism (e.g., an animal, plant, or microorganism thereof, or cells or tissues thereof). An ex vivo event can occur in an environment that is minimally altered from the natural (e.g., in vivo) environment.

[0151] Feature: As used herein, "feature" refers to a characteristic, property, or distinctive element. When referring to a polypeptide, a "feature" is defined as a component based on the unique amino acid sequence of the molecule. Features of polypeptides encoded by the polynucleotides of the present disclosure include surface manifestations, local conformational shapes, folds, loops, half-loops, domains, half-domains, sites, termini, or any combination thereof.

[0152] Formulation: As used herein, a "formulation" includes at least a polynucleotide and one or more of a carrier, excipient, and delivery agent. Fragment: As used herein, "fragment" refers to a portion. For example, a fragment of a protein can include a polypeptide obtained by digesting a full-length protein isolated from cultured cells. In some embodiments, a fragment is a subsequence of the full-length protein (e.g., one of the subunits of IL-23) in which the N-terminus, and / or C-terminus, and / or internal subsequence is deleted. In some preferred aspects of the present disclosure, a fragment of a protein of the present disclosure is a functional fragment.

[0153] Functional: As used herein, a "functional" biomolecule is one in a form in which it exhibits a characteristic property and / or activity. Accordingly, a functional fragment of a polynucleotide of the present disclosure is a polynucleotide capable of expressing a functional interleukin fragment. As used herein, a functional fragment of an interleukin refers to a fragment of a wild-type interleukin (i.e., a fragment of a naturally occurring form of an interleukin), or a mutant or variant thereof, which fragment retains at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of the biological activity of the corresponding full-length protein.

[0154] Helper lipid: As used herein, the term "helper lipid" refers to a compound or molecule that contains a lipidic portion (for insertion into a lipid layer, e.g., a lipid bilayer) and a polar portion (for interaction with the physiological solution at the surface of the lipid layer). Typically, helper lipids are phospholipids. The function of helper lipids is to "complement" amino lipids and increase the membrane fusogenicity of the bilayer and / or to help facilitate, for example, endosomal escape of nucleic acids delivered to cells. Helper lipids are also believed to be key structural components for the surface of LNPs.

[0155] Homology: As used herein, the term "homology" refers to the overall relatedness between polymer molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and / or RNA molecules), and / or between polypeptide molecules. Generally, the term "homology" implies an evolutionary relatedness between two molecules. Thus, two molecules that are homologous are expected to share a common evolutionary ancestry. In the context of the present disclosure, the term homology encompasses both identity and similarity.

[0156] In some embodiments, polymer molecules are considered to be "homologous" to one another if at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% of the monomers in the molecules are identical (actually the same monomers) or similar (conservative substitutions). The term "homologous" necessarily refers to a comparison between at least two sequences (polynucleotide or polypeptide sequences).

[0157] Identity: As used herein, the term "identity" refers to the overall monomer conservation between polymer molecules, for example, between polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. Calculation of the percent identity of two polynucleotide sequences can be performed, for example, by aligning the two sequences for optimal comparison purposes (gaps can be introduced in one or both of the first and second nucleic acid sequences for optimal alignment, and non-identical sequences can be ignored for comparison purposes). In certain embodiments, the length of the aligned sequence for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. Next, the nucleotides at corresponding nucleotide positions are compared. If a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, the molecules are identical at this position. The percentage identity between two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps and the length of each gap that needs to be introduced for optimal alignment of the two sequences. Sequence comparison and determination of the percentage identity between two sequences can be accomplished using a mathematical algorithm. When comparing DNA and RNA, thymine (T) and uracil (U) can be considered equivalent.

[0158] Suitable software programs are available from a variety of sources for aligning both protein and nucleotide sequences. One suitable program for determining percent sequence identity is bl2seq, which is part of the BLAST suite of programs available from the U.S. government's National Center for Biotechnology Information BLAST website (blast.ncbi.nlm.nih.gov). bl2seq performs a comparison between two sequences using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. Other suitable programs are, for example, Needle, Stretcher, Water, or Matcher, which are part of the EMBOSS suite of bioinformatics programs and are available from the European Bioinformatics Institute (EBI) at www.ebi.ac.uk / Tools / psa.

[0159] Sequence alignment can be performed using methods known in the art, such as MAFFT, Clustal (ClustalW, Clustal X, or Clustal Omega), MUSCLE, and the like.

[0160] Each different region in a single polynucleotide or polypeptide target sequence that is aligned with a polynucleotide or polypeptide reference sequence can have its own sequence identity percentage.It is noted that the sequence identity percentage value is rounded to the nearest tenth.For example, 80.11, 80.12, 80.13, and 80.14 are rounded down to 80.1, while 80.15, 80.16, 80.17, 80.18, and 80.19 are rounded up to 80.2.It is also noted that the length is always an integer.

[0161] In certain embodiments, the percent identity (%ID) of a first amino acid sequence (or nucleic acid sequence) to a second amino acid sequence (or nucleic acid sequence) is calculated as %ID=100×(Y / Z), where Y is the number of amino acid residues (or nucleic acid bases) scored as identical matches in an alignment of the first and second sequences (aligned by visual inspection or by a particular sequence alignment program), and Z is the total number of residues in the second sequence. If the length of the first sequence is longer than the second sequence, the percent identity of the first sequence to the second sequence will be greater than the percent identity of the second sequence to the first sequence.

[0162] Those skilled in the art will understand that the generation of sequence alignment for calculating the percentage sequence identity is not limited to the comparison between two sequences performed exclusively by primary sequence data.It will also be understood that sequence alignment can be generated by integrating sequence data with data from different sources, such as structural data (e.g., protein crystal structures), functional data (e.g., mutation locations), or phylogenetic data.A suitable program for integrating different data to generate multiple sequence alignments is T-Coffee, available at www.tcoffee.org, and alternatively available from, for example, EBI.It will also be understood that the final alignment used to calculate the percentage sequence identity can be curated either automatically or manually.

[0163] Immune checkpoint inhibitor: "Immune checkpoint inhibitor" or simply "checkpoint inhibitor" refers to a molecule that prevents immune cells from being turned off by cancer cells. As used herein, the term checkpoint inhibitor refers to a polypeptide (e.g., an antibody) or a polynucleotide (e.g., mRNA) encoding such a polypeptide that neutralizes or inhibits inhibitory checkpoint molecules such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death receptor 1 (PD-1), or PD-1 ligand 1 (PD-L1).

[0164] Immune response: The term "immune response" refers to the action of, for example, lymphocytes, antigen-presenting cells, phagocytes, granulocytes, and soluble macromolecules (including antibodies, cytokines, and complement) produced by these cells or the liver, which result in the selective damage, destruction, or elimination of a human body invaded by a pathogen, cells or tissues infected by a pathogen, cancer cells, or, in the case of autoimmunity or pathological inflammation, normal human cells or tissues.

[0165] Immune response costimulatory signal: The term "immune response costimulatory signal" refers to an immune stimulatory molecule that promotes T cell and / or NK cell recruitment, proliferation, activation, survival, or a combination thereof. In some embodiments, the immune response costimulatory signal is a polypeptide that enhances T cell proliferation, function, and memory formation (e.g., OX40L). In some embodiments, the costimulatory signal promotes Th1, Th2, and / or Th9 development, suppresses Treg development or activity, enhances CD4 and / or CD8 T cell proliferation and / or survival, and / or promotes memory cells. In specific embodiments, the immune response costimulatory signal polypeptide is selected from the group consisting of OX40L, CD80, and IL-15. In some specific embodiments, the immune response costimulatory signal polypeptide is selected from the group consisting of OX40L and CD80.

[0166] Immune response primer: The term "immune response primer" refers to an immune stimulatory molecule that enhances antigen presentation and / or recognition. In some embodiments, an immune response primer is a polypeptide that stimulates dendritic cells, promotes dendritic cell maturation, promotes cytokine / chemokine production by antigen-presenting cells, expands and / or maintains Th17 cells, enhances T cell proliferation, and / or enhances Th1 and / or Th9 differentiation. In some embodiments, an immune response primer is a member of the IL-12 family (e.g., IL-12, IL-23, IL-12p40 subunit, IL-23p19 subunit, IL-27, IL-35). In other embodiments, an immune response primer is a member of the IL-1 family (e.g., IL-1α, IL-1β, IL-1Ra, IL-18, IL-33, IL-36Ra, IL-36α, IL-36β, IL-36γ, IL-37, IL-38). In some embodiments, the immune response primer is a polypeptide selected from the group consisting of IL-23, IL-12p40 subunit, IL-23p19 subunit, IL-12, IL-36-gamma, and IL-18.

[0167] Inflammatory response: "Inflammatory response" refers to an immune response that includes specific and non-specific defense systems. A specific defense system response is an immune system response that is specific to an antigen. Examples of specific defense system responses include antibody responses. A non-specific defense system response is an inflammatory response mediated by white blood cells that are generally incapable of immunological memory, such as macrophages, eosinophils, and neutrophils. In some embodiments, the immune response includes the secretion of inflammatory cytokines, resulting in elevated levels of inflammatory cytokines.

[0168] Inflammatory cytokine: The term "inflammatory cytokine" refers to a cytokine elevated in an inflammatory response. Examples of inflammatory cytokines include interleukin 6 (IL-6), CXCL1 (chemokine (C-X-C motif) ligand 1; also known as GROα), interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα), interferon gamma-inducible protein 10 (IP-10), or granulocyte colony-stimulating factor (G-CSF). The term inflammatory cytokine also includes other cytokines associated with inflammatory responses known in the art, such as interleukin 1 (IL-1), interleukin 8 (IL-8), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin alpha (IFN-α), and the like.

[0169] In vitro: As used herein, the term "in vitro" refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, in a Petri dish, etc., rather than in a living organism (e.g., an animal, plant, or microorganism).

[0170] In vivo: As used herein, the term "in vivo" refers to an event that takes place within a living organism (e.g., an animal, plant, or microorganism, or cells or tissues thereof).

[0171] Insertional and Deletional Variants: An "insertional variant," when referring to a polypeptide, is one that has one or more amino acids inserted immediately adjacent to an amino acid at a particular position in a native or starting sequence. "Immediately adjacent" to an amino acid means attached to either the alpha-carboxy or alpha-amino functionality of the amino acid. A "deletional variant," when referring to a polypeptide, is one that has one or more amino acids in the native or starting amino acid sequence removed. Typically, deletion variants result in the deletion of one or more amino acids in a particular region of the molecule.

[0172] Intact: As used herein, in a polypeptide, the term "intact" means possessing the amino acids corresponding to the wild-type protein, e.g., not mutating or substituting the wild-type amino acids. Conversely, in a nucleic acid, the term "intact" means possessing the nucleobases corresponding to the wild-type nucleic acid, e.g., not mutating or substituting the wild-type nucleobases.

[0173] Ionizable amino lipids: The term "ionizable amino lipids" includes amino lipids having one, two, three, or more fatty acid or fatty alkyl chains and a pH-titratable amino head group (e.g., an alkylamino head group or a dialkylamino head group). Ionizable amino lipids are typically protonated (i.e., positively charged) at a pH below the pKa of the amino head group and are substantially uncharged at a pH above the pKa. Such ionizable amino lipids include, but are not limited to, DLin-MC3-DMA (MC3) and (13Z,165Z)-N,N-dimethyl-3-nonidocosa-13-16-dien-1-amine (L608).

[0174] In vitro: As used herein, the term "in vitro" refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, in a Petri dish, etc., rather than in a living organism (e.g., an animal, plant, or microorganism).

[0175] In vivo: As used herein, the term "in vivo" refers to an event that takes place within a living organism (e.g., an animal, plant, or microorganism, or cells or tissues thereof).

[0176] Isolated: As used herein, the term "isolated" refers to a substance or entity that has been separated from at least some of the components with which it was associated (whether in nature or in an experimental setting). Isolated substances (e.g., nucleotide sequences or protein sequences) can have varying levels of purity with respect to the materials with which it was associated prior to isolation. Isolated substances and / or entities can be separated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more of the other components with which it was originally associated. In some embodiments, an isolated agent is greater than about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or greater than about 99% pure. As used herein, a substance is "pure" if it is substantially free of other components. The term "substantially isolated" means that the compound is substantially separated from the environment in which it was formed or detected. Partial isolation can include, for example, compositions enriched for the compounds of the present disclosure. Substantial isolation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the present disclosure or salts thereof.

[0177] A polynucleotide, vector, polypeptide, cell, or any composition disclosed herein that is "isolated" is a polynucleotide, vector, polypeptide, cell, or composition that is in a form not found in nature. Isolated polynucleotides, vectors, polypeptides, or compositions include those that have been purified to the extent that they are no longer in a form in which they are found in nature. In some embodiments, an isolated polynucleotide, vector, polypeptide, or composition is substantially pure.

[0178] Isomer: As used herein, the term "isomer" refers to any tautomer, stereoisomer, enantiomer, or diastereomer of any compound of the present disclosure. It is recognized that compounds of the present disclosure can possess one or more chiral centers and / or double bonds and, therefore, can exist as stereoisomers, such as double bond isomers (i.e., geometric E / Z isomers) or diastereomers (e.g., enantiomers (i.e., (+) or (-)) or cis / trans isomers). In accordance with the present disclosure, the chiral structures depicted herein, and therefore the compounds of the present disclosure, encompass all corresponding stereoisomers, i.e., both stereomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric and stereoisomeric mixtures, e.g., racemates. Enantiomeric and stereoisomeric mixtures of the compounds of the present disclosure can typically be resolved into the component enantiomers or stereoisomers of the mixture by well-known methods such as chiral-phase gas chromatography, chiral-phase high-performance liquid chromatography, crystallizing the compounds as chiral salt complexes, or crystallizing the compounds in chiral solvents. Enantiomers and stereoisomers can also be obtained from stereomerically or enantiomerically pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.

[0179] Linker: As used herein, "linker" refers to a group of atoms, e.g., 10 to 1,000 atoms, which can be composed of atoms or groups such as, but not limited to, carbon, amino, alkylamino, oxygen, sulfur, sulfoxide, sulfonyl, carbonyl, and imine. The linker can attach to a nucleoside or nucleotide on a modified nucleobase or sugar moiety at one end and to a payload, e.g., a detectable agent or therapeutic agent, at the second end. The linker can be of sufficient length so as not to interfere with incorporation into the nucleic acid sequence. Linkers can be used for any useful purpose, such as to form polynucleotide multimers (e.g., through the attachment of two or more chimeric polynucleotide molecules or IVT polynucleotides) or polynucleotide conjugates and administer payloads, as described herein. Examples of chemical groups that can be incorporated into linkers include, but are not limited to, alkyl, alkenyl, alkynyl, amide, amino, ether, thioether, ester, alkylene, heteroalkylene, aryl, or heterocyclyl, each of which can be optionally substituted as described herein. Examples of linkers include, but are not limited to, unsaturated alkanes, polyethylene glycols (e.g., ethylene or propylene glycol monomer units, e.g., diethylene glycol, dipropylene glycol, triethylene glycol, tripropylene glycol, tetraethylene glycol, or tetraethylene glycol), and dextran polymers and their derivatives. Other examples include, but are not limited to, cleavable moieties within the linker, such as, for example, disulfide bonds (-SS-) or azo bonds (-N=N-), which can be cleaved using reducing agents or photolysis. Non-limiting examples of selectively cleavable bonds include, for example, those that can be cleaved by the use of tris(2-carboxyethyl)phosphine (TCEP) or other reducing agents and / or photolysis, and ester bonds that can be cleaved, for example, by acidic or basic hydrolysis.

[0180] Method of administration: As used herein, "method of administration" can include intravenous, intramuscular, intradermal, subcutaneous, or other methods of delivering a composition to a subject. The method of administration can be selected to target (e.g., specifically deliver) delivery to a particular area or system of the body.

[0181] Modified: As used herein, "modified" refers to an altered state or structure of a molecule of the present disclosure. Molecules can be modified in many ways, including chemical, structural, and functional methods. In some embodiments, mRNA molecules of the present disclosure are modified by the introduction of non-natural nucleosides and / or nucleotides, for example, in relation to the natural ribonucleotides A, U, G, and C. Non-reference nucleotides, such as cap structures, which differ in chemical structure from the A, C, G, and U ribonucleotides, are not considered "modified."

[0182] Nanoparticle composition: As used herein, a "nanoparticle composition" is a composition comprising one or more lipids. Nanoparticle compositions are typically on the order of micrometers or less in size and may comprise a lipid bilayer membrane. Nanoparticle compositions include lipid nanoparticles (LNPs), liposomes (e.g., lipid vesicles), and lipoplexes. For example, a nanoparticle composition may be a liposome having a lipid bilayer membrane with a diameter of 500 nm or less.

[0183] Naturally occurring: As used herein, "naturally occurring" means occurring in nature without artificial additives. Non-human vertebrate: As used herein, "non-human vertebrate" includes all vertebrates other than Homo sapiens, including wild-type and domesticated species. Examples of non-human vertebrates include, but are not limited to, mammals such as alpacas, banteng, bison, camels, cats, cows, deer, dogs, donkeys, gayal, goats, guinea pigs, horses, llamas, mules, pigs, rabbits, reindeer, sheep, water buffalo, and yaks.

[0184] Nucleic acid sequence: The terms "nucleic acid sequence," "nucleotide sequence," or "polynucleotide sequence" are used interchangeably and refer to a contiguous nucleic acid sequence. This sequence can be either single-stranded or double-stranded DNA or RNA, e.g., mRNA.

[0185] The term "nucleic acid," in its broadest sense, includes any compound and / or substance comprising a polymer of nucleotides. These polymers are often referred to as polynucleotides. Exemplary nucleic acids or polynucleotides of the present disclosure include, but are not limited to, ribonucleic acid (RNA), deoxyribonucleic acid (DNA), threose nucleic acid (TNA), glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (LNA; including LNA having a β-D-ribo configuration, α-LNA (a diastereomer of LNA) having an α-L-ribo configuration, 2'-amino-LNA having a 2'-amino functionalization, and 2'-amino-α-LNA having a 2'-amino functionalization), ethylene nucleic acid (ENA), cyclohexenyl nucleic acid (CeNA), or hybrids or combinations thereof.

[0186] The phrase "nucleotide sequence encoding" refers to a nucleic acid (e.g., an mRNA molecule or a DNA molecule) that encodes a polypeptide. The coding sequence can further include initiation and termination signals operably linked to regulatory elements including a promoter and polyadenylation signal capable of directing expression in the cells of an individual or mammal to which the nucleic acid is administered. The coding sequence can further include a sequence encoding a signal peptide.

[0187] Off-target: As used herein, "off-target" refers to any unintended effect on any one or more targets, genes, or cellular transcripts. Open reading frame: As used herein, "open reading frame" or "ORF" refers to a sequence that does not contain a stop codon in a given reading frame.

[0188] Operably linked: As used herein, the phrase "operably linked" refers to a functional connection between two or more molecules, constructs, transcripts, entities, moieties, etc.

[0189] Optionally substituted: As used herein, phrases of the form "optionally substituted X" (e.g., optionally substituted alkyl) are intended to be equivalent to "X optionally substituted X" (e.g., "alkyl optionally substituted alkyl"). The feature of "X" (e.g., alkyl) is not itself intended to imply optionality.

[0190] Portion: As used herein, a "portion" or "region" of a polynucleotide is defined as any portion of the polynucleotide that is less than the full length of the polynucleotide. Patient: As used herein, "patient" refers to a subject who may be seeking or in need of treatment for a particular disease or condition, in need of treatment, undergoing treatment, about to receive treatment, or under the care of a trained professional.

[0191] Pharmaceutically acceptable: The phrase "pharmaceutically acceptable" is employed herein to refer to compounds, materials, compositions, and / or dosage forms that are within the scope of sound medical judgment and suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0192] Pharmaceutically acceptable excipient: The phrase "pharmaceutically acceptable excipient," as used herein, refers to any ingredient (e.g., a vehicle capable of suspending or dissolving an active compound) other than the compounds described herein and that has the properties of being substantially non-toxic and non-inflammatory in a patient. Excipients can include, for example, anti-adherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colorants), emollients, emulsifiers, fillers (diluents), film-forming or film-coating agents, flavorings, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, solvents, suspending or dispersing agents, sweeteners, and water of hydration. Exemplary excipients include, but are not limited to, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, cross-linked polyvinylpyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropylmethylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinylpyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.

[0193] Pharmaceutically acceptable salts: The present disclosure also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds in which the parent compound has been modified by converting an existing acid or base moiety into its salt form (e.g., by reacting a free base group with a suitable organic acid). Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like. Representative acid addition salts include acetate, acetic acid, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzenesulfonic acid, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy- Salts include ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.The pharmaceutically acceptable salts of the present disclosure can be synthesized from parent compounds containing basic or acidic moieties by conventional chemical methods.Generally, these salts can be prepared by reacting the free acid or free base form of these compounds with a stoichiometric amount of suitable base or acid in water or in an organic solvent, or in a mixture of the two, and generally use non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile.A list of suitable salts can be found in Remington's Pharmaceutical. Sciences, 17 th ed., Mack Publishing Company, Easton, Pa., 1985, p.1418, Pharmaceutical Salts: Properties, Selection, and Use, P.H. Stahl and C.G. Wermuth (eds.), Wiley-VCH, 2008, and Berge et al., Journal of Pharmaceutical Science, 66, 1-19 (1977), each of which is incorporated herein by reference in its entirety.

[0194] Pharmaceutically acceptable solvate: As used herein, the term "pharmaceutically acceptable solvate" refers to a compound of the present disclosure in which molecules of a suitable solvent are incorporated into the crystal lattice. The suitable solvent can be physiologically tolerated at the administered dose. For example, solvates can be prepared by crystallization, recrystallization, or precipitation from a solution containing an organic solvent, water, or a mixture thereof. Examples of suitable solvents are ethanol, water (e.g., monohydrate, dihydrate, and trihydrate), N-methylpyrrolidinone (NMP), dimethyl sulfoxide (DMSO), N,N'-dimethylformamide (DMF), N,N'-dimethylacetamide (DMAC), 1,3-dimethyl-2-imidazolidinone (DMEU), 1,3-dimethyl-3,4,5,6-tetrahydro-2-(1H)-pyrimidinone (DMPU), acetonitrile (ACN), propylene glycol, ethyl acetate, benzyl alcohol, 2-pyrrolidone, benzyl benzoate, etc. When water is the solvent, the solvate is referred to as a "hydrate."

[0195] Pharmacokinetics: As used herein, "pharmacokinetics" refers to any one or more properties of a molecule or compound as it relates to determining the fate of an administered substance in an organism. Pharmacokinetics is divided into several areas, including the extent and rate of absorption, distribution, metabolism, and excretion. This is commonly referred to as ADME. (A) Absorption is the process of a substance entering the blood circulation; (D) Distribution is the dispersion or transfer of a substance throughout the body's fluids and tissues; (M) Metabolism (or biotransformation) is the irreversible transformation of a parent compound into daughter metabolites; and (E) Excretion (or elimination) refers to the removal of a substance from the body. In rare cases, some drugs irreversibly accumulate in body tissues.

[0196] Physicochemical: As used herein, a "physicochemical" measure of or relating to physical and / or chemical properties. Polynucleotide: As used herein, the term "polynucleotide" refers to a polymer of nucleotides of any length, comprising ribonucleotides, deoxyribonucleotides, their analogs, or mixtures thereof. The term refers to the primary structure of the molecule. Thus, the term includes triple-, double-, and single-stranded deoxyribonucleic acid ("DNA"), as well as triple-, double-, and single-stranded ribonucleic acid ("RNA"). The term also includes modified forms, for example, by alkylation and / or by capping of the polynucleotide, as well as unmodified forms. More specifically, the term "polynucleotide" includes polydeoxyribonucleotides (containing 2-deoxy-D-ribose), spliced ​​or unspliced ​​polyribonucleotides (containing D-ribose), including tRNA, rRNA, hRNA, siRNA, and mRNA, other types of polynucleotides that are N- or C-glycosides of purine or pyrimidine bases, as well as other polymers containing normucleotidic backbones, such as polyamides (e.g., peptide nucleic acids, "PNAs") and polymorpholino polymers, and other synthetic sequence-specific nucleic acid polymers, provided that the polymer contains nucleobases in a configuration that allows for base pairing and base stacking, as found in DNA and RNA. In certain embodiments, the polynucleotide comprises mRNA. In other embodiments, the mRNA is synthetic mRNA. In some embodiments, the synthetic mRNA comprises at least one unnatural nucleobase. In some embodiments, all of the nucleobases of a particular class are replaced with unnatural nucleobases (e.g., all uridines in the polynucleotides disclosed herein can be replaced with unnatural nucleobases, such as 5-methoxyuridine). In some embodiments, the polynucleotide (e.g., synthetic RNA or synthetic DNA) contains only natural nucleobases, i.e., A, C, T, and U in the case of synthetic DNA, or A, C, T, and U in the case of synthetic RNA.

[0197] Those skilled in the art will understand that while a T base in the codon maps disclosed herein is present in DNA, the T base will be replaced by a U base in the corresponding RNA. For example, a codon-nucleotide sequence in a DNA format, such as a vector or in vitro translation (IVT) template, will have its T base transcribed as a U in the corresponding transcribed mRNA. In this regard, both a codon-optimized DNA sequence (containing a T) and its corresponding RNA sequence (containing a U) are considered codon-optimized nucleotide sequences of the present disclosure. Those skilled in the art will also understand that equivalent codon maps can result from one or more bases being replaced with an unnatural base. Thus, a TTC codon (DNA map) would correspond to a UUC codon (RNA map), which in turn would correspond to a ΨΨC codon (RNA map with U replaced with pseudouridine).

[0198] Standard AT and GC base pairs form under conditions that allow hydrogen bond formation between the N3-H and C4-oxy of thymidine and the N1 and C6-NH2 of adenosine, respectively, and between the C2-oxy, N3, and C4-NH2 of cytidine and the C2-NH2, N'-H, and C6-oxy of guanosine, respectively. Thus, for example, guanosine (2-amino-6-oxy-9-β-D-ribofuranosyl-purine) can be modified to form isoguanosine (2-oxy-6-amino-9-β-D-ribofuranosyl-purine). Such modifications result in nucleoside bases that no longer effectively form standard base pairs with cytosine. However, modification of cytosine (1-β-D-ribofuranosyl-2-amino-4-oxy-pyrimidine) to form isocytosine (1-β-D-ribofuranosyl-2-amino-4-oxy-pyrimidine-) results in a modified nucleotide that does not base pair efficiently with guanosine, but does base pair with isoguanosine (U.S. Patent No. 5,681,702 to Collins et al.). Isocytosine is available from Sigma Chemical Co. (St. Louis, MO); isocytidine can be prepared by the method described by Switzer et al. (1993) Biochemistry 32:10489-10496 and the references cited therein; 2'-deoxy-5-methyl-isocytidine can be prepared by the method of Tor et al. (1993) J. Am. Chem. Soc. 115:4461-4467 and the references cited therein; and isoguanine nucleotides can be prepared using the method described by Switzer et al., 1993, supra, and Mantsch et al. (1993) Biochem. 14:5593-5601, or by the method described in U.S. Pat. No. 5,780,610 to Collins et al.Other unnatural base pairs can be synthesized by the method described in Piccirilli et al. (1990) Nature 343:33-37 for the synthesis of 2,6-diaminopyrimidine and its complement (1-methylpyrazolo-[4,3]pyrimidine-5,7-(4H,6H)-dione). Other such modified nucleotide units that form unique base pairs are known, such as those described in Leach et al. (1992) J. Am. Chem. Soc. 114:3675-3683 and Switzer et al., supra.

[0199] Nucleic acid sequence: The terms "nucleic acid sequence," "nucleotide sequence," or "polynucleotide sequence" are used interchangeably and refer to a contiguous nucleic acid sequence. This sequence can be either single-stranded or double-stranded DNA or RNA, e.g., mRNA.

[0200] The phrase "nucleotide sequence encoding" and variants thereof refer to a nucleic acid (e.g., an mRNA molecule or a DNA molecule) coding sequence that comprises a nucleotide sequence that encodes a polypeptide described herein or a functional fragment thereof. The coding sequence can further comprise initiation and termination signals operably linked to regulatory elements comprising a promoter and a polyadenylation signal that are capable of directing expression in the cells of an individual or mammal to which the nucleic acid is administered. The coding sequence can further comprise a sequence encoding a signal peptide.

[0201] Polypeptide: The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. A polymer can comprise modified amino acids. The term also encompasses amino acid polymers modified, naturally or by intervention, for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids such as homocysteine, ornithine, p-acetylphenylalanine, D-amino acids, and creatine), as well as other modifications known in the art.

[0202] As used herein, the term refers to proteins, polypeptides, and peptides of any size, structure, or function. Polypeptides include gene products, naturally occurring polypeptides, synthetic polypeptides, homologs, orthologs, paralogs, fragments, and other equivalents, variants, and analogs of the above. A polypeptide can be a single polypeptide or a multimolecular complex, such as a dimer, trimer, or tetramer. A polypeptide can also include single-chain or multi-chain polypeptides. Disulfide bonds are most commonly found in multi-chain polypeptides. The term polypeptide can also apply to amino acid polymers in which one or more amino acid residues are artificial chemical analogs of the corresponding naturally occurring amino acids. In some embodiments, a "peptide" can be 50 amino acids or less in length, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids in length.

[0203] Polypeptide variant: As used herein, the term "polypeptide variant" refers to a molecule whose amino acid sequence differs from a native or reference sequence. Amino acid sequence variants can have substitutions, deletions, and / or insertions at certain positions within the amino acid sequence compared to the native or reference sequence. Typically, variants will have at least about 50% identity, at least about 60% identity, at least about 70% identity, at least about 80% identity, at least about 90% identity, at least about 95% identity, or at least about 99% identity to the native or reference sequence. In some embodiments, variants will be at least about 80% or at least about 90% identical to the native or reference sequence.

[0204] Polypeptide per Unit Drug (PUD): As used herein, PUD or product per unit drug is defined as a subdivision of the total daily dose, usually 1 mg, pg, kg, etc. of product (such as a polypeptide) as measured in a body fluid or tissue, usually defined in terms of concentration in the body fluid divided by pmol / mL, mmol / mL, etc.

[0205] Preventing: As used herein, the term "preventing" refers to partially or completely delaying the onset of an infection, disease, disorder, and / or condition; partially or completely delaying the onset of one or more symptoms, characteristics, or clinical manifestations of a particular infection, disease, disorder, and / or condition; partially or completely delaying the onset of one or more symptoms, characteristics, or clinical signs of an infection, a particular disease, disorder, and / or condition; and / or reducing the risk of developing pathology associated with an infection, disease, disorder, and / or condition.

[0206] Prodrug: The present disclosure also includes prodrugs of the compounds described herein. As used herein, "prodrug" refers to any substance, molecule, or entity in a form that determines that the substance, molecule, or entity acts as a therapeutic agent upon chemical or physical change. A prodrug may be covalently attached or sequestered in some manner that releases or is converted to an active drug moiety before, during, or after administration to a mammalian subject. Prodrugs can be prepared by modifying functional groups present in the compound in such a way that the modification is cleaved either in routine manipulation of the parent compound or in vivo. Prodrugs include compounds bonded to any group that, upon administration to a mammalian subject, causes the hydroxyl, amino, sulfhydryl, or carboxyl group to cleave to form a free hydroxyl, amino, sulfhydryl, or carboxyl group, respectively. The preparation and use of prodrugs is discussed in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the ACS Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference in their entireties.

[0207] Proliferate: As used herein, the term "proliferate" means to grow, increase, or increase, or cause to grow, increase, or increase rapidly. "Proliferative" means having the capacity to proliferate. "Antiproliferative" means having properties that are opposed to or inappropriate for proliferative properties.

[0208] Prophylactic: As used herein, "prophylactic" refers to a therapeutic agent or course of action used to prevent the spread of disease. Prophylaxis: As used herein, "prophylaxis" refers to measures taken to maintain health and prevent the spread of disease. "Immunoprophylaxis" refers to measures that produce active or passive immunity to prevent the spread of disease.

[0209] Proteolytic cleavage site: As used herein, "proteolytic cleavage site" refers to a site where controlled cleavage of an amino acid chain can be achieved by chemical, enzymatic, or photochemical means.

[0210] Protein cleavage signal: As used herein, a "protein cleavage signal" refers to at least one amino acid that flags or marks a polypeptide for cleavage.

[0211] Protein of interest: As used herein, the term "protein of interest" or "desired protein" includes those provided herein, as well as fragments, mutants, variants, and variations thereof.

[0212] Proximal: As used herein, the term "proximal" means located closer to the center or to a point or area of ​​interest. Pseudouridine: As used herein, pseudouridine refers to the C-glycoside isomer of the nucleoside uridine. A "pseudouridine analog" is any modification, variant, isoform, or derivative of pseudouridine. For example, pseudouridine analogs include 1-carboxymethyl-pseudouridine, 1-propynyl-pseudouridine, 1-taurinomethyl-pseudouridine, 1-taurinomethyl-4-thio-pseudouridine, 1-methylpseudouridine (m 1 Ψ), 1-methyl-4-thio-pseudouridine (m 1 s 4 Ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m 3Ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydropseudouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine, 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp 3 Examples of suitable pseudouridines include, but are not limited to, 2'-O-methyl-pseudouridine (Ψm), and 2'-O-methyl-pseudouridine (Ψm).

[0213] Purified: As used herein, "purify," "purified," and "purified" mean to make substantially pure or clear from undesired components, contaminating materials, impurities, or imperfections.

[0214] Reference nucleic acid sequence: The term "reference nucleic acid sequence" or "reference nucleic acid" or "reference nucleotide sequence" or "reference sequence" refers to a starting nucleic acid sequence (e.g., an RNA, e.g., an mRNA sequence) whose sequence is to be optimized. In some embodiments, the reference nucleic acid sequence is a wild-type nucleic acid sequence, a fragment, or a variant thereof. In some embodiments, the reference nucleic acid sequence is a nucleic acid sequence whose sequence has been previously optimized.

[0215] Repeated transfection: As used herein, the term "repeated transfection" refers to the transfection of the same cell culture with a polynucleotide multiple times. The cell culture can be transfected at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 11 times, at least 12 times, at least 13 times, at least 14 times, at least 15 times, at least 16 times, at least 17 times, at least 18 times, at least 19 times, at least 20 times, at least 25 times, at least 30 times, at least 35 times, at least 40 times, at least 45 times, at least 50 times, or more.

[0216] Salts: In some embodiments, the pharmaceutical compositions for intratumoral delivery disclosed herein contain salts of some of their lipid components. The term "salt" includes any anionic and cationic complexes. Non-limiting examples of anions include inorganic and organic anions such as fluoride, chloride, bromide, iodide, oxalate (e.g., hemioxalate), phosphate, phosphonate, hydrogen phosphate, dihydrogen phosphate, oxide, carbonate, bicarbonate, nitrate, nitrite, nitride, hydrogen nitrite, sulfide, sulfite, bisulfate, sulfate, thiosulfate, hydrogen sulfate, borate, formate, acetate, benzoate, citrate, tartrate, lactate, acrylate, polyacrylate, fumarate, Included are maleate, itaconate, glycolate, gluconate, malate, mandelate, tiglate, ascorbate, salicylate, polymethacrylate, perchlorate, chlorite, hypochlorite, bromate, hypobromite, iodate, alkylsulfonate, arylsulfonate, arsenate, arsenite, chromate, dichromate, cyanide, cyanate, thiocyanate, hydroxide, peroxide, permanganate, and mixtures thereof.

[0217] Sample: As used herein, the term "sample" or "biological sample" refers to a subset of tissues, cells, or components thereof (e.g., blood, mucus, lymph, synovial fluid, cerebrospinal fluid, saliva, amniotic fluid, umbilical cord blood, urine, vaginal fluid, and semen). Samples can also include, for example, whole organisms or tissues, cells, or components thereof, including, but not limited to, plasma, serum, spinal fluid, lymph, external sections of the skin, trachea, intestinal tract, and genitourinary tract, tears, saliva, breast milk, blood cells, tumors, organs, or homogenates, lysates, or extracts prepared from fractions or portions thereof. Samples also refer to media such as nutrient broths or gels that may contain cellular components such as proteins or nucleic acid molecules.

[0218] Signal sequence: As used herein, the phrases "signal sequence," "signal peptide," and "transit peptide" are used interchangeably and refer to a sequence that directs the transport or localization of a protein to a particular organelle, cellular compartment, or extracellular transport. The term encompasses both signal sequence polypeptides and nucleic acid sequences that encode signal sequences. Thus, in a nucleic acid, reference to a signal sequence actually refers to the nucleic acid sequence that encodes the signal sequence polypeptide.

[0219] Signal Transduction Pathway: A "signal transduction pathway" refers to the biochemical association between various signaling molecules that play a role in the transmission of a signal from one part of a cell to another part of the cell. As used herein, the phrase "cell surface receptor" includes, for example, molecules and complexes of molecules that can receive a signal and the transmission of such a signal across the plasma membrane of a cell.

[0220] Similarity: As used herein, the term "similarity" refers to the overall relatedness between polymer molecules, e.g., between polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. Calculations of the percentage similarity of multiple polymer molecules relative to each other can be performed in the same manner as calculations of percent identity, except that percentage similarity calculations take into account conservative substitutions as understood in the art.

[0221] Specific delivery: As used herein, the terms "specific delivery," "specifically deliver," or "specifically delivering" refer to greater (e.g., at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold) delivery of polynucleotides by nanoparticles to a target tissue of interest (e.g., the liver of a mammal) compared to an off-target tissue (e.g., the spleen of a mammal). The level of nanoparticle delivery to a particular tissue can be measured by comparing the amount of protein produced in the tissue to the weight of the tissue, comparing the amount of polynucleotide in the tissue to the weight of the tissue, comparing the amount of protein produced in the tissue to the weight of total polynucleotide in the tissue, or comparing the amount of polynucleotide in the tissue to the weight of total polynucleotide in the tissue. For example, for renal vascular targeting, if 1.5, 2, 3, 5, 10, 15, or 20 times more polynucleotide is delivered to the kidney per gram of tissue compared to that delivered to the liver or spleen of a mammal after systemic administration of the polynucleotide, the polynucleotide is specifically provided to the kidney compared to the liver and spleen. It will be understood that the ability of nanoparticles to specifically deliver to target tissues need not be measured in the subject being treated, but can be measured in a surrogate, such as an animal model (e.g., a rat model).

[0222] Stable: As used herein, "stable" refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture and, in some cases, can be formulated into an efficacious therapeutic agent.

[0223] Stabilized: As used herein, the terms "stabilize," "stabilized," and "stabilized region" mean to make stable or to become stable. Stereoisomers: As used herein, the term "stereoisomer" refers to all of the different possible isomeric and conformational forms that a compound (e.g., a compound of any formula described herein) may have, particularly with respect to the basic molecular structure, including all possible stereochemically and conformationally isomeric forms, diastereomers, enantiomers, and / or conformers. Some compounds of the present disclosure may exist in different tautomeric forms, all of the latter of which are included within the scope of the present disclosure.

[0224] Subject: By "subject" or "individual" or "animal" or "patient" or "mammal" is meant any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired. Mammalian subjects include, but are not limited to, humans, livestock, farm animals, zoo animals, sport animals, and pet animals, such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, and dairy cows; primates, such as apes, monkeys, orangutans, and chimpanzees; canines, such as dogs and wolves; felines, such as cats, lions, and tigers; equines, such as horses, donkeys, and zebras; food animals, such as bears, dairy cows, pigs, and sheep; ungulates, such as deer and giraffes; rodents, such as mice, rats, hamsters, and guinea pigs; and others. In certain embodiments, the mammal is a human subject. In other embodiments, the subject is a human patient. In certain embodiments, the subject is a human patient in need of treatment for cancer.

[0225] Substantially: As used herein, the term "substantially" refers to the qualitative condition of exhibiting all or nearly all of the extent or degree of a desired characteristic or property. Those skilled in the biology arts will understand that biological and chemical phenomena rarely, if ever, tend to and / or proceed to completion or reach or avoid an absolute result. The term "substantially" is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.

[0226] Substantially equal: As used herein when referring to the time difference between doses, this term means plus / minus 2%. Substantially simultaneous: As used herein and in reference to multiple administrations, this term means within 2 seconds.

[0227] Suffering from: An individual "suffering from" a disease, disorder, and / or condition has been diagnosed with or displays one or more symptoms of that disease, disorder, and / or condition.

[0228] Susceptible to: An individual who is "susceptible to" a disease, disorder, and / or condition may not have been diagnosed with and / or may not exhibit symptoms of the disease, disorder, and / or condition, but has a propensity to develop the disease or its symptoms. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition (e.g., cancer) can be characterized by one or more of the following: (1) a genetic mutation associated with the development of the disease, disorder, and / or condition, (2) a genetic polymorphism associated with the development of the disease, disorder, and / or condition, (3) increased and / or decreased expression and / or activity of proteins and / or nucleic acids associated with the development of the disease, disorder, and / or condition, (4) habits and / or lifestyles associated with the development of the disease, disorder, and / or condition, (5) a family history of the disease, disorder, and / or condition, and (6) exposure to and / or infection by a microorganism associated with the development of the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition will develop the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition will not develop the disease, disorder, and / or condition.

[0229] Sustained release: As used herein, the term "sustained release" refers to the release profile of a pharmaceutical composition or compound that behaves according to a rate of release over a specific period of time. Synthetic: The term "synthetic" means produced, prepared, and / or manufactured by the hand of man. Synthesis of polynucleotides or other molecules of the disclosure can be chemical or enzymatic.

[0230] Targeted Cell: As used herein, "targeted cell" refers to any one or more cells of interest. The cells may be found in vitro, in vivo, in situ, or in a tissue or organ of a living organism. The living organism may be an animal, preferably a mammal, more preferably a human, and most preferably a patient.

[0231] Target tissue: As used herein, "target tissue" refers to any one or more tissue types of interest where delivery of a polynucleotide will result in a desired biological and / or pharmacological effect. Examples of target tissues of interest include specific tissues, organs, and systems or groups thereof. In particular applications, the target tissue may be the kidney, lung, spleen, vascular endothelium in blood vessels (e.g., intracoronary or intrafemoral), or tumor tissue (e.g., via intratumoral injection). "Off-target tissue" refers to any one or more tissue types where expression of the encoded protein does not result in a desired biological and / or pharmacological effect. In particular applications, off-target tissues may include the liver and pancreas.

[0232] Targeted sequence: As used herein, the phrase "targeted sequence" refers to a sequence that is capable of directing the transport or localization of a protein or polypeptide. Terminal: As used herein, the term "terminal(s)," when referring to a polypeptide, refers to the terminus of a peptide or polypeptide. Such terminals are not limited to the initial or final position of a peptide or polypeptide, but can include additional amino acids in the terminal region. Polypeptide-based molecules of the present disclosure can be characterized as having both an N-terminus (terminated by an amino acid having a free amino group (NH)) and a C-terminus (terminated by an amino acid having a free carboxyl group (COOH)). Proteins of the present disclosure are, in some cases, made up of multiple polypeptide chains held together by disulfide bonds or non-covalent forces (multimers, oligomers). These types of proteins are expected to have multiple N- and C-termini. Alternatively, the termini of a polypeptide can optionally be modified to begin or end with a non-polypeptide-based moiety, such as an organic conjugate.

[0233] Therapeutic Agent: The term "therapeutic agent" refers to an agent that has a therapeutic, diagnostic, and / or prophylactic effect and / or induces a desired biological and / or pharmacological effect when administered to a subject. For example, in some embodiments, an mRNA encoding an IL-36-gamma polypeptide can be a therapeutic agent.

[0234] Therapeutically effective amount: As used herein, "therapeutically effective amount" means the amount of an agent (e.g., nucleic acid, drug, therapeutic agent, diagnostic agent, prophylactic agent, etc.) delivered that, when administered to a subject suffering from or susceptible to an infection, disease, disorder, and / or condition, is sufficient to treat, ameliorate the symptoms of, or prevent and / or delay the onset of, the infection, disease, disorder, and / or condition.

[0235] Therapeutically effective result: As used herein, the term "therapeutically effective result" means a result that is sufficient to treat, ameliorate the symptoms of, and / or prevent and / or delay the onset of, an infection, disease, disorder, and / or condition in a subject suffering from or susceptible to the infection, disease, disorder, and / or condition.

[0236] Total daily dose: As used herein, the "total daily dose" is the amount given or prescribed in a 24-hour period. The total daily dose can be administered as a single unit dose or divided doses.

[0237] Transcription factor: As used herein, the term "transcription factor" refers to a DNA-binding protein that regulates the transcription of DNA to RNA, for example, by activating or repressing transcription. Some transcription factors regulate transcription only, while others act together with other proteins. Some transcription factors can both activate and repress transcription under certain conditions. Generally, transcription factors bind to one or more specific target sequences that are highly similar to specific consensus sequences in the regulatory region of target genes. Transcription factors can regulate the transcription of target genes alone or in complexes with other molecules.

[0238] Transcription: As used herein, the term "transcription" refers to a method of introducing exogenous nucleic acid into a cell. Transfection methods include, but are not limited to, chemical methods, physical treatments, and cationic lipids or mixtures.

[0239] Transfection: As used herein, "transfection" refers to the introduction of a polynucleotide into a cell, resulting in expression of a polypeptide encoded by the polynucleotide (e.g., mRNA) or in the regulation of a cellular function (e.g., siRNA, miRNA). As used herein, "expression" of a nucleic acid sequence refers to the translation of the polynucleotide (e.g., translation of mRNA) into a polypeptide or protein and / or post-translational modification of the polypeptide or protein.

[0240] Treating, Therapy, Therapy: As used herein, the terms "treating" or "treatment" or "therapy" refer to partially or completely alleviating, ameliorating, ameliorating, palliating, delaying the onset of, inhibiting the progression of, reducing the severity of, and / or reducing the incidence of one or more symptoms or characteristics of a hyperproliferative disease, e.g., cancer. For example, "treating" cancer can refer to inhibiting tumor survival, growth, and / or spread. Therapy can be administered to subjects who do not exhibit symptoms of a disease, disorder, and / or condition, and / or to subjects who exhibit only early symptoms of a disease, disorder, and / or condition, for the purpose of reducing the risk of developing the pathology associated with the disease, disorder, and / or condition.

[0241] Tumor microenvironment: As used herein, "tumor microenvironment" refers to the composition of cells within a tumor, with respect to infiltrating immune cells and / or inflammatory cells, and the presence or absence of such cell type(s) within the tumor. In one embodiment, the tumor microenvironment is an "inflamed tumor microenvironment," referring to the presence of immune cells and / or inflammatory cells that have infiltrated into the tumor, with the predominant cell type being granulocytes. In another embodiment, the tumor microenvironment is an "immunosuppressive tumor microenvironment," referring to the presence of immune cells and / or inflammatory cells that have infiltrated into the tumor, with the predominant cell types being monocytes and macrophages. In another embodiment, the tumor microenvironment is an "immunologically deficient tumor microenvironment," referring to the lack of significant infiltration of immune cells and / or inflammatory cells into the tumor.

[0242] Unmodified: As used herein, "unmodified" refers to any substance, compound, or molecule before it has been altered in any way. Unmodified can, but does not necessarily, refer to the wild-type or native form of a biomolecule. A molecule can undergo a series of modifications, whereby each modified molecule can serve as the "unmodified" starting molecule for subsequent modifications.

[0243] Uracil: Uracil is one of the four nucleobases in RNA nucleic acids and is represented by the letter U. Uracil can be attached to a ribose ring, or more specifically, to a ribofuranose via a β-N1-glycosidic bond, to give the nucleoside uridine. The nucleoside uridine is also commonly abbreviated by the single-letter designation for its nucleobase, i.e., U. Thus, in this disclosure, when a monomer in a polynucleotide sequence is U, such U is referred to interchangeably as "uracil" or "uridine."

[0244] Uridine content: The terms "uridine content" or "uracil content" are interchangeable and refer to the amount of uracil or uridine present in a particular nucleic acid sequence. Uridine or uracil content can be expressed as an absolute value (the total number of uridines or uracils in the sequence) or relative (the percentage of uridines or uracils relative to the total number of nucleobases in the nucleic acid sequence).

[0245] Uridine-modified sequence: The term "uridine-modified sequence" refers to a nucleic acid (e.g., a synthetic mRNA sequence) whose sequence has been optimized with a different overall or local uridine content (higher or lower uridine content) or with a different uridine pattern (e.g., gradient distribution or clustering) relative to the uridine content and / or uridine pattern of a candidate nucleic acid sequence. In this disclosure, the terms "uridine-modified sequence" and "uracil-modified sequence" are considered equivalent and interchangeable.

[0246] A "uridine-rich codon" is defined as a codon containing two or three uridines, a "low uridine codon" is defined as a codon containing one uridine, and a "uridine-free codon" is a codon that does not have any uridines. In some embodiments, uridine-modified sequences include substitutions of a high uridine codon with a low uridine codon, a high uridine codon with a zero uridine codon, a low uridine codon with a high uridine codon, a low uridine codon with a zero uridine codon, a zero uridine codon with a low uridine codon, a zero uridine codon with a high uridine codon, and combinations thereof. In some embodiments, a high uridine codon can be replaced with another high uridine codon. In some embodiments, a low uridine codon can be replaced with another low uridine codon. In some embodiments, a zero uridine codon can be replaced with another zero uridine codon. Uridine-modified sequences can be uridine-rich or uridine-poor.

[0247] Uridine-rich: As used herein, the term "uridine-rich" and grammatical variations refer to an increase in the uridine content (expressed in absolute terms or as a percentage value) in a sequence-optimized nucleic acid (e.g., a synthetic mRNA sequence) relative to the uridine content of the corresponding candidate nucleic acid sequence. Uridine enrichment can be achieved by substituting codons in the candidate nucleic acid sequence with synonymous codons that contain fewer uridine nucleobases. Uridine enrichment can be global (i.e., over the entire length of the candidate nucleic acid sequence) or local (i.e., over a subsequence or region of the candidate nucleic acid sequence).

[0248] Uridine-scarce: As used herein, the term "uridine-scarce" and grammatical variations refer to a reduction in the uridine content (expressed in absolute terms or as a percentage value) in a sequence-optimized nucleic acid (e.g., a synthetic mRNA sequence) relative to the uridine content of a corresponding candidate nucleic acid sequence. Uridine scarcity can be achieved by substituting codons in the candidate nucleic acid sequence with synonymous codons that contain fewer uridine nucleobases. Uridine scarcity can be global (i.e., over the entire length of the candidate nucleic acid sequence) or local (i.e., over a subsequence or region of the candidate nucleic acid sequence).

[0249] Variant: As used in this disclosure, the term variant refers to both naturally occurring variants (e.g., polymorphisms, isoforms, etc.) and artificial variants in which at least one amino acid residue in a native or starting sequence (e.g., a wild-type sequence) has been removed and a different amino acid sequence has been inserted in its place at the same position. These variants can be described as "substitutional variants." The substitutions can be single, where only one amino acid in the molecule has been substituted, or multiple, where two or more amino acids have been substituted in the same molecule. When amino acids are inserted or deleted, the resulting variants will be "insertion variants" or "deletion variants," respectively. II. Combinations Comprising Polynucleotides Encoding Immunomodulating Polypeptides The present disclosure provides compositions for the treatment of cancer ("compositions of the present disclosure"). In one embodiment, the compositions comprise at least two polynucleotides (e.g., mRNAs) or at least three polynucleotides (e.g., mRNAs) in a single formulation, each selected from a first polynucleotide encoding IL-23, a second polynucleotide encoding IL-36-gamma (or, alternatively, IL-18), and / or a third polynucleotide encoding OX40L. Thus, the present disclosure provides, for example, (i) a first polynucleotide (e.g., mRNA) encoding a first protein comprising an IL-23 polypeptide, (ii) a second polynucleotide (e.g., mRNA) encoding a second protein comprising an IL-36-gamma polypeptide (or an IL-18 polypeptide), and (iii) a third polynucleotide (e.g., mRNA) encoding a third protein comprising an OX40L polypeptide, wherein the first polynucleotide, second polynucleotide, and third polynucleotide are used in various combinations. In one embodiment, the composition comprises a first polynucleotide, a second polynucleotide, and a third polynucleotide. The term "polynucleotide of the disclosure" refers to the first polynucleotide, the second polynucleotide, and the third polynucleotide disclosed herein.

[0250] As used herein, the term "combination of the present disclosure" refers to, for example, (i) a first polynucleotide (e.g., mRNA) encoding a first protein comprising an IL-23 polypeptide, and a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide; (ii) a first polynucleotide (e.g., mRNA) encoding a first protein comprising an IL-23 polypeptide, a third polynucleotide (e.g., mRNA) encoding a third protein comprising an OX40L polypeptide; (iii) an IL-36-gamma polypeptide or an IL-18 polypeptide; or (iv) a combination of a first polynucleotide (e.g., mRNA) encoding a first protein comprising an IL-23 polypeptide, a second polynucleotide (e.g., mRNA) encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide, and a third polynucleotide (e.g., mRNA) encoding a third protein comprising an OX40L polypeptide. It is understood that the term "combination of the present disclosure" is not limited to the physical combination of a first polynucleotide, a second polynucleotide, and / or a third polynucleotide, but also encompasses separate, simultaneous, or sequential administration of any of these polynucleotides.

[0251] Thus, in another embodiment, a composition of the present disclosure comprises a polynucleotide (e.g., mRNA) encoding a single polypeptide, IL-23, IL-36-gamma or IL-18, or OX40L, but each of the compositions (e.g., a composition comprising a first polynucleotide encoding IL-23, a composition comprising a second polynucleotide encoding IL-36-gamma or IL-18, and a third polynucleotide encoding OX40L) can be used together in the methods described herein.

[0252] Those skilled in the art will also recognize that alternative embodiments of the present disclosure include combination therapy of IL-23, IL-36-gamma or IL-18, and / or OX40 as polynucleotides and / or proteins. For example, the present disclosure encompasses combination therapy of (i) a first polynucleotide (e.g., mRNA) encoding IL-23 and a second protein comprising IL-36-gamma or IL-18, a first protein comprising IL-23 and a second polynucleotide (e.g., mRNA) encoding a second protein comprising IL-36gamma or IL-18, or (iii) a first protein comprising IL-23 and a second protein comprising IL-36gamma or IL-18. Similarly, the present disclosure encompasses combination therapy of a first protein comprising an IL-23 polynucleotide (e.g., mRNA) or an IL-23 polypeptide, a second protein comprising an IL-36-gamma polynucleotide or an IL-18 polynucleotide (e.g., mRNA) or an IL-36-gamma polypeptide or an IL-18 polypeptide, an OX40L polynucleotide (e.g., mRNA) or a third protein comprising an OX40L polypeptide, or combinations thereof. Polynucleotides encoding IL-23 IL-23 is a proinflammatory cytokine that plays an important role in innate and adaptive immunity. Croxford et al. (2012) Eur. J. Immunol. 42:2263-2273. IL-23 functions primarily as a 60 kDa heterodimeric protein consisting of disulfide-linked p19 and p40 subunits. IL-23 is structurally and functionally similar to the proinflammatory cytokine IL-12. IL-23 contains the same p40 subunit as IL-12, but contains the p19 subunit rather than the p35 subunit of IL-12. Oppman et al. (2000) Immunity 13:715-725. The precursor form of the p19 subunit (NCBI Reference Sequence: NP_057668; NM_016584; Uniprot: Q9NPF7; also known as IL-23A and IL-23 subunit alpha) is 189 amino acids long, while its mature form is 170 amino acids long. The precursor form of the p40 subunit (NCBI Reference Sequence: NM_002187; Uniprot: P29460; also known as IL-12B, natural killer cell-stimulating factor 2, and cytotoxic lymphocyte maturation factor 2) is 328 amino acids long, while its mature form is 306 amino acids long.

[0253] Many different immune cells, including dendritic cells and macrophages, produce IL-23 upon antigen stimulation. One difference between IL-12 and IL-23 is that IL-12 is associated with the development and activity of TH1 T cell populations, whereas IL-23 is associated with the development and activity of Th17 T cell populations. See Vignali et al. (2014) Nat. Immunol. 13:722-728.

[0254] Although some early studies implicated IL-23 in antitumor therapy (Belladonna et al. (2002) J. Immunol. 168:5448-5454), more recent studies have demonstrated potential pro-tumorigenic functions for IL-23. See, e.g., Croxford et al. (2012) Eur. J. Immunol. 42:2263-2273; Langowski et al. (2007) Trends Immunol. 28:207-212; Langowski et al. (2006) Nature 442:461-465; Teng et al. (2010) Proc. Natl. Acad. Sci. USA 107:8328-8333; Teng et al. (2012) Cancer Res. 72:3987-3996. Langowski (2006) observed increased IL-23 in human tumors. See also Ngiow et al. (2013) Trends Immunol. 34:548-555; Wilke et al. (2011) Carcinogenesis 32:643-649; Xu et al. (2010) Clin. Dev. Immunol. 2010. For example, Wang et al. (2015) Clin. Exp. Rheumatol. 33(Suppl. 92):S87-S90 teaches that increased expression of IL-23 has a pathogenic function in cancer. IL-23 plays a causative role in tumor development and progression and has been linked to adverse prognosis and rapid progression to metastatic disease, suggesting that inhibition of IL-23 expression may be useful in the therapy and prevention of cancer, particularly colorectal cancer. Teng et al. al. (2015) Nature Medicine 21:719-29 teaches that IL-23 indirectly or directly promotes tumorigenesis, growth, and metastasis, and indicates that inhibition of IL-23 expression could be used in cancer therapy and prevention.

[0255] As used in this disclosure, the term "IL-23 polypeptide" refers to, for example, the IL-12p40 subunit of IL-23, the IL-23p19 subunit of IL-23, or a fusion protein comprising an IL-12p40 subunit polypeptide and an IL-23p19 subunit polypeptide. In some embodiments, the fusion protein comprises, from N-terminus to C-terminus: (a) an IL-12p40 subunit containing the IL-12p40 signal peptide, a peptide linker, and a mature IL-23p19 subunit; or (b) IL-23p19 subunit containing the IL-23p19 signal peptide, a peptide linker, and mature IL-12p40.

[0256] In one particular embodiment, the IL-23 polypeptide comprises, consists of, or consists essentially of a human or mouse IL-23 polypeptide of Table 1 (e.g., a precursor or mature form of IL-12p40 or IL-23p19), or a combination thereof. In one particular embodiment, the polynucleotide encoding the IL-23 polypeptide comprises, consists of, or consists essentially of a polynucleotide encoding an IL-23 of Table 1.

[0257] In some embodiments, an IL-23 polypeptide comprises an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to an IL-23 amino acid sequence listed in Table 1 or an amino acid sequence encoded by a nucleotide sequence listed in Table 1, and the IL-23 polypeptide has at least 10% of the activity (e.g., binding to an IL-23 polypeptide receptor) of the corresponding wild-type IL-23 polypeptide. In specific embodiments, an IL-23 polypeptide comprises an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:1, SEQ ID NO:5, or SEQ ID NO:140, and has at least 10% of the activity (e.g., binding to an IL-23 polypeptide receptor) of the corresponding wild-type IL-23 polypeptide. In another specific embodiment, the IL-23 polypeptide consists essentially of SEQ ID NO:1, SEQ ID NO:5, or SEQ ID NO:140 and has at least 10% of the activity (e.g., binding to an IL-23 polypeptide receptor) of the corresponding wild-type IL-23 polypeptide.

[0258] In other embodiments, the IL-23 polypeptide encoded by the polynucleotide of the present disclosure comprises an amino acid sequence listed in Table 1 or the amino acid sequence set forth in SEQ ID NO: 1, 5, or 140 with one or more conservative substitutions, which do not significantly affect the binding activity of the IL-23 polypeptide to its receptor, i.e., the IL-23 polypeptide binds to the IL-23 receptor following the substitutions.

[0259] In some embodiments, the nucleotide sequence encoding an IL-23 polypeptide (i.e., mRNA) comprises a sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to an IL-23 polypeptide encoding nucleic acid sequence listed in Table 1. In specific embodiments, the nucleotide sequence encoding an IL-23 polypeptide (i.e., mRNA) comprises a sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 19, SEQ ID NO: 71, SEQ ID NO: 141, or SEQ ID NO: 142. In another specific embodiment, the nucleotide sequence encoding an IL-23 polypeptide (i.e., mRNA) consists essentially of SEQ ID NO: 19, SEQ ID NO: 71, SEQ ID NO: 141, or SEQ ID NO: 142. It should be understood that the nucleotide sequence encoding the IL-23 polypeptide open reading frame (ORF) (i.e., mRNA, e.g., SEQ ID NO:19, SEQ ID NO:71, or SEQ ID NO:141) may be one element within a larger construct, further comprising, for example, a 5' end cap, a 5' UTR (e.g., SEQ ID NO:27 or SEQ ID NO:44), a 3' UTR (e.g., SEQ ID NO:119 or SEQ ID NO:120), and / or a poly-A tail. Polynucleotides encoding IL-12 polypeptides In some embodiments, the first polynucleotide encodes a first protein comprising an IL-12 polypeptide. As used in this disclosure, the term "IL-12 polypeptide" refers to, for example, the IL-12p40 subunit of IL-12 (i.e., IL12B), the IL-12p35 subunit of IL-12 (i.e., IL12Aa), or a fusion protein comprising an IL-12p40 subunit polypeptide and an IL-12p35 subunit polypeptide. In some embodiments, the fusion protein comprises an IL12B polypeptide selected from the following: (i) a full-length IL12B polypeptide (e.g., having the same or essentially the same length as wild-type IL12B); (ii) functional fragments of the full-length IL12B polypeptide sequence (truncated sequences shorter than the IL12B wild-type (e.g., deletions of carboxy-terminal, amino-terminal, or internal regions) but still retaining IL12B enzymatic activity); (iii) a variant of an IL12B polypeptide (e.g., a full-length or truncated IL12B protein in which one or more amino acids have been replaced, e.g., a variant that retains all or most of the IL12B polypeptide activity relative to the wild-type IL12B polypeptide (e.g., V33I, V298F, or any naturally occurring or artificial variant known in the art), or (iv) a fusion protein comprising (i) a full-length wild-type IL12B, a functional fragment or a variant thereof, and (ii) a heterologous protein; and / or an IL12A polypeptide selected from: (i) a full-length IL12A polypeptide (e.g., having the same or essentially the same length as wild-type IL12A); (ii) a functional fragment of a full-length IL12A polypeptide (e.g., a truncated sequence shorter than the IL12A wild-type (e.g., deletion of the carboxy-terminal region, amino-terminal region, or internal region), but still retaining IL12A enzymatic activity); (iii) a variant of an IL12A polypeptide (e.g., a full-length or truncated IL12A protein in which one or more amino acids have been replaced, e.g., a variant that retains all or most of the IL12A polypeptide activity relative to the wild-type IL12A polypeptide (such as a naturally occurring or artificial variant known in the art)), or (iv) a fusion protein comprising (i) a full-length wild-type IL12A, a functional fragment or a variant thereof, and (ii) a heterologous protein. Includes.

[0260] In one particular embodiment, the IL-12 polypeptide comprises, consists of, or consists essentially of a human or mouse IL-12 polypeptide of Table 1 (e.g., the precursor or mature form of IL-12p40 or IL-12p35), or a combination thereof. In one particular embodiment, the polynucleotide encoding the IL-12 polypeptide comprises, consists of, or consists essentially of a polynucleotide encoding IL-23 of Table 1.

[0261] In some embodiments, the IL-12 polypeptide comprises an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to an IL-12 amino acid sequence listed in Table 1 or an amino acid sequence encoded by a nucleotide sequence listed in Table 1, and the IL-12 polypeptide has at least 10% of the activity (e.g., binding to an IL-12 polypeptide receptor) of the corresponding wild-type IL-12 polypeptide.

[0262] In other embodiments, the IL-12 polypeptide encoded by the polynucleotide of the present disclosure comprises an amino acid sequence listed in Table 1 with one or more conservative substitutions, which do not significantly affect the binding activity of the IL-12 polypeptide to its receptor, i.e., the IL-12 polypeptide binds to the IL-12 receptor following the substitutions.

[0263] In some embodiments, the nucleotide sequence encoding the IL-12 polypeptide (i.e., mRNA) comprises a sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to an IL-12 polypeptide encoding nucleic acid sequence listed in Table 1. In specific embodiments, the nucleotide sequence encoding the IL-12 polypeptide (i.e., mRNA) comprises a sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:183. It should be understood that the nucleotide sequence encoding the IL-12 polypeptide open reading frame (ORF) (i.e., mRNA) may be one element within a larger construct that further includes, for example, a 5' end cap, a 5' UTR (e.g., SEQ ID NO:27 or SEQ ID NO:44), a 3' UTR (e.g., SEQ ID NO:119 or SEQ ID NO:120), and / or a poly-A tail. Polynucleotides encoding IL-36-gamma polypeptides In some embodiments, a first polynucleotide encoding a first protein comprising an IL-23 polypeptide can be combined with a polynucleotide encoding a second comprising an IL-36 polypeptide.

[0264] IL-36-gamma is a member of the interleukin-1 family of cytokines. Like other members of the interleukin-1 family of cytokines, IL-36-gamma requires N-terminal cleavage for full biological activity. IL-36-gamma does not have a signal sequence and therefore is not secreted through the endoplasmic reticulum-Golgi pathway. See Gresnigt and van de Veerdonk (2013) Seminars in Immunology 25:458-465). It is unclear how IL-36-gamma is released from cells to act on, for example, immune cells, other epithelial cells, and fibroblasts (Gabay et al. (2015) Journal of Leukocyte Biology 97:645-652). In an exemplary embodiment of the present invention, a polynucleotide encoding IL-36, e.g., IL-36-gamma, includes a sequence encoding a heterologous signal peptide. Without being bound by theory, it is believed that polynucleotides encoding such "engineered" signal peptide-interleukin chimeric proteins prime the production of active proteins when expressed in vivo in the absence of inflammasome activation.

[0265] In one embodiment, the heterologous signal peptide is derived from an immunoglobulin heavy or light chain. In an exemplary embodiment, the heterologous signal peptide is derived from an immunoglobulin light chain, e.g., from the variable region of the light chain. In an exemplary embodiment, the heterologous signal peptide is derived from the human immunoglobulin kappa light chain variable region hIGVK4. In an exemplary aspect, a polynucleotide of the invention encodes a heterologous signal peptide operably linked to a sequence encoding an IL-36-gamma polypeptide.

[0266] In one particular embodiment, the IL-36-gamma polypeptide comprises, consists of, or consists essentially of an IL-36-gamma polypeptide of Table 1. In one particular embodiment, the polynucleotide encoding the IL-36-gamma polypeptide comprises, consists of, or consists essentially of a polynucleotide encoding an IL-36-gamma of Table 1.

[0267] In some embodiments, the IL-36-gamma polypeptide comprises an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to an IL-36-gamma amino acid sequence listed in Table 1 or an amino acid sequence encoded by a nucleotide sequence listed in Table 1, and the IL-36-gamma polypeptide has at least 10% of the activity (e.g., binding to an IL-36-gamma polypeptide receptor) of the corresponding wild-type IL-36-gamma polypeptide. In certain embodiments, the IL-36-gamma polypeptide comprises an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 16 and has at least 10% of the activity (e.g., binding to an IL-36-gamma polypeptide receptor) of the corresponding wild-type IL-36-gamma polypeptide. In another specific embodiment, the IL-36-gamma polypeptide consists essentially of SEQ ID NO: 16 and has at least 10% of the activity (e.g., binding to an IL-36-gamma polypeptide receptor) of the corresponding wild-type IL-36-gamma polypeptide.

[0268] In other embodiments, the IL-36-gamma polypeptide encoded by the polynucleotide of the present disclosure comprises an amino acid sequence listed in Table 1 or the amino acid sequence set forth in SEQ ID NO: 16 with one or more conservative substitutions, which do not significantly affect the binding activity of the IL-36-gamma polypeptide to its receptor, i.e., the IL-36-gamma polypeptide binds to the IL-36-gamma receptor after the substitutions.

[0269] In some embodiments, the nucleotide sequence (i.e., mRNA) encoding an IL-36-gamma polypeptide comprises a sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to an IL-36-gamma polypeptide encoding a nucleic acid sequence listed in Table 1. In specific embodiments, the nucleotide sequence (i.e., mRNA) encoding an IL-36-gamma polypeptide comprises a sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 17, SEQ ID NO: 94, SEQ ID NO: 143, or SEQ ID NO: 144. In another specific embodiment, the nucleotide sequence (i.e., mRNA) encoding an IL-36-gamma polypeptide consists essentially of SEQ ID NO: 17, SEQ ID NO: 94, SEQ ID NO: 143, or SEQ ID NO: 144. It should be understood that the nucleotide sequence encoding the IL-23 polypeptide open reading frame (ORF) (i.e., mRNA, e.g., SEQ ID NO:17, SEQ ID NO:94, or SEQ ID NO:143) may be one element within a larger construct, further comprising, for example, a 5' end cap, a 5' UTR (e.g., SEQ ID NO:27 or SEQ ID NO:44), a 3' UTR (e.g., SEQ ID NO:119 or SEQ ID NO:120), and / or a poly-A tail. Polynucleotides encoding IL-18 polypeptides In some embodiments, a first polynucleotide encoding a first protein comprising an IL-23 polypeptide can be combined with a second polynucleotide encoding a second protein, where the second protein comprises an IL-18 polypeptide.

[0270] IL-18, also known as interferon gamma-inducing factor (IGIF) and IFN-γ-inducing factor, is a member of the interleukin-1 family of cytokines. IL-18 has two known isoforms, isoform 1 and isoform 2. Isoform 2 differs from isoform 1 by the absence of residues 27-30. Like other members of the interleukin-1 family of cytokines, IL-18 requires N-terminal cleavage for full biological activity (Dinarello et al. (2013) Frontiers in Immunology 4:289). IL-18 does not have a signal sequence and therefore is not secreted through the endoplasmic reticulum-Golgi pathway (see Gresnigt and van de Veerdonk (2013) Seminars in Immunology 25:458-465).

[0271] IL-18 is an inflammatory agonist that signals through IL-18α and IL-18β co-receptors to induce NFκB and MAPK, which activate signaling cascades (Dinarello et al. (2013)). As with IL-23, there are conflicting reports regarding the promising use of IL-18 for anti-cancer therapy. Ma et al. (2016) Clin. Cancer Res. 22:2969-2680 teach that combination treatment with IL-18 enhances anti-PD-L1 and / or anti-CTLA-4 induced anti-tumor activity. However, Fabbi et al. (2015) J. Leukoc. Biol. 97:665-675 teaches that IL-18 may play different roles in cancer, with anti-cancer activity in some cases and tumor-promoting activity in others. Fabbi notes that while preclinical studies and some clinical trials suggest that IL-18 has anti-tumor activity, other studies have shown that IL-18 may exert pro-invasive, pro-angiogenic, and immunomodulatory activities in different tumor models. For example, Term et al. (2011) Cancer Res. 71:5393-9 teaches that IL-18 is an immunosuppressive cytokine in cancer and that IL-18 produced by tumor cells promotes the development of NK-regulated metastasis in a PD-1-dependent manner. Kang et al. (2009) Carcinogenesis 30:1987-86 teaches that IL-18 increases metastasis and immune escape in gastric cancer.

[0272] In an exemplary embodiment of the invention, a polynucleotide encoding IL-18 includes a sequence encoding a heterologous signal peptide. Without being bound by theory, it is believed that polynucleotides encoding such "engineered" signal peptide-interleukin chimeric proteins prime the production of active proteins when expressed in vivo in the absence of inflammasome activation.

[0273] In one embodiment, the heterologous signal peptide is derived from an immunoglobulin heavy or light chain. In an exemplary embodiment, the heterologous signal peptide is derived from an immunoglobulin light chain, e.g., from the variable region of the light chain.

[0274] In an exemplary embodiment, the heterologous signal peptide is derived from the human immunoglobulin kappa light chain variable region hIGVK4. In an exemplary aspect, a polynucleotide of the invention encodes a heterologous signal peptide operably linked to a sequence encoding an IL-18 polypeptide.

[0275] In one particular embodiment, the IL-18 polypeptide comprises, consists of, or consists essentially of an IL-18 polypeptide of Table 1. In one particular embodiment, the polynucleotide encoding the IL-18 polypeptide comprises, consists of, or consists essentially of a polynucleotide encoding an IL-18 of Table 1.

[0276] In some embodiments, an IL-18 polypeptide comprises an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to an IL-18 amino acid sequence listed in Table 1 or an amino acid sequence encoded by a nucleotide sequence listed in Table 1, and the IL-18 polypeptide has at least 10% of the activity (e.g., binding to an IL-18 polypeptide receptor) of a corresponding wild-type IL-18 polypeptide. In specific embodiments, a nucleotide sequence encoding an IL-18 polypeptide (i.e., mRNA) comprises a sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:148, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, or SEQ ID NO:162. In another specific embodiment, the nucleotide sequence encoding an IL18 polypeptide (i.e., mRNA) consists essentially of SEQ ID NO: 148, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, or SEQ ID NO: 162. It should be understood that the nucleotide sequence encoding an IL-18 polypeptide open reading frame (ORF) (i.e., mRNA, e.g., SEQ ID NO: 148, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, or SEQ ID NO: 162) may be one element within a larger construct, further comprising, for example, a 5' end cap, a 5' UTR (e.g., SEQ ID NO: 27 or SEQ ID NO: 44), a 3' UTR (e.g., SEQ ID NO: 119 or SEQ ID NO: 120), and / or a poly-A tail. Polynucleotides encoding OX40L polypeptides In some embodiments, a first polynucleotide encoding a first protein comprising an IL-23 polypeptide can be combined with a third polynucleotide encoding a third protein, where the third protein comprises an OX40L polypeptide. In other embodiments, a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide can be combined with a third polynucleotide encoding a third protein, where the third protein comprises an OX40L polypeptide. In certain embodiments, a first polynucleotide encoding a first protein comprising an IL-23 polypeptide and a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide can be combined with a third polynucleotide encoding a third protein, where the third protein comprises an OX40L polypeptide.

[0277] Human OX40L was first identified on the surface of human T-cell leukemia virus type I (HTLV-I)-infected human lymphocytes by Tanaka et al. (Tanaka et al., International Journal of Cancer (1985), 36(5):549-55). OX40L is a ligand for OX40 (CD134). OX40L has also been called CD252 (cluster of differentiation 252), tumor necrosis factor (ligand) superfamily member 4, tax transcription-activating glycoprotein 1 (TXGP1), or gp34. Human OX40L is 183 amino acids long and contains three domains: a cytoplasmic domain from amino acids 1 to 23, a transmembrane domain from amino acids 24 to 50, and an extracellular domain from amino acids 51 to 183.

[0278] In some embodiments, the third polynucleotide comprises an mRNA encoding a mammalian OX40L polypeptide. In some embodiments, the mammalian OX40L polypeptide is a mouse OX40L polypeptide. In some embodiments, the mammalian OX40L polypeptide is a human OX40L polypeptide. In some embodiments, the OX40L polypeptide comprises the amino acid sequence shown in Table 1A.

[0279] In some embodiments, each polynucleotide of the present disclosure comprises mRNA, i.e., mRNA encoding an IL-23 polypeptide, mRNA encoding an IL-36-gamma polypeptide, and mRNA encoding an OX40L polypeptide. In some embodiments, the mRNA encoding an IL-23 polypeptide encodes a mammalian IL-23 polypeptide. In some embodiments, the mRNA encoding an IL-36-gamma polypeptide encodes a mammalian IL-36-gamma polypeptide. In some embodiments, the mRNA encoding an OX40L polypeptide encodes a mammalian OX40L polypeptide. In some embodiments, the mRNA encoding an IL-23 polypeptide encodes a murine IL-23 polypeptide. In some embodiments, the mRNA encoding an IL-36-gamma polypeptide encodes a murine IL-36-gamma polypeptide. In some embodiments, the mRNA encoding an OX40L polypeptide encodes a murine OX40L polypeptide. In some embodiments, the mRNA encoding an IL-23 polypeptide encodes a human IL-23 polypeptide. In some embodiments, the mRNA encoding an IL-36-gamma polypeptide encodes a human IL-36-gamma polypeptide. In some embodiments, the mRNA encoding the OX40L polypeptide encodes a human OX40L polypeptide.

[0280] In some embodiments, the IL-23 polypeptide comprises the human amino acid sequence shown in Table 1. In some embodiments, the IL-36-gamma polypeptide comprises the human amino acid sequence shown in Table 1. In other embodiments, the OX40L polypeptide comprises the human amino acid sequence shown in Table 1A.

[0281] In some embodiments, the OX40L polypeptide comprises an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to an amino acid sequence listed in Table 1A or an amino acid sequence encoded by a nucleotide sequence listed in Table 1A, and the amino acid sequence is capable of binding to the OX40 receptor. In specific embodiments, the OX40L polypeptide comprises an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:21 and is capable of binding to the OX40 receptor. In another specific embodiment, the OX40L polypeptide consists essentially of SEQ ID NO:21 and is capable of binding to the OX40 receptor.

[0282] In certain embodiments, the OX40L polypeptide encoded by the polynucleotide of the present disclosure comprises an amino acid sequence listed in Table 1A or the amino acid sequence set forth in SEQ ID NO: 21 with one or more conservative substitutions, which do not significantly affect the binding activity of the OX40L polypeptide to its receptor, i.e., the OX40L polypeptide binds to the OX40 receptor after the substitutions.

[0283] In other embodiments, the nucleotide sequence (i.e., mRNA) encoding the OX40L polypeptide comprises a sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to a nucleic acid sequence listed in Table 1A. In specific embodiments, the nucleotide sequence (i.e., mRNA) encoding the OX40L polypeptide comprises a sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:116, SEQ ID NO:145, or SEQ ID NO:146. In another specific embodiment, the nucleotide sequence (i.e., mRNA) encoding the OX40L polypeptide consists essentially of SEQ ID NO:116, SEQ ID NO:145, or SEQ ID NO:146. It should be understood that the nucleotide sequence encoding the OX40L polypeptide open reading frame (ORF) (i.e., mRNA, e.g., SEQ ID NO:116 or SEQ ID NO:145) may be one element within a larger construct that further includes, for example, a 5' end cap, a 5' UTR (e.g., SEQ ID NO:27 or SEQ ID NO:44), a 3' UTR (e.g., SEQ ID NO:119 or SEQ ID NO:120), and / or a poly-A tail.

[0284] In some embodiments, a polynucleotide (e.g., mRNA) useful in the present methods and compositions comprises an open reading frame encoding the extracellular domain of OX40L. In other embodiments, a polynucleotide (e.g., mRNA) comprises an open reading frame encoding the cytoplasmic domain of OX40L. In some embodiments, a polynucleotide (e.g., mRNA) comprises an open reading frame encoding the transmembrane domain of OX40L. In certain embodiments, a polynucleotide (e.g., mRNA) comprises an open reading frame encoding the extracellular domain of OX40L and the transmembrane domain of OX40L. In other embodiments, a polynucleotide (e.g., mRNA) comprises an open reading frame encoding the extracellular domain of OX40L and the cytoplasmic domain of OX40L. In still other embodiments, the polynucleotide (e.g., mRNA) comprises an open reading frame encoding the extracellular domain of OX40L, the transmembrane domain of OX40L, and the cytoplasmic domain of OX40L.

[0285] Table 1 or Table 1A, for example, represents precursor and mature sequences for IL-23, IL-36-gamma, and OX40L, as well as constructs comprising IL-23 or IL-36-gamma. In the present disclosure, IL-23 polynucleotides or IL-23 polypeptides encompass both the "precursor" and "mature" forms. Furthermore, constructs comprising polynucleotides encoding IL-23, IL-36-gamma, and OX40L, and further comprising components such as 3' UTRs and 5' UTRs, would be considered polynucleotides encoding IL-23, IL-36-gamma, and OX40L. Those skilled in the art will understand that other signal sequences can be used in addition to the native signal and propeptide sequences (sequences present in the precursor for the mature corresponding form and sequences absent in the mature corresponding form) explicitly disclosed in Table 1 or Table 1A, and the non-native signal peptides (IgKV4 signal peptides) disclosed in Table 1 or Table 1A. Thus, references to IL-23, IL-36-gamma, and OX40L polypeptides or polynucleotides according to Table 1 encompass variants in which alternative signal peptides (or coding sequences) known in the art are attached to the IL-23, IL-36-gamma, and OX40L polypeptides (or polynucleotides). It is also understood that references throughout this application to the sequences disclosed in Table 1 are equally applicable and encompass orthologs and functional variants (e.g., polymorphic variants) and isoforms of the sequences known in the art.

[0286] [Table 1-1]

[0287] [Table 1-2]

[0288] [Table 1-3]

[0289]

Table 1-4

[0290]

Table 1-5

[0291]

Table 1-6

[0292]

Table 1-7

[0293]

Table 1-8

[0294]

Table 1-9

[0295]

Table 1-10

[0296]

Table 1-11

[0297]

Table 1-12

[0298]

Table 1-13

[0299]

Table 1-14

[0300]

Table 1-15

[0301]

Table 1-16

[0302]

Table 1-17

[0303]

Table 1-18

[0304]

Table 1-19

[0305]

Table 1-20

[0306]

Table 1-21

[0307]

Table 1-22

[0308]

Table 1-23

[0309]

Table 1-24

[0310]

Table 1-25

[0311]

Table 1-26

[0312]

Table 1-27

[0313]

Table 1-28

[0314]

Table 1-29

[0315]

Table 1A-1

[0316]

Table 1A-2

[0317] Table 1A-3

[0318]

Table 1A-4

[0319] [Table 1A-5]

[0320] [Table 1A-6]

[0321] [Table 1A-7]

[0322] [Table 1A-8]

[0323] [Table 1A-9]

[0324] [Table 1A-10]

[0325] [Table 1A-11]

[0326] [Table 1A-12]

[0327] Based on the RNA sequences provided herein, and particularly in Tables 1 and 1A, one of skill in the art will recognize the corresponding DNA sequences (e.g., uracil to thymine conversions). Similarly, based on the DNA sequences provided, one of skill in the art will recognize the corresponding RNA sequences (e.g., thymine to uracil conversions).

[0328] In some embodiments, the first polynucleotide comprises an mRNA comprising a codon-optimized sequence encoding an IL-23 polypeptide (e.g., SEQ ID NO: 141). In some embodiments, the second polynucleotide comprises an mRNA comprising a codon-optimized sequence encoding an IL-36-gamma polypeptide (e.g., SEQ ID NO: 143). In other embodiments, the third polynucleotide comprises an mRNA comprising a codon-optimized sequence encoding an OX40L polypeptide (e.g., SEQ ID NO: 145).

[0329] In some embodiments, the first polynucleotide comprises an mRNA encoding a full-length IL-23 polypeptide, hi some embodiments, the first polynucleotide comprises an mRNA encoding a human IL-23 polypeptide that is missing at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 14, or at least 15 amino acids at the N-terminus or C-terminus of wild-type IL-23 polypeptide.

[0330] In some embodiments, the second polynucleotide comprises an mRNA encoding a full-length IL-36-gamma polypeptide, hi some embodiments, the second polynucleotide comprises an mRNA encoding a human IL-36-gamma polypeptide that is missing at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 14, or at least 15 amino acids at the N-terminus or C-terminus of wild-type IL-36-gamma polypeptide.

[0331] In some embodiments, the polynucleotide comprises an mRNA encoding a full-length OX40L polypeptide. In some embodiments, the polynucleotide comprises an mRNA encoding a human OX40L polypeptide that is 183 amino acids in length. In certain embodiments, the OX40L polypeptide can be missing at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 14, or at least 15 amino acids at the N-terminus or C-terminus of the OX40L polypeptide.

[0332] In some embodiments, polynucleotides (e.g., mRNA) of the present disclosure are "structurally modified" or "chemically modified." As used herein, a "structural" modification is one in which two or more linked nucleosides are inserted, deleted, duplicated, inverted, or randomized in a polynucleotide without significant chemical modification of the mRNA itself. Because chemical bonds must be broken and reformed to result in a structural modification, the structural modification is chemical in nature and is therefore a chemical modification. However, the structural modification will result in a different nucleotide sequence. For example, an mRNA called "AUCG" can be chemically modified to "AU-5meC-G." The same mRNA can be structurally modified from "AUCG" to "AUCCCG," where a "CC" dinucleotide is inserted, resulting in a structural modification to the polynucleotide.

[0333] In some embodiments, a polynucleotide (e.g., mRNA) of the disclosure can have a uniform chemical modification of all or any of the same nucleoside type, or can have a population of modifications resulting from simple downward titration of the same starting modification of all or any of the same nucleoside type, or can have a measured percentage of chemical modifications of all of the same nucleoside type but with random incorporation, such as when all uridines are replaced with uridine analogs, e.g., pseudouridine or 5-methoxyuridine. In another embodiment, a polynucleotide (e.g., mRNA encoding an IL-23 polypeptide, an IL-36-gamma polypeptide, and / or an OX40L polypeptide) can have uniform chemical modifications of two, three, or four of the same nucleoside type throughout the entire polynucleotide (e.g., mRNA) (such as where all uridines and all cytosines are modified in the same way). When a polynucleotide of the disclosure (e.g., an mRNA encoding an IL-23 polypeptide, an mRNA encoding an IL-36-gamma polypeptide, and / or an mRNA encoding an OX40L polypeptide) is chemically and / or structurally modified, the mRNA can be referred to as a "modified mRNA." Non-limiting examples of chemical modifications are provided elsewhere herein.

[0334] In some embodiments, the first polynucleotide and / or the second polynucleotide comprises at least one chemically modified nucleoside, which in some embodiments is selected from the group consisting of any of the chemically modified nucleosides disclosed herein and combinations thereof.

[0335] In some embodiments, the at least one chemically modified nucleoside is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and combinations thereof.

[0336] In some embodiments, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% of the nucleosides in the first polynucleotide, second polynucleotide, and / or third polynucleotide are chemically modified.

[0337] In some embodiments, the chemically modified nucleosides in the first polynucleotide, the second polynucleotide, and / or the third polynucleotide are selected from the group consisting of uridine, adenine, cytosine, guanine, and any combination thereof. In some embodiments, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% of the uridine nucleosides in the first polynucleotide, the second polynucleotide, and / or the third polynucleotide are chemically modified.

[0338] In some embodiments, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% of the adenosine nucleosides in the first polynucleotide, the second polynucleotide, and / or the third polynucleotide are chemically modified.

[0339] In some embodiments, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% of the cytidine nucleosides in the first polynucleotide, the second polynucleotide, and / or the third polynucleotide are chemically modified.

[0340] In some embodiments, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% of the guanosine nucleosides in the first polynucleotide, the second polynucleotide, and / or the third polynucleotide are chemically modified.

[0341] In some embodiments, the mRNA encoding the first protein, the mRNA encoding the second protein, and the mRNA encoding the third protein each comprise an open reading frame.

[0342] In some embodiments, the IL-23 polypeptide comprises an IL-12p40 subunit comprising an amino acid sequence that is at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% of the amino acid sequence of an IL-23 polypeptide sequence listed in Table 1, which amino acid sequence is capable of binding to an IL-23p19 subunit to form IL-23 having IL-23 activity.

[0343] In some embodiments, the IL-12p40 subunit is encoded by a nucleic acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% identical to a sequence encoding an IL-23 polypeptide listed in Table 1.

[0344] In some embodiments, the IL-23 polypeptide comprises an IL-23p19 subunit comprising an amino acid sequence at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% identical to an IL-23 polypeptide sequence listed in Table 1, which amino acid sequence is capable of binding to an IL-12p40 subunit to form IL-23 having IL-23 activity.

[0345] In some embodiments, the IL-23p19 subunit is encoded by a nucleic acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% identical to an IL-23 polypeptide coding sequence listed in Table 1.

[0346] In some embodiments, the IL-12p40 subunit and the IL-23p19 subunit of the IL-23 protein are on a single polypeptide chain or on two different chains. In some embodiments, the IL-12p40 subunit and the IL-23p19 subunit are fused by a linker. In some embodiments, the IL-12p40 subunit comprises a signal peptide. In some embodiments, the IL-23p19 subunit comprises a signal peptide. In some embodiments, the IL-12p40 subunit is mature IL-12p40 (i.e., does not comprise a signal peptide). In some embodiments, the IL-23p19 subunit is mature IL-23p19 (i.e., does not comprise a signal peptide). In some embodiments, the IL-12p40 subunit comprises a non-native signal peptide. In some embodiments, the IL-23p19 subunit comprises a non-native signal peptide.

[0347] In some embodiments, the IL-23 is a fusion polypeptide comprising an IL-12p40 subunit and an IL-23p19 subunit according to any of the following alternative formulas: [Signal peptide 1]-[IL-12p40]-[Linker]-[IL-23p19] [Signal peptide 2]-[IL-23p19]-[Linker]-[IL-12p40] In the formula, [signal peptide 1] can be the IL-12p40 signal peptide or a non-native signal peptide, [signal peptide 2] can be the IL-23p19 signal peptide or a non-native signal peptide, [IL-12p40] is mature IL-12p40, [IL-23p19] is mature IL-23p29, and [linker] is a peptide linker.

[0348] In some embodiments, the peptide linker comprises a (GS) linker. In some embodiments, the (GS) linker comprises a (GnS) sequence, where n is 1 to 20 and m is 1 to 100. In some embodiments, the (GS) linker comprises the sequence GGS, GGGS, GGGGS (SEQ ID NO: 136), GGGGGS (SEQ ID NO: 137), GGGGGGS (SEQ ID NO: 138), GGGGGGGS (SEQ ID NO: 139), GGSGGGGSGG (SEQ ID NO: 183), GGSGGGGG (SEQ ID NO: 184), or GSGSGSGS (SEQ ID NO: 185). In some embodiments, the linker can comprise (EAAAK)q (SEQ ID NO: 163), where q is an integer from 1 to 5. In one embodiment, the linker can comprise (EAAAK)3, i.e., EAAAAKEAAAKEAAAK (SEQ ID NO: 164). In some embodiments, the linker can be a Gly-rich linker, for example, (Gly) pand p is an integer from 1 to 40. In some embodiments, a Gly-rich linker can include GGGGG (SEQ ID NO: 165), GGGGGG (SEQ ID NO: 166), GGGGGGG (SEQ ID NO: 167), or GGGGGGGG (SEQ ID NO: 168). Further exemplary linkers include, but are not limited to, GGGGSLVPRGSGGGGS (SEQ ID NO: 169), GSGSGS (SEQ ID NO: 170), GGGGSLVPRGSGGGG (SEQ ID NO: 171), GGSGGHGMGSGG (SEQ ID NO: 172), GGSGGSGSGSGG (SEQ ID NO: 173), GGSGG (SEQ ID NO: 174), GSGSGSGS (SEQ ID NO: 175), GGGSEGGGSEGGGSEGGG (SEQ ID NO: 176), AAGAATAA (SEQ ID NO: 177), GGSSG (SEQ ID NO: 178), GSGGGTGGGSG (SEQ ID NO: 179), GSGSGSGSGGSG (SEQ ID NO: 180), GSGGSGSGGSGGSG (SEQ ID NO: 181), and GSGGSGGSGGSGGS (SEQ ID NO: 182). The linkers described herein can be used in any of the polynucleotides described herein.

[0349] In some embodiments, an IL-23 polypeptide according to the above formula (i.e., an IL-23 polypeptide comprising an IL-12p40 subunit and an IL-23p19 subunit) comprises an amino acid sequence that is at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% identical to an IL-23 polypeptide sequence listed in Table 1, and which amino acid sequence is capable of having at least one IL-23 activity (e.g., binding to an IL-23 receptor).

[0350] In some embodiments, an IL-23 polypeptide according to the above formula (i.e., an IL-23 polypeptide comprising an IL-12p40 subunit and an IL-23p19 subunit) is encoded by a nucleic acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% identical to a sequence listed in Table 1.

[0351] In some embodiments, an IL-36-gamma polypeptide comprises an amino acid sequence at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% identical to an IL-36-gamma polypeptide sequence listed in Table 1, and the polypeptide is capable of having IL-36-gamma activity (e.g., binding to an IL-36 receptor).

[0352] In some embodiments, the IL-36-gamma polypeptide is encoded by a nucleic acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% identical to an IL-36-gamma polypeptide coding sequence listed in Table 1.

[0353] In some embodiments, the IL-18 polypeptide comprises an amino acid sequence at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% identical to an IL-18 polypeptide sequence listed in Table 1, and the polypeptide is capable of having IL-18 activity (e.g., binding to an IL-18 receptor).

[0354] In some embodiments, the IL-18 polypeptide is encoded by a nucleic acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% identical to an IL-18 polypeptide coding sequence listed in Table 1.

[0355] In another embodiment, the composition of the present disclosure further comprises a third polynucleotide encoding a third protein. In one embodiment, the third polynucleotide comprises an mRNA encoding the third protein. In another embodiment, the third polynucleotide encodes an OX40L polypeptide.

[0356] In some embodiments, an OX40L polypeptide comprises an amino acid sequence at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% identical to an OX40L polypeptide sequence listed in Table 1A, and the polypeptide has OX40L activity (e.g., is capable of binding to an OX40L receptor).

[0357] In some embodiments, the OX40L polypeptide is encoded by a nucleic acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% identical to an OX40L polypeptide coding sequence listed in Table 1A.

[0358] In certain embodiments, the composition further comprises a fourth polynucleotide encoding a fourth protein. In some embodiments, the fourth polynucleotide comprises an mRNA encoding the fourth protein. In some embodiments, the first polynucleotide, the second polynucleotide, the third polynucleotide, and / or the fourth polynucleotide further comprises a nucleic acid sequence comprising an miRNA binding site.

[0359] In some embodiments, the miRNA binding site binds to miR-122. In some embodiments, the miRNA binding site binds to miR-122-3p or miR-122-5p. In some embodiments, the miRNA binding site comprises a nucleotide sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, or 100% identical to SEQ ID NO:24, and the miRNA binding site binds to miR-122 (miR-122-3p, 22nt-aacgccauuaucacacuaaaua). In some embodiments, the miRNA binding site comprises a nucleotide sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, or 100% identical to SEQ ID NO:26, and the miRNA binding site binds to miR-122 (miR-122-5p, 22nt-uggaguguga caaugguguuug). In some embodiments, the first polynucleotide, the second polynucleotide, the third polynucleotide, and / or the fourth polynucleotide comprises two different miRNA binding sites or the same miRNA binding site, hi some embodiments, the first polynucleotide, the second polynucleotide, the third polynucleotide, and / or the fourth polynucleotide comprises at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten miRNA binding sites.

[0360] In some embodiments, the first polynucleotide, the second polynucleotide, the third polynucleotide, and / or the fourth polynucleotide further comprises a 5' UTR. In some embodiments, the 5' UTR comprises a nucleic acid sequence at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to a 5' UTR sequence listed in Table 3. In another specific embodiment, the 5' UTR comprises a nucleic acid sequence at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to SEQ ID NO:27 or SEQ ID NO:44. In another specific embodiment, the 5' UTR consists essentially of the nucleic acid sequence of SEQ ID NO:27 or SEQ ID NO:44. It should be understood that the 5' UTR may be one element within a larger construct that further comprises, for example, a 5' end cap, an OFR (e.g., SEQ ID NOs: 17, 19, 71, 94, and 116), a 3' UTR (e.g., SEQ ID NOs: 119 or 120), and / or a poly-A tail. In some embodiments, one or more miRNA binding sites can be positioned within the 5' UTR at one or more possible insertion sites.

[0361] In some embodiments, the first polynucleotide, the second polynucleotide, the third polynucleotide, and / or the fourth polynucleotide comprises a 3'UTR. In some embodiments, the 3'UTR comprises a nucleic acid sequence at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to a 3'UTR sequence listed in Table 4A or Table 4B. In certain embodiments, the 3'UTR comprises a nucleic acid sequence at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to SEQ ID NO: 119 or SEQ ID NO: 120. In another specific embodiment, the 3'UTR consists essentially of the nucleic acid sequence of SEQ ID NO: 119 or SEQ ID NO: 120. It should be understood that the 3'UTR may be one element within a larger construct that further includes, for example, a 5' end cap, a 5'UTR (e.g., SEQ ID NO: 27 or SEQ ID NO: 44), an OFR (e.g., SEQ ID NOs: 17, 19, 71, 94, and 116), and / or a poly-A tail.

[0362] In some embodiments, the miRNA binding site (e.g., miR-122 binding site) is inserted within the 3'UTR. In some embodiments, the miRNA binding site (e.g., miR-122 binding site) is inserted within the 3'UTR downstream of the stop codon of a polyribonucleotide of the invention, e.g., an internal coding region of an mRNA, when there are 3'UTR bases between the stop codon and the miRNA binding site(s). In some embodiments, when there are multiple copies of the stop codon in the construct, the miRNA binding site (e.g., miR-122 binding site) is inserted downstream of the final stop codon. In some embodiments, the miRNA binding site (e.g., miR-122 binding site) is inserted about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, or about 100 bases downstream of the stop codon (or the final stop codon when there are multiple stop codons in the construct). In certain embodiments, the miRNA binding site (e.g., miR-122 binding site) is inserted downstream of the stop codon (or the final stop codon if there are multiple stop codons in the construct) such that there are 79 3'UTR bases between the stop codon and the miR binding site(s).

[0363] In some embodiments, the first polynucleotide, second polynucleotide, third polynucleotide, and / or fourth polynucleotide further comprises a spacer sequence fused to the miRNA binding site. In some embodiments, the spacer sequence comprises at least about 10 nucleotides, at least about 15 nucleotides, at least about 20 nucleotides, at least about 25 nucleotides, at least about 30 nucleotides, at least about 35 nucleotides, at least about 40 nucleotides, at least about 45 nucleotides, at least about 50 nucleotides, at least about 55 nucleotides, at least about 60 nucleotides, at least about 65 nucleotides, at least about 70 nucleotides, at least about 75 nucleotides, at least about 80 nucleotides, at least about 85 nucleotides, at least about 90 nucleotides, at least about 95 nucleotides, or at least about 100 nucleotides.

[0364] In some embodiments, the first polynucleotide, second polynucleotide, third polynucleotide, and / or fourth polynucleotide further comprises a 5'-end cap. In some embodiments, the 5'-end cap is Cap0, Cap1, ARCA, inosine, N1-methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azidoguanosine, Cap2, Cap4, 5'methyl G-cap, or an analog thereof. In some embodiments, the first polynucleotide, second polynucleotide, third polynucleotide, and / or fourth polynucleotide comprises a 3' poly-A tail. In some embodiments, the first polynucleotide, second polynucleotide, third polynucleotide, and / or fourth polynucleotide is codon-optimized. In some embodiments, the first polynucleotide, the second polynucleotide, the third polynucleotide, and / or the fourth polynucleotide are in vitro transcribed (IVT). In some embodiments, the first polynucleotide, the second polynucleotide, the third polynucleotide, and / or the fourth polynucleotide are chimeric. In some embodiments, the first polynucleotide, the second polynucleotide, the third polynucleotide, and / or the fourth polynucleotide are circular.

[0365] In some embodiments, the IL-23 polypeptide IL-12p40 subunit, the IL-23 polypeptide IL-23p19 subunit, the IL-36-gamma polypeptide, and / or the OX40L polypeptide are fused to a heterologous polypeptide.

[0366] In some embodiments, the first polynucleotide (e.g., mRNA), the second polynucleotide (e.g., mRNA), and the third polynucleotide (e.g., mRNA) comprise, consist essentially of, or consist of a 5' cap, a 5' UTR, an open reading frame (ORF), a 3' UTR, and a poly-A tail. In one embodiment, the first polynucleotide (e.g., mRNA) comprises, consists essentially of, or consists of the nucleic acid sequence of SEQ ID NO: 27 or 44, SEQ ID NO: 19, 71, or 141, and SEQ ID NO: 119 or 120. In another embodiment, the second polynucleotide (e.g., mRNA) comprises, consists essentially of, or consists of the nucleic acid sequence of SEQ ID NO: 27 or 44, SEQ ID NO: 17, 94, or 143, and SEQ ID NO: 119 or 120. In yet another embodiment, the third polynucleotide (e.g., mRNA) comprises, consists essentially of, or consists of the nucleic acid sequence of SEQ ID NO: 27 or 44, SEQ ID NO: 116 or 145, and SEQ ID NO: 119 or 120.

[0367] In certain embodiments, the first polynucleotide comprises a nucleic acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to SEQ ID NO: 142. In another specific embodiment, the first polynucleotide consists essentially of the nucleic acid sequence of SEQ ID NO: 142. In yet another specific embodiment, the first polynucleotide consists of the nucleic acid sequence of SEQ ID NO: 142.

[0368] In certain embodiments, the second polynucleotide comprises a nucleic acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to SEQ ID NO: 144. In another specific embodiment, the second polynucleotide consists essentially of the nucleic acid sequence of SEQ ID NO: 144. In yet another specific embodiment, the second polynucleotide consists of the nucleic acid sequence of SEQ ID NO: 144.

[0369] In certain embodiments, the third polynucleotide comprises a nucleic acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to SEQ ID NO: 146. In another specific embodiment, the third polynucleotide consists essentially of the nucleic acid sequence of SEQ ID NO: 146. In yet another specific embodiment, the third polynucleotide consists of the nucleic acid sequence of SEQ ID NO: 146.

[0370] In some embodiments, the first polynucleotide comprises a nucleotide sequence that is at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% identical to any of the IL-23 coding sequences disclosed in Table 1.

[0371] In some embodiments, the second polynucleotide comprises a nucleotide sequence that is at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% identical to any of the IL-36-gamma coding sequences disclosed in Table 1.

[0372] In some embodiments, the second polynucleotide comprises a nucleotide sequence that is at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% identical to a sequence encoding IL-18, which sequence comprises an IL-18 coding sequence disclosed in Table 1.

[0373] In some embodiments, the third polynucleotide comprises a nucleotide sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least about 99%, or 100% identical to the OX40L coding sequence or OX40L_miR-122 construct of Table 1A.

[0374] In other embodiments, the compositions for the present disclosure include a fourth protein or a fourth polynucleotide encoding the fourth protein. For example, the fourth polynucleotide can include an mRNA encoding the fourth protein.

[0375] In some embodiments, the compositions disclosed herein are for use in reducing or decreasing tumor size or inhibiting tumor growth in a subject in need thereof. In some embodiments, the compositions disclosed herein are for use in reducing or decreasing tumor size or inhibiting tumor growth in a subject in need thereof.

[0376] In some embodiments, the compositions disclosed herein are administered to a subject in need thereof to treat cancer, wherein administration of the composition treats or alleviates a symptom of the cancer. In some embodiments, the cancer is adrenocortical carcinoma, advanced cancer, anal cancer, aplastic anemia, bile duct cancer, bladder cancer, bone cancer, bone metastasis, brain tumor, brain cancer, breast cancer, childhood cancer, cancer of unknown primary, Castleman's disease, cervical cancer, colon / rectal cancer, endometrial cancer, esophageal cancer, Ewing's family of tumors, eye cancer, gallbladder cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gestational trophoblastic disease, Hodgkin's disease, Kaposi's sarcoma, renal cell carcinoma, pharyngeal and hypopharyngeal cancer, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, liver cancer, hepatocellular carcinoma (HCC), non-small cell lung cancer, small cell lung cancer, The cancer is selected from the group consisting of lung carcinoid tumor, lymphoma of the skin, malignant mesothelioma, multiple myeloma, myelodysplastic syndrome, nasal cavity and paranasal sinus cancer, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin's lymphoma, oral cavity and oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumor, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, adult soft tissue sarcoma, basal cell and squamous cell skin cancer, melanoma, small intestine cancer, gastric cancer, testicular cancer, pharyngeal cancer, thymic cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia, Wilms' tumor, secondary cancers resulting from cancer therapy, and any combination thereof.

[0377] In some embodiments, the first polynucleotide, second polynucleotide, and / or third polynucleotide is formulated for delivery by a device comprising a pump, patch, drug reservoir, short-needle device, single-needle device, multiple-needle device, microneedle device, rapid injection device, ballistic powder / particle delivery device, catheter, lumen, cryostat, cannula, microcannula, or device utilizing heat, RF energy, electric current, or any combination thereof. In some embodiments, an effective amount of the compositions disclosed herein is about 0.10 mg / kg to about 1000 mg / kg. In some embodiments, the compositions disclosed herein are formulated for administration to a human subject.

[0378] In some embodiments, the compositions and formulations disclosed herein are for use in the treatment of cancer, hi some embodiments, the disclosed compositions and formulations are used in the manufacture of a medicament for the treatment of cancer.

[0379] It should be understood that the polynucleotide combinations disclosed herein (e.g., a first polynucleotide comprising an mRNA encoding an IL-23 polypeptide, a second polynucleotide comprising an mRNA encoding an IL-36-gamma polypeptide or an IL-18 polypeptide, and a third polynucleotide comprising an mRNA encoding an OX40L polypeptide) are in no way intended to be limited to the particular forms disclosed. In this regard, the disclosure in this section relating to particular polynucleotides and their respective encoded polypeptides is equally applicable to additional polynucleotides and their respective encoded polypeptides, e.g., third, fourth, fifth, etc. polypeptides, to be combined with the IL-23-, IL-36-gamma-, IL-18-, and / or OX40L-encoding polynucleotides disclosed herein. Thus, disclosure relating to a "first polynucleotide" or a "second polynucleotide" (or the respective encoded polypeptides) is equally applicable to a "third polynucleotide" and consecutive polynucleotides (or the respective encoded polypeptides).

[0380] Additionally, specific disclosures relating to particular proteins encoded by a first or second polynucleotide, e.g., the disclosure that "the second polynucleotide comprises an mRNA encoding a human IL-36-gamma polypeptide lacking at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 14, or at least 15 amino acids at the N-terminus or C-terminus of wild-type IL-36-gamma polypeptide," would be equally applicable to a third consecutive protein. Thus, one skilled in the art would understand that where the third protein is, for example, OX40L, the third polynucleotide could comprise an mRNA encoding a human OX40L polypeptide lacking at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 14, or at least 15 amino acids at the N-terminus or C-terminus of the wild-type OX40L polypeptide, as disclosed above with respect to the first or second polypeptides of the present disclosure. III. Methods for Combining Polynucleotides Encoding Immunomodulating Polypeptides Immunotherapy, also known as immuno-oncology, has revolutionized cancer treatment by introducing therapies that target the host immune system rather than the tumor, that have unique adverse event profiles, and that may cure many types of cancer. As used herein, the term "immunotherapy" refers to the treatment of disease by inducing, enhancing, or suppressing an immune response. Immunotherapies designed to induce or amplify an immune response are referred to as "activating immunotherapies," while immunotherapies that reduce or suppress an immune response are referred to as "suppressing immunotherapies."

[0381] Cancers of the lung, kidney, bladder, and skin, among others, have induced substantial benefits from treatment with immuno-oncology approaches in terms of survival or tumor response, with melanoma perhaps showing the greatest benefit. Immunotherapy is often characterized by checkpoint inhibitor treatment using an exciting new class of biologics known as checkpoint inhibitor antibodies. Targets include, for example, PD-1, PD-L1, and CTLA-4.

[0382] Monoclonal antibodies that target PD-1, PD-L1, or CTLA-4 can boost the immune response against cancer cells and have shown great promise in treating certain cancers. For example, pembrolizumab (Keytruda®) and nivolumab (Opdivo®) target PD-1, atezolizumab (Tecentriq®) targets PD-L1, and ipilimumab (Yervoy®) binds to and inhibits CTLA-4.

[0383] One concern about these drugs is that they can cause the immune system to attack some normal organs in the body, which can lead to serious or even life-threatening side effects in some people.One way to reduce these side effects is to administer other agents in combination with these checkpoint inhibitor antibodies, which would ideally allow doctors to lower the therapeutic dose of the antibody.

[0384] Thus, the present disclosure provides methods for treating cancer (e.g., reducing or reducing tumor size or inhibiting tumor growth in a subject in need thereof) comprising administering any of the compositions disclosed in Section II above. In particular, the present disclosure provides methods for treating cancer comprising administering to a subject in need thereof (reducing or reducing tumor size or inhibiting tumor growth): (i) at least one polynucleotide comprising an mRNA encoding a protein comprising an IL-23 polypeptide; (ii) at least one polynucleotide comprising an mRNA encoding a protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide; and / or (iii) at least one polynucleotide comprising an mRNA encoding a protein comprising an OX40L polypeptide;

[0385] In some embodiments, the present disclosure provides methods for reducing or reducing tumor size and / or inhibiting tumor growth in a subject in need thereof, comprising administering to the subject at least two polynucleotides, wherein the at least two polynucleotides are selected from a first polynucleotide encoding an IL-23 polypeptide, a second polynucleotide encoding an IL-36-gamma polypeptide or an IL-18 polypeptide, and a third polynucleotide encoding an OX40L polypeptide. In one particular aspect, the method for reducing or reducing tumor size and / or inhibiting tumor growth in a subject in need thereof comprises administering to the subject (i) a first polynucleotide encoding a first protein comprising an IL-23 polypeptide, (ii) a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide, (iii) a third polypeptide encoding a third protein comprising an OX40L polypeptide, and / or (iv) a combination thereof. In another specific embodiment, a method for reducing or decreasing tumor size or inhibiting tumor growth in a subject in need thereof comprises administering to the subject (i) a first polynucleotide encoding a first protein comprising an IL-23 polypeptide (e.g., SEQ ID NO: 141), (ii) a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide (e.g., SEQ ID NO: 143), and (iii) a third polypeptide encoding a third protein comprising an OX40L polypeptide (e.g., SEQ ID NO: 145), preferably in a 1:2:1 w / w mass ratio.In some particular embodiments, the method of reducing or decreasing tumor size and / or inhibiting tumor growth in a subject in need thereof further comprises administering to the subject an effective amount of an additional polynucleotide, e.g., a fourth or fifth polynucleotide encoding a fourth or fifth protein.

[0386] In other embodiments, the present disclosure provides methods of promoting an anti-tumor effect (e.g., inducing T cell proliferation, inducing T cell infiltration in tumors, inducing memory T cell responses, increasing NK cell numbers, etc.) by administering a first, second, and / or third polynucleotide (e.g., mRNA) disclosed herein.

[0387] In one embodiment, the present disclosure provides a method of activating T cells in a subject in need thereof, inducing T cell proliferation in a subject in need thereof, inducing T cell infiltration into a tumor in a subject in need thereof, and / or inducing a memory T cell response in a subject in need thereof, the method comprising administering to the subject a first polynucleotide encoding IL-23, a second polynucleotide encoding IL-36-gamma or IL-18, a third polynucleotide encoding OX40L, or a combination thereof. In certain embodiments, a method for activating T cells in a subject in need of activating T cells, inducing T cell proliferation in a subject in need of inducing T cell proliferation, inducing T cell infiltration into a tumor in a subject in need of inducing T cell infiltration into a tumor, and / or inducing a memory T cell response in a subject in need of inducing a memory T cell response comprises administering to the subject (i) a first polynucleotide encoding a first protein comprising an IL-23 polypeptide (e.g., SEQ ID NO: 141), (ii) a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide (e.g., SEQ ID NO: 143), and (iii) a third polynucleotide encoding a third protein comprising an OX40L polypeptide (SEQ ID NO: 145), preferably in a 1:2:1 w / w mass ratio. In certain embodiments, intratumoral administration of a first polynucleotide (e.g., mRNA), a second polynucleotide (e.g., mRNA), and / or a third polynucleotide (e.g., mRNA) can increase the efficacy of the anti-tumor effect (e.g., T cell infiltration into the tumor) compared to other routes of administration.

[0388] In one embodiment, the activated T cells in a subject reduce or decrease the size of a tumor or inhibit the growth of a tumor in the subject. T cell activation can be measured using applications in the art, such as measuring T cell proliferation, measuring cytokine production using enzyme-linked immunosorbent assay (ELISA) or enzyme-linked immunospot assay (ELISPOT), or detecting cell surface markers associated with T cell activation (e.g., CD69, CD40L, CD137, CD25, CD71, CD26, CD27, CD28, CD30, CD154, and CD134) using techniques such as flow cytometry.

[0389] In one embodiment, T cell proliferation in a subject is directed toward an anti-tumor immune response in the subject. In another aspect, T cell proliferation in a subject reduces or decreases tumor size or inhibits tumor growth in the subject. T cell proliferation can be measured using techniques known in the art, such as cell counting, viability staining, optical density assays, or detection of cell surface markers associated with T cell activation (e.g., CD69, CD40L, CD137, CD25, CD71, CD26, CD27, CD28, CD30, CD154, and CD134) using techniques such as flow cytometry.

[0390] In one embodiment, infiltration of T cells into a subject's tumor is directed toward an anti-tumor immune response in the subject. In another aspect, infiltration of T cells into a subject's tumor reduces or decreases the size of the tumor in the subject or inhibits tumor growth. Infiltration of T cells into tumors can be measured using techniques in the art, such as preparing tissue sections and staining for cell markers, measuring local cytokine production at the tumor site, or detecting T cell surface markers using techniques such as flow cytometry.

[0391] In one embodiment, the memory T cell response in the subject is directed to the anti-tumor immune response in the subject.In another embodiment, the memory T cell response in the subject reduces or decreases the size of the tumor in the subject, or inhibits the growth of the tumor.Memory T cell response can be measured by applying techniques in the art, such as measuring the T cell markers associated with memory T cells, measuring the local cytokine production associated with memory immune response, or detecting memory T cell surface markers using techniques such as flow cytometry.

[0392] In certain embodiments, the T cells activated by the method are CD4 + cells, CD8 + cells, CD62 + (L-selectin + ) cells, CD69 + cells, CD40L + cells, CD137 + cells, CD25 + cells, CD71 + cells, CD26 + cells, CD27 + cells, CD28 + cells, CD30 + cells, CD45 + cells, CD45RA + cells, CD45RO + cells, CD11b + cells, CD154 + cells, CD134 + cells, CXCR3 + cells, CCR4 + cells, CCR6 + cells, CCR7 + cells, CXCR5 + cells, Crth2 + In some embodiments, the T cells activated by the present methods are Th1 cells. In other embodiments, the T cells activated by the present methods are Th2 cells. In other embodiments, the T cells activated by the present disclosure are cytotoxic T cells.

[0393] In some embodiments, the T cells infiltrated by this method are CD4 + cells, CD8 + cells, CD62 + (L-selectin + ) cells, CD69 + cells, CD40L + cells, CD137 + cells, CD25 + cells, CD71 + cells, CD26 + cells, CD27 + cells, CD28 + cells, CD30 + cells, CD45 + cells, CD45RA + cells, CD45RO + cells, CD11b + cells, CD154 + cells, CD134 + cells, CXCR3 + cells, CCR4 + cells, CCR6 + cells, CCR7 + cells, CXCR5 + cells, Crth2 + In some embodiments, the T cells infiltrated by the present method are Th1 cells. In other embodiments, the T cells infiltrated by the present method are Th2 cells. In other embodiments, the T cells infiltrated by the present disclosure are cytotoxic T cells.

[0394] In some embodiments, the memory T cells induced by the method are CD4 + cells, CD8 + cells, CD62 + (L-selectin + ) cells, CD69 + cells, CD40L + cells, CD137 + cells, CD25 + cells, CD71 + cells, CD26 + cells, CD27 + cells, CD28+ cells, CD30 + cells, CD45 + cells, CD45RA + cells, CD45RO + cells, CD11b + cells, CD154 + cells, CD134 + cells, CXCR3 + cells, CCR4 + cells, CCR6 + cells, CCR7 + cells, CXCR5 + cells, Crth2 + In some embodiments, the memory T cells according to the present method are Th1 cells. In other embodiments, the memory T cells according to the present method are Th2 cells. In other embodiments, the memory T cells according to the present disclosure are cytotoxic T cells.

[0395] The present disclosure further provides a method for increasing the number of natural killer (NK) cells in a subject in need thereof, the method comprising administering a polynucleotide comprising mRNA encoding an OX40L polypeptide, a polynucleotide comprising mRNA encoding IL-23, and / or a polynucleotide comprising mRNA encoding IL-36-gamma or IL-18. In certain embodiments, the method for increasing the number of natural killer (NK) cells in a subject in need thereof comprises administering to the subject (i) a first polynucleotide encoding a first protein comprising an IL-23 polypeptide (e.g., SEQ ID NO: 141), (ii) a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide (e.g., SEQ ID NO: 143), and (iii) a third polypeptide encoding a third protein comprising an OX40L polypeptide (e.g., SEQ ID NO: 145), preferably in a mass ratio of 1:2:1 w / w. In one aspect, increasing the number of NK cells in the subject is directed toward an anti-tumor immune response in the subject. In another embodiment, increasing the number of NK cells in a subject reduces or decreases the size of a tumor or inhibits tumor growth in the subject. The increase in the number of NK cells in a subject can be measured using techniques in the art, such as detecting NK cell surface markers (e.g., CD335 / NKp46, CD336 / NKp44, CD337 / NPp30) or intracellular NK cell markers (e.g., perforin, granzyme, granulysin).

[0396] In certain embodiments, administration of at least two mRNAs selected from mRNA encoding IL-23, mRNA encoding IL-36-gamma, or mRNA encoding IL-18, and mRNA encoding an OX40L polypeptide increases the total number of NK cells in a subject compared to the number of NK cells in a subject not administered the at least two mRNAs or in a subject administered mRNA encoding IL-23 alone, mRNA encoding IL-36-gamma alone, mRNA encoding IL-18, or mRNA encoding OX40L alone. In other embodiments, administration of at least two mRNAs selected from mRNA encoding IL-23, mRNA encoding IL-36-gamma, mRNA encoding IL-18, and mRNA encoding an OX40L polypeptide increases the total number of NK cells in a subject compared to a subject administered dendritic cells transfected with mRNA encoding OX40L polypeptide alone, mRNA encoding IL-23 alone, mRNA encoding IL-36-gamma alone, or mRNA encoding IL-18. In other embodiments, administration of at least two mRNAs selected from mRNA encoding IL-23, mRNA encoding IL-36-gamma, mRNA encoding IL-18, and mRNA encoding an OX40L polypeptide increases the total number of NK cells in the subject within the tumor microenvironment compared to a subject not receiving the at least two mRNAs or a subject receiving mRNA encoding IL-23 alone, mRNA encoding IL-36-gamma alone, mRNA encoding IL-18 alone, or mRNA encoding an OX40L polypeptide alone.In other embodiments, administration of at least two mRNAs selected from mRNA encoding IL-23, mRNA encoding IL-36-gamma, mRNA encoding IL-18, and mRNA encoding an OX40L polypeptide increases the number of NK cells in the subject within the tumor microenvironment compared to subjects administered mRNA encoding an OX40L polypeptide alone, mRNA encoding IL-23 alone, mRNA encoding IL-18 alone, or mRNA encoding IL-36-gamma alone. In other embodiments, the concentration of NK cells within the tumor microenvironment increases, while the total number of NK cells in the subject remains the same.

[0397] In certain embodiments of the present disclosure, the number of NK cells is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, or at least about 10-fold compared to a control (e.g., saline or mRNA that does not result in expression of IL-23, IL-36-gamma, or OX40L). In certain embodiments, the number of NK cells is increased by at least two mRNAs selected from mRNA encoding IL-23, mRNA encoding IL-36-gamma, mRNA encoding IL-18, and mRNA encoding an OX40L polypeptide, as compared to a control (e.g., saline or mRNA that does not result in expression of IL-23, IL-36-gamma, IL-18, or OX40L).

[0398] In one embodiment, administration of a combination disclosed herein reduces or decreases tumor size or inhibits tumor growth by at least 1.5-fold, at least 2-fold, at least 2.5-fold, at least 3-fold, at least 3.5-fold, at least 4-fold, at least 4.5-fold, or at least 5-fold more than administration of (i) a first polynucleotide encoding a first protein alone (e.g., a polynucleotide encoding a protein comprising an IL-23 polypeptide), (ii) a second polynucleotide encoding a second protein alone (e.g., a polynucleotide encoding a protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide), or (iii) a third polynucleotide encoding a third protein alone (e.g., a polynucleotide encoding a protein comprising an OX40L polypeptide). Reduction or decrease in tumor size or inhibition of tumor growth can be determined without undue experimentation using any method known in the art.

[0399] In some embodiments, the reduction or decrease in tumor size or inhibition of tumor growth is at least 1.5-fold, at least 2-fold, at least 2.5-fold, at least 3-fold, at least 3.5-fold, at least 4-fold, at least 4.5-fold, or at least 5-fold greater than a control (e.g., treatment with PBS, treatment with a polynucleotide encoding a control protein, or treatment with a control protein).

[0400] In some embodiments, a first polynucleotide administered by the methods disclosed herein comprises RNA, e.g., an mRNA encoding a first protein (e.g., a protein comprising an IL-23 polypeptide). In some embodiments, a second polynucleotide administered by the methods disclosed herein comprises RNA, e.g., an mRNA encoding a second protein (e.g., a protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide). In some embodiments, a third polynucleotide administered by the methods disclosed herein comprises RNA, e.g., an mRNA encoding a third protein (e.g., a protein comprising an OX40L polypeptide).

[0401] The methods disclosed herein include intratumoral, intestinal, gastrointestinal, epidural, oral, transdermal, epidural / peridural, intracerebral (into the cerebrum), intraventricular (into the ventricles of the brain), epicutaneous (applied onto the skin), intradermal (into the skin itself), subcutaneous (under the skin), intranasal administration (through the nose), intravenous (into a vein), intraperitoneal (into the abdominal cavity), intraarterial (into an artery), intramuscular (into a muscle), intracardiac (into the heart), bone marrow administration (into the bone marrow), intrathecal (into the spinal canal), This includes administering any of the compositions of the present disclosure by any available route, including, but not limited to, intraperitoneal (infusion or injection into the abdominal cavity), intravesical instillation, intravitreal (through the eye), intracavernosal injection (into the base of the penis), intravaginal administration, intrauterine, extra-amniotic administration, transdermal (diffusion through intact skin for systemic distribution), transmucosal (diffusion through mucous membranes), inhalation (breathing through the nose), sublingual, sublabial, enema, ophthalmic (onto the conjunctiva), or ear drops.

[0402] In some embodiments, the methods disclosed herein comprise administering the first polynucleotide, the second polynucleotide, and / or the third polynucleotide subcutaneously, intravenously, intramuscularly, intra-articularly, intrasynovially, intrasternally, intrathecally, intrahepatically, intralesionally, intracranially, intracerebroventricularly, orally, by inhalation spray, topically, rectally, intranasally, buccally, vaginally or via an implanted reservoir.

[0403] In some embodiments, the methods disclosed herein include administering a first polynucleotide, a second polynucleotide, and / or a third polynucleotide in a formulation for intramuscular, subcutaneous, intratumoral, or intradermal delivery. In some embodiments, the formulation for intramuscular, subcutaneous, intratumoral, or intradermal delivery includes an additional polynucleotide, e.g., a third, fourth, or fifth polynucleotide. In certain embodiments, intratumoral administration of the first polynucleotide, the second polynucleotide, and / or the third polynucleotide can enhance the efficacy of anti-tumor effects compared to other administration routes. In some embodiments, the additional polynucleotide, e.g., a third, fourth, or fifth polynucleotide, is administered intratumorally, enhancing the efficacy of anti-tumor effects compared to other administration routes.

[0404] In some aspects of the methods disclosed herein, the first polynucleotide, the second polynucleotide, and / or the third polynucleotide are formulated for delivery in vivo. In some embodiments, the first polynucleotide, the second polynucleotide, and the third polynucleotide can be co-formulated in various weight ratios, for example, with the same amount (by weight) of each polynucleotide, or with any one of the polynucleotides present in 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 times the amount (by weight) of the other polynucleotide. In one embodiment, the IL-23:IL-36 gamma:OX40L polynucleotides are co-formulated in a weight ratio such that the IL-23 and OX40L polynucleotides are in approximately equal amounts and the IL-36 gamma polynucleotide is present in a higher amount by weight, such as 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0 times more by weight. In one particular embodiment, the IL-23:IL-36 gamma:OX40L polynucleotides are co-formulated in a 1:2:1 weight ratio. As used herein, the weight ratio can also be referenced by reference to a composition comprising a polynucleotide (e.g., mRNA) encoding OX40L:IL-23:IL-36 gamma formulated in a 1:1:2 weight ratio.

[0405] In other embodiments, the IL-23:IL-36 gamma:OX40L polynucleotide is 1:1:1, 2:1:1, 1:2:1, 1:1:2, 3:1:1, 1:3:1, 1:1:3, 4:1:1, 1:4:1, 1:1:4, 5:1:1, 1:5:1, 1:1:5, 6:1:1, 1:6:1, 1:1:6, 7:1:1, 1:7:1, 1:1:8, 9:1:1, 1:9:1, 1:1:9, 10:1:1, 1:10:1, 1:1:10, 11:1:1, 1:11:1, 1:1:11, 12:1:1, 1:12:1, 1:1:12, 13:1:1, 1:13:1, 1:1:13, 14:1:1, 1:14:1, 1:1: 14, 15:1:1, 1:15:1, 1:1:15, 16:1:1, 1:16:1, 1:1:16, 17:1:1, 1:17:1, 1:1:17, 18:1:1, 1:18:1, 1:1:18, 19:1:1, 1:19:1, 1:1:19, 20:1:1, 1:20:1, 1:1:20, 25:1:1, 1 In other embodiments, the three polynucleotides are co-formulated at a weight (mass) ratio of 1:25:1, 1:1:25, 30:1:1, 1:30:1, 1:1:30, 35:1:1, 1:35:1, 1:1:35, 40:1:1, 1:40:1, 1:1:40, 45:1:1, 1:45:1, 1:1:45, 50:1:1, 1:50:1, or 1:1:50. In other embodiments, each of the three polynucleotides can be present in the co-formulation at a different weight. By way of example only, IL-23:IL-36 gamma:OX40L polynucleotides can be formulated together in a weight (mass) ratio of 1:2:3, 1:3:2, 2:1:3, 2:3:1, 3:1:2, or 3:2:1, or in a weight (mass) ratio of 1:3:5, 1:5:3, 3:5:1, 3:1:5, 5:1:3, or 5:3:1, or in a weight (mass) ratio of 1:5:10, 1:10:5, 5:1:10, 5:10:1, 10:1:5, or 10:5:1.In certain embodiments, (i) a first polynucleotide encoding a first protein comprising an IL-23 polypeptide (e.g., SEQ ID NO: 140), (ii) a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide (e.g., SEQ ID NO: 16), and (iii) a third polypeptide encoding a third protein comprising an OX40L polypeptide (e.g., SEQ ID NO: 21) are formulated in a weight (mass) ratio of 1:2:1. While this is a preferred formulation, one of skill in the art will readily recognize that amounts of any one of the three components other than this ratio may also provide a formulation suitable for use in any of the methods disclosed herein.

[0406] The polynucleotide co-formulation can be administered as a single dose or multiple doses. Co-formulations with various weight (mass) ratios, for example, Co-formulation #1 in which the first polynucleotide, the second polynucleotide, and the third polynucleotide are present in a ratio of 1:2:1 w / w, and Co-formulation #2 in which the first polynucleotide, the second polynucleotide, and the third polynucleotide are present in a ratio of 1:1:2 w / w, can each be administered in a single dose or multiple doses, consecutively, sequentially, or simultaneously.

[0407] In one embodiment, a 1:2:1 enclosed formulation of (i) a first polynucleotide encoding a first protein comprising an IL-23 polypeptide (e.g., SEQ ID NO: 140), (ii) a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide (e.g., SEQ ID NO: 16), and (iii) a third polypeptide encoding a third protein comprising an OX40L polypeptide (e.g., SEQ ID NO: 21) is administered as a single dose or as multiple doses.

[0408] In some embodiments of the methods disclosed herein, administering a composition disclosed herein treats cancer. In certain embodiments of the methods disclosed herein, the compositions disclosed herein are used to treat a variety of cancers, including adrenocortical carcinoma, advanced cancer, anal cancer, aplastic anemia, bile duct cancer, bladder cancer, bone cancer, bone metastasis, brain tumor, brain cancer, breast cancer, childhood cancer, cancer of unknown primary, Castleman's disease, cervical cancer, colon / rectal cancer, endometrial cancer, esophageal cancer, Ewing's family of tumors, eye cancer, gallbladder cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gestational trophoblastic disease, Hodgkin's disease, Kaposi's sarcoma, renal cell carcinoma, laryngopharyngeal carcinoma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, liver cancer, hepatocellular carcinoma (HCC), non-small cell lung cancer, small cell lung cancer, The compound is administered to treat a cancer selected from the group consisting of lung cancer, pulmonary carcinoid tumor, lymphoma of the skin, malignant mesothelioma, multiple myeloma, myelodysplastic syndrome, nasal and paranasal cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin's lymphoma, oral and oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumor, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, adult soft tissue sarcoma, basal cell and squamous cell skin cancer, melanoma, small intestine cancer, gastric cancer, testicular cancer, pharyngeal cancer, thymic cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia, Wilms' tumor, secondary cancers resulting from cancer therapy, and any combination thereof.

[0409] In some embodiments of the methods disclosed herein, the first polynucleotide, the second polynucleotide, and / or the third polynucleotide are delivered by a device comprising a pump, a patch, a drug reservoir, a short-needle device, a single-needle device, a multiple-needle device, a microneedle device, a rapid injection device, a ballistic powder / particle delivery device, a catheter, a lumen, a cryostat, a cannula, a microcannula, or a device utilizing heat, RF energy, electric current, or any combination thereof. In other embodiments of the methods disclosed herein, an additional polynucleotide, e.g., a third, fourth, or fifth polynucleotide, is also delivered by a device comprising a pump, a patch, a drug reservoir, a short-needle device, a single-needle device, a multiple-needle device, a microneedle device, a rapid injection device, a ballistic powder / particle delivery device, a catheter, a lumen, a cryostat, a cannula, a microcannula, or a device utilizing heat, RF energy, electric current, or any combination thereof.

[0410] In some embodiments, the effective amount of the compositions disclosed herein used in the methods of the present disclosure is from about 0.10 mg / kg to about 1000 mg / kg. In some embodiments, the subject is a human.

[0411] In some embodiments of the methods disclosed herein, the first polynucleotide encoding the first protein comprising an IL-23 polypeptide, the second polynucleotide encoding the second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide, and the third polynucleotide encoding the third protein comprising an OX40L polypeptide are part of the same composition (e.g., a solution contains all of the first, second, and third polynucleotides). In some embodiments of the methods disclosed herein, the first polynucleotide encoding the first protein comprising an IL-23 polypeptide, the second polynucleotide encoding the second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide, and the third polynucleotide encoding the third protein comprising an OX40L polypeptide are part of different compositions (e.g., each polynucleotide can be in a different solution or can be combined in a different solution).

[0412] In some embodiments of the methods disclosed herein, a first polynucleotide encoding a first protein comprising an IL-23 polypeptide and a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide are administered simultaneously. In some embodiments of the methods disclosed herein, a first polynucleotide encoding a first protein comprising an IL-23 polypeptide and a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide are administered sequentially. In some embodiments of the methods disclosed herein, a first polynucleotide encoding a first protein comprising an IL-23 polypeptide and a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide are administered sequentially (i.e., the first polynucleotide can be administered first, followed by the second polynucleotide, or vice versa).

[0413] In some embodiments of the methods disclosed herein, a polynucleotide encoding a first protein comprising an OX40L polypeptide and a polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide are administered simultaneously. In some embodiments of the methods disclosed herein, a polynucleotide encoding a protein comprising an OX40L polypeptide and a polynucleotide encoding a protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide are administered sequentially. In some embodiments of the methods disclosed herein, a polynucleotide encoding a protein comprising an OX40L polypeptide and a polynucleotide encoding a protein comprising an IL-36-gamma polypeptide are administered sequentially (i.e., an OX40L polynucleotide can be administered first, followed by an IL-36-gamma polynucleotide or an IL-18 polynucleotide, or vice versa).

[0414] In some embodiments of the methods disclosed herein, a first polynucleotide encoding a first protein comprising an IL-23 polypeptide, a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide, and a third polynucleotide encoding a third protein comprising an OX40L polypeptide are administered simultaneously. In some embodiments of the methods disclosed herein, a first polynucleotide encoding a first protein comprising an IL-23 polypeptide, a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide, and a third polynucleotide encoding a third protein comprising an OX40L polypeptide are administered sequentially. In some embodiments of the methods disclosed herein, a first polynucleotide encoding a first protein comprising an IL-23 polypeptide, a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide, and a third polynucleotide encoding a third protein comprising an OX40L polypeptide are administered sequentially (i.e., the first, second, and third polynucleotides can be administered in any order). In certain embodiments, the first protein comprising an IL-23 polypeptide (e.g., SEQ ID NO: 140 encoded by SEQ ID NO: 141), the second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide (e.g., SEQ ID NO: 16 encoded by SEQ ID NO: 143), and the third polynucleotide encoding a third protein comprising an OX40L polypeptide (e.g., SEQ ID NO: 21 encoded by SEQ ID NO: 145) are administered in a final weight (mass) ratio of 1:2:1, regardless of the order of administration.

[0415] In some embodiments, the present disclosure provides methods for treating (e.g., reducing tumor size) tumors located distally relative to the tumor being treated (proximal tumor). In some embodiments, the proximal tumor is treated with a first polynucleotide (e.g., mRNA) encoding a first protein comprising an IL-23 polypeptide, a second polynucleotide (e.g., mRNA) encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide, and a third polynucleotide (e.g., mRNA) encoding a third protein comprising an OX40L polypeptide, or a combination thereof. The methods disclosed herein can be used, for example, to treat tumors located in locations where intratumoral administration of therapy would be unsafe or impractical by intratumoral administration of a composition disclosed herein (e.g., mRNA encoding an IL-23 polypeptide (e.g., SEQ ID NO: 141), mRNA i.e., an IL-36-gamma polypeptide (e.g., SEQ ID NO: 143), and a third mRNA encoding an OX40L polypeptide (SEQ ID NO: 145)) to one or more accessible tumors.

[0416] In some embodiments, the present disclosure provides methods of treating tumors that are not responsive or have little response to a checkpoint inhibitor (e.g., a molecule that targets PD-1 or PD-L1, such as an anti-PD-L1 antibody), comprising administering a first polynucleotide (e.g., mRNA) encoding a first protein comprising an IL-23 polypeptide, a second polynucleotide (e.g., mRNA) encoding a second protein comprising an IL-36-gamma polypeptide or an IL-18 polypeptide, and a third polynucleotide (e.g., mRNA) encoding a third protein comprising an OX40L polypeptide, or combinations thereof, together with a checkpoint inhibitor (e.g., an anti-PD-L1 antibody and / or an anti-PD-1 antibody and / or an anti-CTLA-4 antibody). In a specific embodiment, a first protein comprising an IL-23 polypeptide (e.g., SEQ ID NO:140 encoded by SEQ ID NO:141), a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide (e.g., SEQ ID NO:16 encoded by SEQ ID NO:143), and a third polynucleotide encoding a third protein comprising an OX40L polypeptide (e.g., SEQ ID NO:21 encoded by SEQ ID NO:145) are administered together with a checkpoint inhibitor (e.g., an anti-PD-L1 antibody and / or an anti-PD-1 antibody and / or an anti-CTLA-4 antibody).

[0417] As used herein, the terms "dual agent," "dual therapy," "dual combination therapy," "dual mRNA therapy," and grammatical variations thereof refer to a combination therapy in which two mRNAs encoding two proteins selected from an IL-23 polypeptide, an IL-36-gamma polypeptide, or an IL-18 polypeptide, and an OX40L polypeptide are administered to a patient in need thereof. In some embodiments, the dual therapy consists essentially of or consists of two mRNAs encoding an IL-23 polypeptide and an IL-36-gamma polypeptide or an IL-18 polypeptide, respectively. The dual therapy can be administered (i) as a single composition containing both mRNAs, or (ii) as separate compositions, each one containing each mRNA. In some embodiments, the mRNAs in the dual therapy are administered simultaneously. In other embodiments, the mRNAs in the dual therapy are administered sequentially.

[0418] As used herein, the terms "triple drug," "triple therapy," "triple combination therapy," "triple mRNA therapy," and grammatical variations thereof, are used interchangeably and refer to a combination therapy in which three mRNAs encoding an IL-23 polypeptide, an IL-36-gamma polypeptide or an IL-18 polypeptide, and an OX40L polypeptide are administered to a patient in need thereof. In some embodiments, the triple therapy consists essentially of or consists of three mRNAs encoding an IL-23 polypeptide, an IL-36-gamma polypeptide or an IL-18 polypeptide, and an OX40L polypeptide, respectively. Triple therapy can be administered, for example, as (i) a single composition containing the three mRNAs (e.g., in a final weight (mass) ratio of IL-23:IL-36 gamma:OX40L of 1:2:1 w / w), or (ii) as separate compositions containing one or two mRNAs each (e.g., in a final weight (mass) ratio of IL-23:IL-36 gamma:OX40L of 1:2:1 w / w). In some embodiments, the mRNAs in the triple therapy are administered simultaneously. In other embodiments, each mRNA in the triple therapy, or a combination thereof, is administered sequentially. In certain embodiments, the triple therapy comprises or consists essentially of (i) a first polynucleotide encoding a first protein comprising an IL-23 polypeptide (e.g., SEQ ID NO:140 encoded by SEQ ID NO:141), (ii) a second polynucleotide encoding a second protein comprising an IL-36-gamma polypeptide (e.g., SEQ ID NO:16 encoded by SEQ ID NO:143), and (iii) a third polypeptide encoding a third protein comprising an OX40L polypeptide (e.g., SEQ ID NO:145 encoded by SEQ ID NO:145), preferably formulated in a weight (mass) ratio of 1:2:1 and administered in any order (e.g., sequentially, sequentially, or simultaneously).

[0419] In some embodiments, the present disclosure provides methods of treatment in which administration of a polynucleotide or combination of polynucleotides disclosed herein (e.g., mRNA) to a subject in need thereof results in: (a) an increase in granulocyte levels in one or more samples obtained from the subject after administration of the two or three agents relative to a threshold level or relative to levels following administration of a single polynucleotide encoding an IL-23, IL-36-gamma or IL-18 polypeptide, or an OX40L polypeptide; (b) an increase in the level of cross-presenting dendritic cells in one or more sam...

Claims

1. A pharmaceutical composition for treating a subject having cancer, the pharmaceutical composition comprising an mRNA comprising an open reading frame (ORF) encoding a human IL-23 polypeptide and an mRNA comprising an ORF encoding a human IL-36-gamma polypeptide, the IL-23 polypeptide comprising a human IL-12p40 polypeptide fused directly or via a linker to a human IL-23p19 polypeptide, the mRNA being formulated to be encapsulated in a lipid nanoparticle (LNP), the LNP comprising an ionic amino lipid, a phospholipid, a sterol and a PEG-modified lipid.

2. The pharmaceutical composition of claim 1, further comprising an mRNA including an ORF encoding a human OX40L polypeptide.

3. The pharmaceutical composition of claim 1 or claim 2, wherein the IL-12p40 polypeptide comprises the amino acid sequence of SEQ ID NO:3 and the IL-23p19 polypeptide comprises the amino acid sequence of SEQ ID NO:

5.

4. The pharmaceutical composition of claim 1 or claim 2, wherein the human IL-12p40 polypeptide is linked to the human IL-23p19 polypeptide via a linker.

5. The pharmaceutical composition of claim 4 , wherein the linker is a Gly / Ser linker.

6. The pharmaceutical composition of claim 1 or claim 2, wherein the human IL-23 polypeptide comprises the amino acid sequence of SEQ ID NO:

140.

7. The pharmaceutical composition of claim 1 or claim 2, wherein the human IL-36-gamma polypeptide comprises an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 10, the amino acid sequence of SEQ ID NO: 12 and the amino acid sequence of SEQ ID NO:

16.

8. 3. The pharmaceutical composition of claim 2, wherein the human OX40L polypeptide comprises an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO:2 and the amino acid sequence of SEQ ID NO:

21.

9. 3. The pharmaceutical composition of claim 2, wherein the human IL-23 polypeptide comprises the amino acid sequence of SEQ ID NO: 140, the human IL-36-gamma polypeptide comprises the amino acid sequence of SEQ ID NO: 16, and the human OX40L polypeptide comprises the amino acid sequence of SEQ ID NO:

21.

10. 3. The pharmaceutical composition of claim 1 or claim 2, wherein the ORF encoding a human IL-23 polypeptide comprises, in a 5' to 3' direction, a nucleotide sequence selected from: (i) a nucleotide sequence encoding the IL-12p40 polypeptide, a nucleotide sequence encoding a peptide linker, and a nucleotide sequence encoding the IL-23p19 polypeptide; (ii) a nucleotide sequence encoding the IL-12p40 polypeptide and a nucleotide sequence encoding the IL-23p19 polypeptide; (iii) a nucleotide sequence encoding the IL-23p19 polypeptide, a nucleotide sequence encoding a peptide linker, and a nucleotide sequence encoding the IL-12p40 polypeptide; and (iv) a nucleotide sequence encoding the IL-23p19 polypeptide and a nucleotide sequence encoding the IL-12p40 polypeptide.

11. 3. The pharmaceutical composition of claim 1 or claim 2, wherein (i) the ORF encoding the human IL-23 polypeptide comprises a nucleotide sequence set forth in SEQ ID NO: 141, or a nucleotide sequence which is at least 70% or 80% identical to SEQ ID NO: 141, and / or (ii) the mRNA comprising an ORF encoding the human IL-23 polypeptide comprises a nucleotide sequence set forth in SEQ ID NO: 142, or a nucleotide sequence which is at least 70% or 80% identical to SEQ ID NO:

142.

12. 3. The pharmaceutical composition of claim 2, wherein (i) the ORF encoding the human IL-36-gamma polypeptide comprises a nucleotide sequence set forth in SEQ ID NO: 143 or a nucleotide sequence which is at least 70% or 80% identical to SEQ ID NO: 143, and / or (ii) the mRNA comprising an ORF encoding the human IL-36-gamma polypeptide comprises a nucleotide sequence set forth in SEQ ID NO: 144 or a nucleotide sequence which is at least 70% or 80% identical to SEQ ID NO:

144.

13. The pharmaceutical composition of claim 2, wherein (i) the ORF encoding the human OX40L polypeptide comprises a nucleotide sequence set forth in SEQ ID NO: 145 or a nucleotide sequence that is at least 70% or 80% identical to SEQ ID NO: 145, and / or (ii) the mRNA comprising an ORF encoding the human OX40L polypeptide comprises a nucleotide sequence set forth in SEQ ID NO: 146 or a nucleotide sequence that is at least 70% or 80% identical to SEQ ID NO:

146.

14. The pharmaceutical composition of claim 1 or claim 2, wherein the mRNA is formulated in separate LNPs.

15. The pharmaceutical composition of claim 1 or claim 2, wherein the mRNA is formulated in the same LNP.

16. 3. The pharmaceutical composition of claim 2, wherein the mRNA comprising an ORF encoding a human IL-23 polypeptide, the mRNA comprising an ORF encoding a human IL-36-gamma polypeptide, and the mRNA comprising an ORF encoding a human OX40L polypeptide are formulated in the LNPs in a mass ratio of 1:2:

1.

17. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition is administered by separate administration, either simultaneously or sequentially, of the separate LNPs.

18. The pharmaceutical composition according to claim 1 or 2, wherein the LNP comprises, in a molar ratio, 20-60% ionic amino lipid, 5-25% phospholipid, 25-55% sterol, and 0.5-15% PEG-modified lipid.

19. The pharmaceutical composition according to claim 1 or 2, wherein the LNP comprises, in a molar ratio, 40-60% ionic amino lipid, 8-16% phospholipid, 30-45% sterol, and 1-5% PEG-modified lipid.

20. The pharmaceutical composition according to claim 1 or 2, wherein the LNP comprises, in a molar ratio, 45-65% ionic amino lipid, 5-10% phospholipid, 25-40% sterol, and 0.5-5% PEG-modified lipid.

21. The ionic amino lipid is compound 18: [Formula 1] The pharmaceutical composition according to claim 1 or claim 2,

22. 3. The pharmaceutical composition of claim 2, wherein the mRNA comprising an ORF encoding a human IL-23 polypeptide, the mRNA comprising an ORF encoding a human IL-36-gamma polypeptide, and / or the mRNA comprising an ORF encoding a human OX40L polypeptide is fully modified with chemically modified uridines, and optionally the chemically modified uridine is N1-methylpseudouridine.

23. 3. The pharmaceutical composition of claim 2, wherein the mRNA comprising an ORF encoding a human IL-23 polypeptide, the mRNA comprising an ORF encoding a human IL-36-gamma polypeptide, and / or the mRNA comprising an ORF encoding a human OX40L polypeptide comprises one or more microRNA (miR) binding sites, and optionally, (a) the one or more miR binding sites are located in the 3'UTR, and / or (b) the one or more miR binding sites are miR-122 binding sites, and further optionally, are miR-122-3p binding sites, miR-122-5p binding sites, or both.

24. A lipid nanoparticle (LNP) comprising (i) a first mRNA comprising an open reading frame (ORF) encoding a human IL-23 polypeptide and (ii) a second mRNA comprising an ORF encoding a human IL-36-gamma polypeptide, the LNP comprising an ionic amino lipid, a phospholipid, a sterol and a PEG-modified lipid.

25. The LNP of claim 24, wherein the human IL-23 polypeptide comprises a human IL-12p40 polypeptide directly fused to a human IL-23p19 polypeptide.

26. The LNP of claim 24, wherein the human IL-23 polypeptide comprises a human IL-12p40 polypeptide linked via a linker to a human IL-23p19 polypeptide.

27. The LNP of claim 26, wherein the linker is a Gly / Ser linker.

28. The LNP of any one of claims 24, 26 and 27, wherein the IL-23 polypeptide comprises the amino acid sequence of SEQ ID NO:

140.

29. The LNP of any one of claims 24 to 27, wherein the IL-36-gamma polypeptide comprises an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 10, the amino acid sequence of SEQ ID NO: 12, and the amino acid sequence of SEQ ID NO:

16.

30. The LNP of any one of claims 24 to 27, further comprising a third mRNA comprising an ORF encoding a human OX40L polypeptide.

31. The LNP of claim 30, wherein the OX40L polypeptide comprises an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO:2 and the amino acid sequence of SEQ ID NO:

21.

32. The LNP of claim 30, wherein the human IL-23 polypeptide comprises the amino acid sequence of SEQ ID NO: 140, the human IL-36-gamma polypeptide comprises the amino acid sequence of SEQ ID NO: 16, and the human OX40L polypeptide comprises the amino acid sequence of SEQ ID NO:

21.

33. 25. The LNP of claim 24, wherein the ORF encoding a human IL-23 polypeptide comprises, in a 5' to 3' direction, a nucleotide sequence selected from: (i) a nucleotide sequence encoding the IL-12p40 polypeptide, a nucleotide sequence encoding a peptide linker, and a nucleotide sequence encoding the IL-23p19 polypeptide; (ii) a nucleotide sequence encoding the IL-12p40 polypeptide and a nucleotide sequence encoding the IL-23p19 polypeptide; (iii) a nucleotide sequence encoding the IL-23p19 polypeptide, a nucleotide sequence encoding a peptide linker, and a nucleotide sequence encoding the IL-12p40 polypeptide; and (iv) a nucleotide sequence encoding the IL-23p19 polypeptide and a nucleotide sequence encoding the IL-12p40 polypeptide.

34. The LNP of any one of claims 24, 26 and 27, wherein (i) the ORF encoding a human IL-23 polypeptide comprises a nucleotide sequence set forth in SEQ ID NO: 141, or a nucleotide sequence that is at least 70% or 80% identical to SEQ ID NO: 141, and / or (ii) the mRNA comprising an ORF encoding a human IL-23 polypeptide comprises a nucleotide sequence set forth in SEQ ID NO: 142, or a nucleotide sequence that is at least 70% or 80% identical to SEQ ID NO:

142.

35. The LNP of any one of claims 24 to 27, wherein (i) the ORF encoding the human IL-36-gamma polypeptide comprises a nucleotide sequence set forth in SEQ ID NO: 143 or a nucleotide sequence that is at least 70% or 80% identical to SEQ ID NO: 143, and / or (ii) the mRNA comprising an ORF encoding the human IL-36-gamma polypeptide comprises a nucleotide sequence set forth in SEQ ID NO: 144 or a nucleotide sequence that is at least 70% or 80% identical to SEQ ID NO:

144.

36. The LNP of claim 30, wherein (i) the ORF encoding the human OX40L polypeptide comprises a nucleotide sequence set forth in SEQ ID NO: 145 or a nucleotide sequence that is at least 70% or 80% identical to SEQ ID NO: 145, and / or (ii) the mRNA comprising an ORF encoding the human OX40L polypeptide comprises a nucleotide sequence set forth in SEQ ID NO: 146 or a nucleotide sequence that is at least 70% or 80% identical to SEQ ID NO:

146.

37. The LNP of claim 30, wherein the mRNA comprising an ORF encoding a human IL-23 polypeptide, the mRNA comprising an ORF encoding a human IL-36-gamma polypeptide, and the mRNA comprising an ORF encoding a human OX40L polypeptide are formulated in the LNP in a mass ratio of 1:2:

1.

38. The LNP according to any one of claims 24 to 27, comprising, in a molar ratio, 20 to 60% ionic amino lipid, 5 to 25% phospholipid, 25 to 55% sterol, and 0.5 to 1.5% PEG-modified lipid.

39. The LNP according to any one of claims 24 to 27, comprising, in a molar ratio, 40 to 60% ionic amino lipid, 8 to 16% phospholipid, 30 to 45% sterol and 1 to 5% PEG-modified lipid.

40. The LNP according to any one of claims 24 to 27, comprising, in a molar ratio, 45 to 65% ionic amino lipid, 5 to 10% phospholipid, 25 to 40% sterol and 0.5 to 5% PEG-modified lipid.

41. The ionic amino lipid is compound 18: [chemical 2] The LNP according to any one of claims 24 to 27,

42. The LNP of claim 30, wherein the mRNA comprising an ORF encoding a human IL-23 polypeptide, the mRNA comprising an ORF encoding a human IL-36-gamma polypeptide, and / or the mRNA comprising an ORF encoding a human OX40L polypeptide is fully modified with chemically modified uridines, and optionally the chemically modified uridine is N1-methylpseudouridine.

43. The LNP of claim 30, wherein the mRNA comprising an ORF encoding a human IL-23 polypeptide, the mRNA comprising an ORF encoding a human IL-36-gamma polypeptide, and / or the mRNA comprising an ORF encoding a human OX40L polypeptide comprises one or more microRNA (miR) binding sites, and optionally, (a) the one or more miR binding sites are located in the 3'UTR, and / or (b) the one or more miR binding sites are miR-122 binding sites, and further optionally, are miR-122-3p binding sites, miR-122-5p binding sites, or both.

Citation Information

Patent Citations

  • Engineered nucleic acid delivery and formulation

    JP2014511687A

  • Signal sensor polynucleotides for modifying cell phenotypes

    JP2016504050A

  • Combination therapy comprising ox40 binding agonists and PD-1 axis binding antagonists

    WO2015095423A2

  • Nucleic acid vaccines

    WO2015164674A1